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ABSTRACT 
 
Our current understanding of Alzheimer’s disease (AD) is incomplete due to 
uncertainties in experimental models and the multi-faceted nature of Aβ.  These difficulties 
have not prevented models being used to explore AD preventatives and therapeutics.  As a 
result, a variety of hypotheses on the cause of AD and a range of assays to measure 
outcomes in different treatments have evolved. However, knowledge of the precise causes of 
AD is fundamental to develop rational preventative measures and treatment. My research 
has aimed at elucidating some of the biological effects and toxic mechanisms of intracellular 
Aβ, which is implicated in causing AD.  
Genome-wide transcription in yeast producing intracellular Aβ fused to GFP (which 
may be likened to a disease state due to Aβ) compared to yeast producing GFP (which may 
be likened to a normal state) implied that intracellular Aβ may affect the cell cycle, 
intracellular copper availability, and stress responses like oxidative stress response and heat 
shock response, probably via the MAPK signalling pathway. Signs of protein misfolding, 
oxidative stress, proteasomal activity and ubiquitination were observed in the functional 
analysis of differentially expressed genes. In vivo yeast assays revealed that Aβ species, 
Aβ42 and Aβ40, are toxic enough to living cells to induce a heat shock response in the cells. 
Truncated Aβ species, Aβ28 and Aβ16, produced only basal stress levels similar to that seen 
in GFP producing cells. Though it is not clear whether Aβ caused GFP to misfold or the 
fusion to oligomerize, aberrant protein folding, oxidative stress and hydrophobicity of the 
residues in Aβ were noted as factors that influence the toxicity of Aβ. These factors may 
have the potential to convert normal Aβ to pathological plaques. HSR is a protective 
response that either reduces aggregation or facilitates proper folding of proteins. Consistent 
with this idea, it was observed that sustaining HSR could protect against Aβ toxicity. By 
increasing stress defence mechanisms, protein turn-over may be increased, thereby 
reducing the cell damage. Analysis of the in vivo interactions of Aβ with metals and clioquinol 
(CQ), a metal-chelator that has been suggested to be an AD chemopreventative, suggested 
that the toxicity of Aβ involved metals. The toxicity of Aβ could also be modulated by CQ. 
Further studies on CQ revealed that Cu2+, and not Fe2+ or Zn2+, could revert the growth 
inhibitory effects of CQ when added in molar excess. 
Taken together, these studies affect our understanding of Aβ biology in the context of 
AD. It is notable that an enhanced HSR enabled better folding of Aβ. The yeast HSR model 
presented in this study and data from the literature reinforces the development of HSR as an 
ideal AD therapeutic target as it confers protection against the multiple effects of the 
pleiotrophic AD proteins. Furthermore, the yeast HSR assay was established to be a robust 
 ix
and reliable assay as it could accurately reproduce the increased and decreased toxicity of 
known mutants. These studies indicate that yeast may be a new tractable model system for 
the screening for inhibitors of the stress caused by Aβ. 
 
 
 
 
 
 
 
 
 
 x
PREFACE 
 
This thesis presents the research accomplished during my PhD studies at RMIT University 
and CSIRO-Molecular and Health Technologies, Parkville under the expert supervision of 
Prof. Ian G. Macreadie. All work in this thesis, unless otherwise stated, was performed by the 
candidate. 
 
Research described in this thesis has been published in parts as mentioned below: 
Book Chapter 
Antony H and Macreadie I. (2008) “Alzheimer’s disease, the importance of Aβ and the 
hopes for chemopreventatives”, Medicinal Chemistry Research Progress, Nova publishers 
(in press) 
Journal Article 
Caine J, Sankovich S, Antony H, Waddington L, Macreadie P, Varghese J, Macreadie I. 
(2007) “Alzheimer's Aβ fused to green fluorescent protein induces growth stress and a heat 
shock response”, FEMS Yeast Res. 7(8):1230-1236.  
Abstracts 
George H, Iliades P, Caine J, Sankovich S, Kornfeld G, Macreadie P, Macreadie I and 
Varghese J. (2007) “Determining the effects of Alzheimer's Aβ in yeast and towards high-
throughput assays for compounds that prevent Alzheimer's disease”, The XXIIIrd 
International Conference on Yeast Genetics and Molecular Biology Melbourne, Australia.  
Yeast 24 (S1): S117-S127 
 
Macreadie I, Lotfi-Miri M, Bharadwaj P, Sankovich S, Caine J, Antony H, Shapira D, Carver 
J, Münch G, Bennett L, Varghese J. (2008) “Development of high throughput yeast assays 
for novel AD chemo preventatives”, Keystone Symposia Conference – Alzheimer’s Disease. 
 xi
ACKNOWLEDGEMENTS 
 
It is difficult to overstate my gratitude to my Ph.D. supervisor, Prof. Ian G. Macreadie. With 
his enthusiasm, inspiration and patient efforts, he made research fun for me. Throughout my 
research tenure, he continually provided encouragement, sound advice, good teaching, good 
company and lots of good ideas. He always guided me towards opportunities that would 
sharpen my research and communication skills. He was always there to support me 
whenever I needed him and provided me fatherly advice. I purely enjoyed working with him 
and am proud to be his student. 
Equally important in my life are two of my colleagues and best friends - Sonia Sankovich and 
Dr. Joanne Caine. This work would not have been possible without their love, care, support 
and encouragement. They have been my advisors and mentors all through-out my work. 
They have been abundantly helpful and have assisted me in numerous ways, including my 
scientific and personal development. I certainly would feel lost without them. 
I would like to extend my deepest gratitude to Ian, Sonia and Jo for their patience and timely 
help to review and correct my thesis drafts in a short time and enabling me to submit on time.  
All three of them have played such a great role in my research and personal life that I cannot 
thank them enough. Continual scientific discussions with them have honed my abilities to 
critically analyse my results and also think from a variety of perspectives. 
I would like to extend my heart-felt thanks to Dr. Geoff Kornfeld and Dr. Peter Iliades for 
taking me through the world of microarrays. I also thank Dr. Gordon Smyth (for guiding me 
through the statistical analysis) and Dr. Victoria Perreau (for helping me with pathway and 
GO analyses). Special thanks also go to Mehrnoush Lotfi-Miri, Mitchell Paul, Dr. Jaekwon 
Lee, Prof. Peter Piper and Dr. Dennis Winge for help and advices rendered. 
I would like to acknowledge all my colleagues and friends who have been there to support 
me through this research period. 
I cannot end without thanking my family, on whose constant encouragement and love I have 
relied throughout my research. The unflinching courage and conviction of my father, Mr. P.A. 
George, always inspires me and the continuous selfless effort he is putting up for my 
upbringing always kept me going with a strong will-power to achieve my goal.  Also to my 
loving and caring mom, who have always supported my studies and wanted to see me reach 
great heights. It is to them I dedicate this work. I would also like to extend my deepest love, 
gratitude and thanks to my loving husband, Dr. Antony P.J., who has worked so hard to 
 xii
guide me and make me a successful researcher. Without him, I would not have completed 
this work. 
 
 
 xiii
LIST OF FIGURES 
 
Fig.1.1 APP proteolytic processing pathways.   4 
 
Fig.1.2 Aβ cascade hypothesis.   9 
 
Fig.1.3 FAD mutations in APP surrounding the cleavage sites of the three 
secretases 
 
11 
 
Fig.3.1 Schematic outline of experiments and analyses performed in this 
study 
39 
Fig.3.2 Image of native agarose gel loaded with total RNA extracted and 
purified from BY4743 yeast transformed with pAS1N.GFP, 
pAS1N.Aβ42GFP, pAS1N.GFPAβ42 and pAS1N.GFPAβ28 after 
electrophoresis 
 
40 
Fig.3.3 Design scheme of microarray experiments used in this study 41 
 
Fig.3.4 MA plots of individual arrays of experiment 1 – before and after 
normalisation 
 
43 
 
Fig.3.5 MA plots of individual arrays of experiment 2 – before and after 
normalisation 
 
44 - 45 
Fig.3.6 M box plots of all arrays included in analysis of experiment 1 – 
before and after normalisation 
 
46 
Fig.3.7 M box plots of all arrays included in analysis of experiment 2 – 
before and after normalisation 
 
47 
Fig.3.8 Overview of genes targeted by HSF 69 
 
Fig.3.9 Comprehensive involvement of Hsf1 70 
 
Fig.3.10 Copper Pathway including all genes involved in regulation and 
transport of copper 
 
72 
Fig.3.11 Differential expression profile of genes in copper pathway 73 
 
Fig.4.1 Induction of heat shock response (HSR) – schematic 
representation 
77 
Fig.4.2 HSR induced in BY4743 [pAS1N.GFP], BY4743 
[pAS1N.GFPAβ42] and BY4743 [pAS1N.Aβ42GFP] 
 
78 
Fig.4.3 Quantification of HSR induced in BY4743 [pAS1N.GFP], BY4743 
[pAS1N.GFPAβ42] and BY4743 [pAS1N.Aβ42GFP] (n≥3) 
 
79 
Fig.4.4 HSR induced in W303-1A [pAS1N.GFP], W303-1A 
[pAS1N.Aβ42GFP], W303-1A [pAS1N.GFPAβ42], W303-1A 
[pAS1N.GFPAβ40] & W303-1A [pAS1N.GFPAβ28] (n=6) 
 
80 
Fig.4.5 HSR induced in W303-1A [p416.GFP], W303-1A [p416.GFPAβ42] 
and W303-1A [p416.GFPAβ16] (n=3) 
 
 
80 
Fig.4.6 Green fluorescence in yeast cells (W303-1A) producing GFP, 81 
 xiv
GFP-Aβ42, GFP-Aβ28 and GFP-Aβ16 in yeast (n=3) 
 
Fig.4.7 HSR induced in BY4743 [pAS1N.GFP], BY4743 
[pAS1N.GFPAβ42], BY4743 [pAS1N.GFPmt] and BY4743 
[pAS1N.GFPmt-Aβ42] (n≥5) 
 
82 
Fig.4.8 HSR levels induced in BY4743 [pAS1N.GFP], BY4743 
[pAS1N.Aβ42GFP] and BY4743 [pAS1N.GFPAβ42] with ascorbic 
acid treatment (n=1) 
 
83 
Fig.4.9 β-galactosidase levels in K. lactis following ascorbic acid 
treatment (n=3) 
83 
 
Fig.4.10 β-galactosidase levels in K. lactis following treatment with (A) DTT 
(n=1) and (B) GSH (n=1) 
 
84 
Fig.4.11 HSR induced by GFP, Aβ42-GFP and GFP-Aβ42 in mutant yeast 
lacking Ahp1 (n=3) 
 
85 
Fig.4.12 Fluorescence microscopy images of yeast (W303-1A) producing 
GFP, GFPAβ42 and mutants of GFPAβ42 with the changes, 
F19S/L34P, M35R/V36E and I32N/V36A within Aβ. 
 
89 
Fig.4.13 Green fluorescence in yeast (W303-1A) transformed with 
pAS1N.GFP, pAS1N.GFPAβ42 and mutants of pAS1N.GFPAβ42 
with two changes each in Aβ42 (i.e. F19S/L34P, M35R/V36E and 
I32N/V36A) (n=3) 
 
90 
Fig.4.14 HSR induced in yeast (W303-1A) doubly transformed with the 
plasmid-borne HSF reporter and plasmids directing synthesis of 
pAS1N.GFP, pAS1N.GFPAβ42 and mutants of pAS1N.GFPAβ42 
with two changes each in Aβ42 (i.e. F19S/L34P, M35R/V36E and 
I32N/V36A) (n=5) 
 
91 
Fig.4.15 Coomassie staining after SDS-PAGE 91 
 
Fig.4.16 Western blots of lysates of W303-1a yeast cells producing 
GFPAβ42 and GFPAβ42 F19S/L34P probed with antibody to GFP 
 
92 
Fig.4.17 GFP fluorescence in yeast W303-1a transformed with 
pAS1N.GFP, pAS1N.Aβ42GFP and mutants of pAS1N.Aβ42GFP 
with changes M35V or M35S within Aβ (n=3) 
 
93 
Fig.4.18 HSR induced in yeast (W303-1A) transformed with pAS1N.GFP, 
pAS1N.Aβ42GFP and mutants of pAS1N.Aβ42GFP with M35V or 
M35S changes within Aβ (n=3) 
 
94 
Fig.4.19 HSR induced in yeast (BY4743) transformed with pAS1N.GFP, 
pAS1N.Aβ42GFP and mutants of pAS1N.Aβ42GFP with mutations 
of histidine residues in Aβ i.e. H13N, H13N/H14N and 
H6N/H13N/H14N (n≥5) 
 
95 
Fig.4.20 HSR in yeast (W303-1A) transformed with pAS1N.GFP, 
pAS1N.Aβ42GFP and the FAD mutant forms of pAS1N.Aβ42GFP 
containing Dutch (E22Q) and Iowa (D23N) mutations within Aβ 
(n=4) 
 
95 
Fig.4.21 Growth of wild-type (wt) strain p82a and heat shock mutant (HS 99 
 xv
mt) hsp82E381K transformed with p416.GFP and p416.GFPAβ42 
(n=6) 
 
Fig.4.22 Green fluorescence in wild-type (wt) strain p82a and heat shock 
mutant (HS mt) hsp82E381K transformed with p416.GFP and 
p416.GFPAβ42 (n=6) 
 
100 
Fig.4.23 Green fluorescence in yeast (BY4743) transformed with pAS1N-
GFPAβ42 following treatment with a food fraction, P0206 (n=2) 
 
101 
Fig.4.24 HSR induced in yeast (BY4743) transformed with pAS1N 101 
Fig.4.25 HSPs known to prevent Aβ toxicity and their mechanisms of 
inhibition 
105 
Fig.4.26 Chemical structure of clioquinol (5-chloro-7-iodo-quinolin-8-ol) 106 
 
Fig.4.27 Effect of Cu2+ on β-galactosidase (and HSR) activity 108 
 
Fig.4.28 Growth and HSR in HSE reporter containing yeast (W303-1A) 
transformed with pAS1N.GFP, pAS1N.Aβ42GFP and 
pAS1N.GFPAβ42 as well as the heat shock reporter plasmid on 
treatment with CQ 
 
109 
Fig.4.29 Green fluorescence produced in yeast (W303-1A) transformed 
with pAS1N.GFPAβ42 on treatment with CQ (n=2) 
 
110 
Fig.4.30 Growth curve of wild-type yeast (BY4743) treated with increasing 
amounts of CQ (n=3) 
 
111 
Fig.4.31 Rescue of CQ cytotoxicity in wild-type yeast (BY4741 and 
BY4743) by metal ions – Cu2+, Fe3+ and Zn2+ (n=6) 
 
112 
Fig.4.32 Rescue of CQ cytotoxicity by Cu2+ in wild-type yeast (BY4741) on 
YEPD plates (n=4) 
 
113 
Fig.4.33 Green fluorescence produced in yeast (W303-1A) transformed 
with pAS1N.GFPAβ42 treated with CQ and/or Cu (n=2) 
 
114 
Fig.4.34 Intracellular metal levels in wild-type yeast (BY4741) on treatment 
with CQ (n=3) 
115 
 
 
 xvi
 
LIST OF TABLES 
 
Table 1.1 Clinical Features of AD (Rathmann and Conner, 2007) 2 
 
Table 1.2 The two Aβ pools 5 
 
Table 1.3 Brief overview of the conflicting views concerning intracellular 
and extracellular Aβ as the toxic moiety (extracted from Antony 
and Macreadie, 2008) 
 
7 
Table 2.1 Yeast strains used in this study 24 
 
Table 2.2 Plasmids used in this study 26 
 
Table 3.1 Fluorescent labelling of cDNAs hybridised on arrays 41 
 
Table 3.2 GO analysis based on biological process of top 100 DE genes 
in experiment 1 
 
49 
Table 3.3 GO analysis based on molecular function of top 100 DE genes 
in experiment 1 
 
50 - 51 
Table 3.4 GO analysis based on cellular component of top 100 DE genes 
in experiment 1 
 
51 
Table 3.5 GO analysis based on biological process of top 100 DE genes 
in experiment 2 
 
52 - 53 
Table 3.6 GO analysis based on molecular function of top 100 DE genes 
in experiment 2 
 
54 
Table 3.7 GO analysis based on cellular component of top 100 DE genes 
in experiment 2 
 
55 
Table 3.8 FunSpec analysis of top 100 DE genes in experiment 1 57 - 59 
 
Table 3.9 FunSpec analysis of top 100 DE genes in experiment 2 59 
 
Table 3.10 TF analysis of top 100 DE genes in experiment 1 60 - 63 
 
Table 3.11 TF analysis of top 100 DE genes in experiment 2 64 - 68 
 
Table 4.1 Association of HSPs with AD components 103 
 xvii
LIST OF ABBREVIATIONS 
 
A mnemonic for add as A = (log R + log G) /2 
ABAD Aβ-Binding Alcohol Dehydrogenase 
ACE Angiotensin-Converting Enzyme 
AD Alzheimer’s Disease 
AICD APP IntraCellular Domain 
Al aluminium 
AMP Adenosine Mono-Phosphate 
ANOVA ANalysis Of VAriance 
ApoE Apolipoprotein E 
APP Amyloid Precursor Protein 
ATP Adenosine Tri-Phosphate 
Aβ β-amyloid 
Aβm-n Aβ with m to n residues  
Aβn Aβ with 1 to n residues 
Aβn-GFP Aβn with its C-terminus tagged with GFP 
β-CTF Beta C-terminal fragment 
BACE Beta-site APP-Cleaving Enzyme 
CAA Cerebral Amyloid Angiopathy 
CaCl2 Calcium chloride 
cDNA Complimentary De-oxyribo Nucleic Acid 
CSF CerebroSpinal Fluid 
CSIRO 
Commonwealth Science and Innovation Research Organisation 
(Australia) 
Cu copper 
Cu2+ copper in (+2) oxidation state 
CVT Cytoplasm to Vacuole Targeting 
DE Differentially Expressed genes 
DEPC Di Ethyl PyroCarbonate 
DNA De-oxyribo Nucleic Acid 
DTT Dithiothreitol 
ECE Endothelin Converting Enzyme 
EDTA Ethylene Di-amine Tetra Acetic acid 
EOAD Early Onset Alzheimer’s Disease 
ER Endoplasmic Reticulum 
FA Focal Adhesion 
FAD Familial Alzheimer’s Disease 
Fe iron 
Fe3+ iron in (+3) oxidation state 
FunSpec Functional Specification 
GAL Genepix Array List 
GFP Green Fluorescent Protein 
GFP-Aβn Aβn with its N-terminus tagged with GFP 
GO Gene Ontology 
GSH Glutathione (reduced form) 
HCl Hydrochloric acid 
HS Heat Shock 
HSE Heat Shock Element 
 xviii
HSF Heat Shock Factor 
HSP Heat Shock Protein 
Hsp Heat Shock Protein 
HSR Heat Shock Response 
HTML HyperText Markup Language 
IDE Insulin Degrading Enzyme 
JNK Jun N-terminal Kinase 
KCl Potassium chloride 
KH2PO4  Potassium bi-phosphate 
LDL Low Density Lipoprotein 
LIMMA Linear Models for MicroArray  
limmaGUI Linear Models for MicroArray – Graphical User Interphase 
LOAD Late Onset Alzheimer’s Disease 
LRP LDL-Related Protein 
M mnemonic for minus as M = log2 R/G i.e. M = log2 R – log2 G 
MA plot graph between M and A 
MAPK Mitogen-Activated Protein Kinase 
MAPKK Mitogen-Activated Protein Kinase Kinase 
MgSO4.7H2O Magnesium sulphate hepta hydrate 
mt mutant 
Na2HPO4 Disodium hydrogen phosphate 
Na2HPO4.7H2O Disodium hyrogen phosphate hepta hydrate 
NaCl Sodium chloride 
NAD Nicotinamide Adenine Dinucleotide 
NADP Nicotinamide Adenine Dinucleotide Phosphate 
NaH2PO4 Sodium bi-phosphate 
NaOH Sodium hydroxide 
NEP Neprilysin or Neutral M13 EndoPeptidase 
NFTs Neuro Fibrillary Tangles 
NMDA N-methyl-D-aspartate 
NO Nitric Oxide 
OD Optical Density 
ONP o-Nitro Phenol 
ONPG o-NitroPhenyl-β-D-Galactoside 
ORC Origin Recognition Complex 
P P value i.e. Probability of error 
PBS Phosphate Buffered Saline 
PEG Poly Ethylene Glycol 
pH -Log [H+] 
PI Propidium Iodide 
PMT Photo Multiplier Tube 
PS-1 presenilin-1 
PS-2 presenilin-2 
RNA Ribo Nucleic Acid 
ROS Reactive Oxygen Species 
rpm rotations per minute 
rRNA Ribosomal RNA 
SAM Self Assembled Monolayer 
SAPK Stress Activated Protein Kinase 
 xix
SDS Sodium Dodecyl Sulphate 
SDS-PAGE Sodium Dodecyl Sulphate – PolyAcrylamide Gel Electrophoresis 
SEM  Standard Error of Mean 
sensu in the sense of 
snoRNA small nuclear RNAs 
SSC Sodium chloride/Sodium Citrate 
TF Transcription Factor 
TMB 3,3’,5,5’-TetraMethylBenzidine 
UV Ultra-Violet  
wt wild-type 
YEPD Yeast Extract Peptone Dextrose 
YNB Yeast Nitrogen Base 
YPER Yeast Protein Extraction Reagent 
YT Yeast extract/Tryptone 
Zn zinc 
Zn2+ zinc in (+2) oxidation state 
 
 1
CHAPTER 1 
INTRODUCTION 
Alzheimer’s disease (AD) is one of the most devastating diseases of society, posing 
escalating societal and financial burdens especially with the ageing “baby boomer” 
generation.  In 2007, 29.8 million people in the world had dementia, with the incidence 
expected to be 81.1 million by 2050 unless a cure or prevention is found.  In 2005, the total 
worldwide societal cost of dementia was estimated to be US$315.4 billion including US$105 
billion for informal care for a dementia population of 29.3 million in that year.  Of these 
dementia cases, 50-70% are due to AD (Alzheimer’s Australia, 2008). In Australia, AD is the 
second major cause of disability burden which exerts an immense toll on both the people and 
the government. Of the affected Australians, 98.5% are classified as disabled (Access 
Economics Pty Ltd. 2003). The number of affected individuals is predicted to reach 500,000 
by 2040 (Access Economics Pty Ltd. 2003). Currently, AD represents significant cost to the 
health care system. The cost of AD will increase from about 1% of GDP (gross domestic 
product) to more than 3% of GDP as the Australian population peaks in the coming decades 
(Access Economics Pty Ltd. 2003). This massive boom stresses the importance of AD 
research. 
Due to uncertainties in experimental models and the pleiotrophic nature of the 
Alzheimer’s protein, Aβ, a variety of hypotheses on the cause of AD and a range of assays to 
measure outcomes in different treatments have evolved. However, knowledge of the precise 
causes of AD is fundamental to develop rational preventative measures and treatment. The 
identification of cellular pathways affected by Aβ and the development of screening assays 
for inhibitory compounds in simple genetic organisms can lead to novel chemo-preventatives. 
The yeast model presented in this study enables better understanding of Aβ biology by 
elucidating some of the biological effects and toxic mechanisms of intracellular Aβ, which is 
implicated in causing AD. This study also implicates that yeast may be a new tractable model 
system for the screening of potential chemo-preventatives. 
1.1 REVIEW OF THE LITERATURE 
1.1.1 Alzheimer’s Disease 
AD is a highly debilitating progressive mental disorder characterized by severe 
cognitive impairment that causes disturbances in speech, memory and thought.  It is the 
most prevalent form of dementia, generally affecting people over the age of 65, but those as 
young as 40-50 years can have early-onset AD, a genetically inherited form of AD.   
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An AD brain typically shows irreversible brain atrophy and protein aggregation in 
areas of information acquisition and processing and memory formation.  The two seminal 
pathological brain lesions in AD are neuritic plaques that occur as extracellular deposits, and 
neurofibrillary tangles (NFTs) that are intracellular aggregates.  The plaques predominantly 
consist of fibrillar aggregates of a 4 kDa β-amyloid protein (Aβ) (Masters et al., 1985), while 
the NFTs are formed by hyperphosphorylation of the microtubule associated protein, tau.  
These aggregates block neurotransmission, cause changes in cerebrovasculature and lead 
to neuronal death and loss of brain functions.  The most frequent disorders observed in AD 
patients include aggression (95%), anxiety/agitation (70%), hypophagia (70%), diurnal 
rhythm disturbance (65%), “trailing & checking” i.e. following carer (60%), and paranoid ideas 
(45%) (Gillman, 1997).  The clinical features of each phase in AD have been summarised in 
Table.1.1 
Table 1.1 Clinical Features of AD (Rathmann and Conner, 2007) 
 
Early Symptoms 
 
Mid-Phase 
 
Advanced AD 
 
Death 
 
 short-term memory 
loss  
 visual-spatial 
confusion 
 less energetic 
 
 loss of independent activity in 
daily tasks 
 loss of well-known skills 
 failure of identification of objects 
& people 
 sudden outbursts of violence due 
to agitation and psychosis 
 
 weakening of 
musculature and 
mobility 
 incontinence 
 severe language 
distortion/loss 
 
 external cause 
like heart attack, 
pneumonia, etc. 
1.1.2 What causes AD?  
The precise etiology of AD remains obscure as the pathophysiology is quite complex, 
involving multiple pathways comprising abnormal Aβ-protein processing, impaired 
neurotransmission, disturbed metal ion homeostasis, oxidative stress, mitochondrial and 
endoplasmic reticulum dysfunction, cholesterol dyshomeostasis, amyloid angiopathy, 
apoptosis and neuronal inflammation.  The incidence of AD is also associated with age, sex 
and genetic factors (all discussed below). 
AD may be classed as: i) early onset (EOAD) or familial AD (FAD), and ii) late onset 
(LOAD) or sporadic AD.  The former is rare (<10%) with FAD being caused by genetic 
mutations, while the major (90%) sporadic AD is thought to be caused by a variety of factors 
acting together (discussed below).  A plethora of molecular studies firmly establish the 
central role of Aβ in both types of AD biogenesis; however tau also appears to play a role. 
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1.1.3 Molecular mechanisms and risk factors of AD 
The prominent ideas about molecular mechanisms and risk factors involved are 
discussed below. 
1.1.3.1 Aβ versus Tau 
 Both plaques and NFTs are polymeric forms of proteins that are found in normal 
brains.  Though the crystal structure of full-length Aβ has not yet been established, there 
have been structures of Aβ fragments (Takano et al., 2006; Sawaya et al., 2007 ) and recent 
data suggests that plaques consist of β-strands of Aβ in a packing similar to that of a β-spine 
structure (Nelson et al., 2005).  On the other hand, NFTs constitute assemblies of paired 
helical filaments of hyperphosphorylated tau.  Normally tau is involved in microtubular 
structure and hence tau deposition may represent neuronal injury.  Caspase activation and 
tau cleavage may precede and lead to NFT pathology (Rohn et al., 2002; Rohn et al., 2001; 
Guo et al., 2004).  It has also been proposed that the amyloid deposits may act as reservoirs 
for the dispersal of Aβ which may influence tau pathology over the course of many years 
(Bloom et al., 2005).  In support of these ideas is the observation that, when added to 
neurons, Aβ peptides enhanced pathological tau filament assembly by activating caspase 
cleavage of tau and producing a proteolytic product with enhanced polymerization kinetics 
(Gamblin et al., 2003).   
Tau co-localized with intra-neuronal Aβ42, and Aβ accumulation triggered caspase 
activation leading to the cleavage of tau (Rissman et al., 2004)  Together, these studies 
illustrate that Aβ may precede tangle formation and they may be linked to the pathogenicity 
through the caspase cleavage (Cotman et al., 2005).  Moreover, tau deposits are not as 
specific for AD as the Aβ deposition since they occur even in the absence of amyloid 
formation in a variety of other conditions like progressive supranuclear palsy, corticobasal 
degeneration, Pick’s disease and frontotemporal dementia with Parkinsonism linked to 
Chromosome 17, etc.  
The key evidence for incriminating Aβ in AD includes the presence of Aβ plaques in 
all AD patients in amounts greater than observed in normal ageing (Blessed et al., 1968) 
(Perry et al., 1978), increased Aβ production caused by all known genes involved in AD 
susceptibility (Citron et al., 1992; Citron et al., 1994; Cai et al., 1993; Scheuner et al., 1996; 
Citron et al., 1997; Schmechel et al., 1993), increased production of Aβ from birth and plaque 
formation preceding other AD lesions in Down’s syndrome patients (Lemere et al. 1996; 
Mann, 1989; Rumble et al. 1989; Querfurth et al., 1995), prevention of neuronal toxicity by 
inhibition of Aβ fibril formation (Lorenzo and Yankner, 1994)  and the absence of hypotheses 
not involving Aβ for AD (Alzheimer Research Forum, 2008). 
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1.1.3.2 APP pathway and Aβ metabolism 
Although the hallmark plaques of AD consist of multiple components, their core is 
principally (~90%) made of Aβ, a 42 amino acid long peptide, 
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA), that is generated by the 
proteolytic cleavage of a type 1 transmembrane glycoprotein known as amyloid precursor 
protein (APP) (Kang et al., 1987).  APP is a naturally-occurring protein that when membrane-
anchored is thought to be functionally important as a G-protein coupled receptor (Okamoto et 
al., 1995; Wilquet and De Strooper, 2004), while fragments of APP (including Aβ) are 
involved in axonal transport (Kamal et al., 2000), gene expression (Cao and Sudhof, 2001), 
microglial activation (Bodles and Barger, 2005), cell adhesion and motility (Breen et al., 
1991; Chen and Yankner, 1991; Sabo et al., 2001), lipid metabolism (Hartmann, 2006, 
Grimm et al., 2005; Liu et al., 2007) regulation of phosphoinositide-mediated calcium 
signalling (Leissring et al., 2002), and regulation of cell excitability, synaptic plasticity, 
learning and memory (Turner et al., 2003).   
C
γ secretase
N
APP
Cytoplasm
Lumen or 
extracellular
Non-amyloidogenic
pathway
Amyloidogenic
pathway
sAPPα
sAPPβ
Aβ
β secretase
α secretaseγ secretase
p3
AICD
AICD
 
Fig.1.1 APP proteolytic processing pathways.  The majority of APP is processed via the non-
amyloidogenic pathway (upper pathway) in which the first excision is by α-secretase within 
the Aβ domain [red] followed by γ-secretase cleavage, leading to release of sAPPα, p3 
peptide and AICD [yellow].  Alternatively, in amyloidogenesis (bottom pathway), β-secretase 
excision is followed by γ-secretase cleavage, producing sAPPβ, Aβ and AICD. 
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APP consists of a large ectopic N-terminal domain, a transmembrane domain and a 
small cytoplasmic C-terminal.  APP is synthesized in the endoplasmic reticulum (ER), 
trafficked through the constitutive secretory pathway and re-internalized from the cell surface 
into the endosomal-lysosomal system for degradation (Wilson et al., 2008).  APP may yield 
Aβ and a variety of other products (Nunan and Small, 2002), depending on the combination 
of proteolytic secretases that act on APP (Fig.1.1).  These proteolytic events are highly 
compartmentalized in the cell, with Aβ production taking place both within intracellular 
compartments and in the plasma membrane, especially in lipid raft domains (Vetrivel et al., 
2004 ; Vetrivel et al., 2005). 
The first cleavage in the amyloidogenic pathway is by a membrane-bound aspartic 
protease, β-secretase [also known as BACE (β-site APP-cleaving enzyme), Asp2 or 
Memapsin2], that is localized within acidic intracellular compartments (Vassar and Citron, 
2000).  BACE cleaves between residues 671-672 in the extracellular or lumenal domain of 
APP, resulting in the release of a large soluble fragment, sAPPβ, while leaving behind a 
membrane-bound fragment, β-CTF (C-terminal fragment) or C99.  This residual fragment is 
further cleaved by γ-secretase within the transmembrane domain of APP, between residues 
711-714 (termed γ-site) or near residue 721 (termed ε-site), to yield Aβ and AICD (APP 
intracellular domain).  The greater part of γ-secretase cleavage seems to occur in late 
transport compartments and in the endosomal pathway (Vassar and Citron, 2000; Vetrivel et 
al., 2004), while BACE cleavage occurs within endoplasmic reticulum or in the trans-golgi 
network (Huse et al., 2002; Huse et al., 2003).  The precise mechanism by which this 
amyloidogenic pathway may be favoured is still unknown. 
Table 1.2 The two Aβ pools (Turner et al., 1996; Skovronsky et al., 1998; Cook et al., 1997; 
Wild-Bode et al., 1997; Tienari et al., 1997; Hartmann et al., 1997; Wilson et al., 2008; 
Greenfield et al., 1999) 
 Major Minor 
Production site/ 
Cell-type 
Neurons Æ Trans-golgi network (TGN) 
or post-golgi vesicles 
Non-neuronal cells Æ Endosomal-
lysosomal system 
Endoplasmic reticulum (ER) or intermediate 
compartment in all cells 
Composition Aβ42/Aβ40 = 1:10 Aβ42/Aβ40 = 1:3 
Destination Secreted after intracellular production Remains intracellular 
Aβ appears to have varied destinies depending on the site and the cell type in which 
it is produced (see Table 1.2).  Most of it is secreted while a minority remains intracellular.  
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Aβ levels are also regulated by amyloid-degrading proteases (Turner et al., 2004), including 
three zinc metallopeptidases: 
1) insulin degrading enzyme (IDE), or insulysin, that regulates both intracellular 
(Kurochkin and Goto, 1994; McDermott and Gibson, 1997) and extracellular Aβ (Qiu 
et al., 1998; Vekrellis et al., 2000); 
2) neprilysin or neutral M13 endopeptidase (NEP) that degrades both Aβ40 and Aβ42 
(Iwata et al., 2000; Carson and Turner, 2002); and 
3) endothelin converting enzyme (ECE), a homologue of neprilysin (Weeraratna et al., 
2007; Funalot et al., 2004).   
Other amyloid-degrading proteases proposed are (i) angiotensin-converting enzyme 
(ACE), an M2 peptidyl dipeptidase that degrades Aβ40 at residues Asp7-Ser8 (Hu et al., 
2001; Oba et al., 2005; Hemming and Selkoe, 2005) or regulates Aβ42/Aβ40 ratio by 
converting Aβ42 to Aβ40 (Zou et al., 2007); (ii) plasmin (product of plasminogen activation) 
that cleaves Aβ40 at residues Arg5-His6 (Van Nostrand and Porter, 1999); (iii) acyl peptide 
hydrolase (Yamin et al., 2007); (iv) some matrix metalloproteinases (Selkoe, 2001); and (v) 
thimet oligopeptidase (endopeptidase-24.15) (Carson and Turner, 2002).  
Based on these data, Selkoe postulates that both NEP and IDE may contribute to 
overall Aβ degradation in the brain by functioning in separate subcellular loci with different 
forms of Aβ, and additional proteases may principally degrade different Aβ pools (Selkoe, 
2001).  Indeed, it is shown that IDE degrades soluble Aβ monomers more efficiently than 
insoluble and/or oligomeric Aβ (Qiu et al., 1998; Vekrellis et al., 2000). NEP, in contrast, 
readily degrades buffer-insoluble SDS-extractable Aβ associated with membranes (Selkoe, 
2001), but is unable to degrade soluble Aβ (Iwata et al., 2001). 
Collectively, the APP proteases degrade fibrillogenic and oligomeric types of Aβ in 
the brain.  Alternatively, Aβ may be cleared by export via alpha-2-macroglobulin (A2M) and 
ApoE to the LDL-receptor-related protein (LRP) (Hyman et al., 2000; Shibata et al., 2000; 
Qiu et al., 1999) and subsequent degradation by the lysosomal aspartyl protease, cathepsin 
D (McDermott and Gibson, 1996).  Therefore, reduced expression of any of these proteases 
may enhance the development of AD. 
Between the two plaque-associated Aβ species, Aβ42 is predominant probably due to 
its rapid aggregation and higher toxicity (McGowan et al., 2005; Iversen et al., 1995), related 
to the two additional hydrophobic amino acids compared to Aβ40 (Jarrett et al., 1993).  The 
key role of Aβ42 in AD has been established through diverse histopathological, genetic and 
biochemical studies (reviewed in Findeis, 2007).  Given this information, it is important to 
note that the non-secreted pool has higher Aβ42 than the secreted pool (see Table 1.2).  This 
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may suggest that intracellular Aβ may be the source of the extracellular AD plaques.  
Conversely, several studies argue that extracellular Aβ aggregation and accumulation can 
occur before or in the absence of any detectable intracellular accumulation.  Currently, the 
question of whether internal or extracellular Aβ initiates AD is a topic of major debate among 
researchers (see Table 1.3). Researchers argue that focal plaque-like deposition is less likely 
to be initiated in the extracellular space where Aβ concentration is uniform, and the failure to 
detect the intraneuronal fibrils may be due to challenges in intraneuronal Aβ quantification 
(Alzheimer Research Forum, 2008).  A possibility is that Aβ released from dead neurons 
could stimulate Aβ production in neighbouring cells and create a site for accumulation of Aβ 
into plaques, given that plaques are always observed within the locality of dead cells (Wilson 
et al., 2008). 
Table 1.3 Brief overview of the conflicting views concerning intracellular and extracellular Aβ 
as the toxic moiety (extracted from Antony and Macreadie, 2008) 
 
Favouring Extracellular Aβ 
 
Favouring Intracellular Aβ 
 
• Plaque related variables correlated accurately 
to cognitive dysfunction (Berg et al., 1998; 
Cummings et al., 1996) 
• Evidence of "full-blown" structural pathology 
in pre-demented human brains (Price and 
Morris, 1999; Crystal et al., 1988) 
• Micromolar concentrations of aggregated Aβ 
necessary for Aβ toxicity in vitro is in the 
range of levels in affected AD cortex (Selkoe 
et al., 1986)    
• Aβ toxicity in vivo requires only a single 
plaque-equivalent dose (Geula et al., 1998) 
• Association of neurofilament 
immunoreactivity largely with plaques and 
only occasionally with neuronal cell bodies in 
transgenic mice models (Masliah et al., 2001) 
• Various Aβ deposition enhancers are found in 
the extracellular space and proposed to exert 
their activities extracellularly e.g. heparan 
sulfate proteoglycans pathway, ApoE, etc. 
• Extracellular addition of aggregated Aβ 
produces toxicity in vitro (Yankner et al., 
1990) and in vivo (Geula et al., 1998) 
 
• No significant relation between senile 
plaques and severity of dementia or synaptic 
pathology (Blennow et al., 1996), instead 
plaque-independent neuronal and cognitive 
dysfunction observed (Hsia et al., 1999; 
Moechars et al., 1999; Dickson et al., 1995) 
• Intraneuronal Aβ accumulation and abnormal 
synaptic morphology preceding plaque 
formation in brains of transgenic mice 
(Wirths et al., 2001), aged macaques 
(Murphy et al., 1994), Down syndrome (Mori 
et al., 2002 ; Gyure et al., 2001) and human 
AD (Takahashi et al., 2002; Gouras et al., 
2000) 
• Presence of markers of apoptosis (LaFerla et 
al., 1997),oxidative injury (Guo et al., 1998) 
and inflammation (Sheng et al., 2000) even 
before senile plaque and NFT formation 
• Presence of increased intracellular  Aβ42 in 
APP transgenic mice (Masliah et al., 1996) , 
PS-1 mutant mice (Chui et al., 1999) and 
cultured primary neurons (Greenfield et al., 
1999) 
 8
• Other human amyloidotic diseases are 
believed to result from extracellular 
accumulation of the respective amyloid 
protein (Hou et al., 2007; Rysava, 2007) 
• Extracellular Aβ can increase de novo 
production of intracellular species (Yang et 
al., 1999) 
• Transgenic model with a neuronal promoter 
for APP showed extracellular Aβ deposition 
in vasculature and brain parenchyma 
(Calhoun et al., 1999) 
• Aβ can be internalized; therefore intracellular 
Aβ (and associated toxicity) may arise from 
extracellular Aβ (Bahr et al., 1998) 
• Neuronal degeneration in presence of 
intraneuronal Aβ42 accumulation and with no 
plaque formation in FAD transgenic mice 
(Chui et al., 1999) 
• Intracellular Aβ42, but not extracellular 
soluble Aβ peptides, induces neuronal 
apoptosis (Kienlen-Campard et al., 2002) 
• Max. CSF levels of Aβ42 observed (less than 
1nM) are too low to initiate fibril formation 
that requires ~1mM (Giedraitis et al., 2007) 
• Monoclonal antibodies detect Aβ deposits 
related to neuronal intracytoplasmic 
organelles prior to appearance of PHF-
immunoreactive structures (Fernandez-
Vizarra et al., 2004) 
• Emerging data suggests higher intracellular 
concentration of the more amyloidogenic 
Aβ42 (Gouras et al., 2000; Skovronsky et al., 
1998) 
• Reduced intraluminal pH in cellular 
organelles (Linder and Shoshan, 2005) can 
favour fibril formation (Inouye and 
Kirschner, 2000) 
 
1.1.3.3 Aβ cascade hypothesis 
The 'amyloid cascade hypothesis' proposes that altered APP expression or proteolytic 
processing leads to differential Aβ production and can result in aggregation, instability and 
disordered clearance of Aβ (Hardy and Allsop, 1991; Hardy and Higgins, 1992).  The 
hypothesis postulates that the gradual accumulation of soluble Aβ (secreted and non-
secreted) into aggregates instigates a complex multi-step cascade of microglial activation, 
inflammatory changes, neuritic/synaptic changes, tangles and neurotransmission failure. This 
relates the age of onset to the time taken by Aβ to aggregate and accumulate.  Over a 
decade later, the hypothesis has two principal modifications in the light of new data (Hardy, 
2006; Tanzi and Bertram, 2005).  Plaques are now considered as reservoirs of toxic Aβ 
rather than being toxic themselves, and it is more evident that Aβ42 is the chief toxic entity 
rather than total Aβ (Hardy, 2006).  Studies revealing the strong correlation of soluble Aβ 
levels with severity of the disease (McLean et al., 1999; Lue et al., 1999; Wang et al., 1999) 
has further led to the re-framing of the hypothesis as “amyloid oligomer hypothesis”, 
 9
according to which detergent-stable low-n oligomers form the fundamental building blocks of 
insoluble amyloid deposits and consequently are the earliest mediators of neuronal 
dysfunction in AD.  
 
Dementia
Neuronal dysfunction 
and death
Accumulation of Aß
oligomers, intracellular aggregates,
fibrils, plaques, amyloid angiopathy
Toxicity
Inflammation, oxidative stress,
defective axonal transport, NFT formation
Inherited AD
(FAD or EOAD)
Sporadic AD
(LOAD)
Small effects on 
synaptic efficacy
Increasing levels of Aβ
in the brain with age
Increased levels of 
Aβ
 
Fig.1.2 Aβ cascade hypothesis.  Both inherited and sporadic forms of AD lead to gradual 
accumulation of Aβ (secreted and non-secreted) into aggregates (fibrils and plaques) that 
instigate a complex multi-step cascade of microglial activation, inflammatory changes, 
neuritic/synaptic changes and NFTs, leading to neurotransmission failure and neuronal 
death.  Final consequence of these is dementia. 
The amyloid hypothesis remains strong despite its opponents and alternative 
hypotheses.  The amyloid hypothesis explains the extremely complex pathogenesis via the 
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multiple neurotoxic effects of Aβ that include mitochondrial dysfunction through binding of the 
Aβ-binding alcohol dehydrogenase (ABAD) protein (Lustbader et al., 2004; Yan and Stern 
2005), stimulation of apoptotic genes through inhibition of Wnt pathway (Caricasole et al., 
2003; Chong et al., 2005) and inhibition of insulin signalling (Xie et al., 2002; Revill et al., 
2006), formation of amyloid ion channels (Lal et al., 2007; Kagan et al., 2002) inducing 
calcium dyshomeostasis (Smith et al., 2005; Goodman and Mattson, 1994), activation of the 
JNK/SAPK pathway (Savage et al., 2002), activation of microglial cells leading to the 
expression of pro-inflammatory genes (Bamberger and Landreth, 2001), increase in reactive 
oxygen species (Shi and Gibson, 2007), disturbed axonal transport (Wirths et al., 2006), 
eventual neuronal toxicity (Bamberger and Landreth, 2001) and ultimately death. 
1.1.3.4 Role of genetic defects 
Genetic studies on AD provide strong evidence for amyloid being a cause, and not 
just a consequence, of AD.  Both EOAD and LOAD occur in genetically heterogeneous 
backgrounds, but various genes lead to changes in APP expression, proteolytic processing, 
Aβ stability or aggregation (Hutton et al., 1998; St George-Hyslop, 2000).  The four major 
genetic determinants of AD are: APP, PS-1, PS-2 and ApoE.  A Spanish study of 94 AD 
patients reported the frequency of mutations in PS-1, PS-2 and APP as 54.6% among the 
autosomal dominant group, 6.2% among the sporadic group and 4% among the familial non-
autosomal dominant AD group (Lleo et al., 2002).  Currently the websites www.alzgene.org 
and http://www.molgen.ua.ac.be/ADMutations/ curate the data relating various genetic 
polymorphisms with the incidence of AD.  The number of genes, and of genetic 
polymorphisms, continues to increase with further AD research. 
Missense mutations in any one of the three genes, APP on chromosome 21 (21q21), 
presenilin-1 (PS-1) on chromosome 14 (14q24) and presenilin-2 (PS-2) gene on 
chromosome 1 (1q42), leads to the autosomal dominant EOAD/FAD by altering the rate of 
generation or length of Aβ.  Of the FAD mutations, PS-1 mutations are the most common 
(>50%) (Raux et al., 2005; Janssen et al., 2003), followed by APP mutations (5-10%) (Goate, 
1998) which affect the cleavage site of the different secretases (Fig.3) (Wilquet and De 
Strooper, 2004).  PS-2 mutations are the rarest (Marechal et al., 2003).  Additionally, in 
Down’s syndrome patients (trisomy 21) the presence of increased APP predisposes them to 
AD with disease development mostly within the fourth decade of life (Rumble et al., 1989). 
In late onset AD (LOAD), the major genetic determinant is the cholesterol transport 
protein, ApoE (apolipoprotein E) which is encoded on chromosome 19.  It directly promotes 
amyloid fibril formation by increasing the total amount of amyloid and rate of fibrillogenesis 
(Castano et al., 1995; Coon et al., 2007).  ApoE has three common epsilon (ε) alleles: ε2, ε3 
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and ε4. The allelic polymorphism and gene dosage of these three ε alleles in ApoE genes 
appear to be the basis of this enhanced susceptibility with an increasing vulnerability 
incidence in the order of ε4>ε3>ε2 (Wilhelmus et al., 2005; Rocchi et al., 2003; Chartier-
Harlin et al., 1994; Corder et al., 1994; Corder et al., 1993).   
The AlzGene database established by Bertram and co-workers pinpoints several 
potential AD susceptibility genes apart from ApoE ε4 allele (ACE, CHRNB2, CST3, ESR1, 
GAPDHS, IDE, MTHFR, NCSTN, PRNP, TF, TFAM, TNF and more) with statistically-
significant allelic summary odds ratios via meta-analysis (Bertram et al., 2007).  The 
database also provides a complete, unbiased and regularly updated collection of genetic 
association studies performed world-wide on AD phenotypes.  A variety of linkage and 
association studies reveal novel LOAD genes on chromosomes 12, 10, 9 and 6 (Rogaeva et 
al., 1998; Scott et al., 2000; Kuwano et al., 2006), reviewed in (Bertram and Tanzi, 2001).  It 
is certain that additional genetic factors influencing AD will be found with further study 
(reviewed by Lambert and Amouyel, 2007; Bertram and Tanzi, 2004). 
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Fig.1.3 FAD mutations in APP surrounding the cleavage sites of the three secretases 
The amino acid sequence of Aβ (red) and adjacent regions (black) are given at the top.  Only 
the FAD amino acids changes (green) are shown in the figure under the position of each 
mutation. The corresponding name/country of origin or the founder of mutation is shown on 
the right.  Arrow heads point to the cleavage sites of α-, β- and γ-secretases. 
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1.1.3.5 Role of oxidative stress and metal dyshomeostasis 
The amyloid cascade hypothesis is inextricably linked with oxidative stress (reviewed 
by Benzi and Moretti, 1995; Zhu et al., 2005; Polidori et al., 2007).  Oxidative stress may be 
one of the earliest events in the development of AD, ahead of Aβ accumulation and other 
cytopathological changes.  In a transgenic mouse model, lipid peroxidation was found to 
precede amyloid plaque formation (Pratico et al., 2001).  Brains of individuals with Down’s 
Syndrome, which is highly associated with AD, also showed increased levels of oxidative 
damage very early (Odetti et al., 1998; Nunomura et al., 2000; Nunomura et al., 2001). 
Oxidative stress is an imbalance in pro-oxidant and anti-oxidant homeostasis leading 
to the generation of cytotoxic ROS (reactive oxygen species).  ROS are generated through a 
number of different pathways of which the prominent sources in AD include direct interaction 
of Aβ with redox-active metals like Fe and Cu via Fenton or Fenton-like reactions (Barnham 
et al., 2004), mediated by biologic reducing agents (Opazo et al., 2002) and impaired 
mitochondrial function causing electron leakage in the respiratory chain (Marlatt et al., 2004; 
Manczak et al., 2006; Shi and Gibson, 2007).  Perturbation of redox homeostasis due to the 
abnormal expression and/or activity of anti-oxidant proteins like catalase, SOD, glutathione 
peroxidase and glutathione reductase has also been observed in AD brains (Barnham et al., 
2004; Benzi and Moretti, 1995).  Although excess ROS are toxic due to its high reactivity with 
lipids, proteins and DNA, regulated ROS is pivotal for cell signalling (Vina et al., 2007; 
Calabrese et al., 2007).  Redox regulation is also crucial for apoptosis activation (Vina et al., 
2007) and excitotoxicity (Barnham et al., 2004), the two main causes of neuronal death 
(Emerit et al., 2004).  
Numerous reports evidence that Aβ deposition may be mediated by the abnormal 
metal interaction with Aβ in addition to the metal-mediated oxidative stress.  The three 
histidine residues at positions 6, 13 and 14 in the N-terminal hydrophilic region of Aβ are 
shown to provide primary metal binding sites by spectroscopic studies (Miura et al., 2000; 
Barnham et al., 2004).  Zn, Cu and Fe are all known to induce Aβ aggregation at various pH 
(Miura et al., 2000; Barnham et al., 2004).  Aluminium has been suggested to be “redox” 
active in the presence of Cu2+ and also propagate oxidative damage (Khan et al., 2006).  
However, it is likely that Al exerts its effect through the co-precipitation of Fe and Cu with Aβ 
(Exley, 2006).  Interestingly, while excessive amounts of Cu promote Aβ aggregation by 
binding to Aβ, physiological amounts of Cu inhibit Zn-induced aggregation (Suzuki et al., 
2001). Additionally, soluble Aβ degradation by metalloproteases is promoted by physiological 
levels of Cu and Zn (Strozyk et al., 2007).  Collectively these findings emphasize the 
significance of metal homeostasis in AD.  AD plaques are often described as metal sinks due 
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to their extremely high metal content.  A plethora of evidence exists for significant Zn, Cu and 
Fe dyshomeostasis in AD brains (reviewed in (Atwood et al., 1999)).  Conversely, studies 
that quantified metal levels in brains, CSF and blood of AD patients have produced 
inconsistent results (reviewed by Cuajungco and Faget, 2003).  Metal imbalance in brains 
also occurs as a consequence of normal ageing (Takahashi et al., 2001) which in turn 
aggravates the oxidative damage.  However, it is still controversial whether AD may be 
associated with higher or lower levels of Cu; perhaps the best data is pointing towards lower 
Cu levels due to the lower levels of copper enzymes (reviewed in Macreadie, 2007). 
1.1.3.6 Inflammatory responses  
Brain inflammation is also associated with AD.  It is thought that insoluble Aβ deposits 
and NFTs indirectly cause neuronal dysfunction and loss by triggering inflammatory 
responses.  For example, Aβ deposits are found co-localized with activated microglia and 
astrocytes, prostaglandins, secreted proteases, pro-inflammatory cytokines, membrane 
attack complex and acute-phase proteins (for reviews see Eikelenboom et al., 2006; 
Akiyama et al., 2000; Hoozemans et al., 2002).  These inflammatory mediators may lie 
discretely microlocalized in the early preclinical stages and may accumulate over years to 
become evident only in the terminal stages of the disease (Akiyama et al., 2000 ).  Although 
the major players are activated microglia and reactive astrocytes (Zilka et al., 2006), the 
classical complement cascade is the first to be activated after compaction of Aβ42 deposits, 
and as the plaques mature, the membrane-attack complex develops (Stoltzner et al., 2000).  
Aβ fibrils form ionic interactions with the complement proteins that can directly activate both 
the classical and the alternative complement pathways (Emmerling et al., 2000).  These 
complements then activate microglia and astrocytes through high-affinity cell surface 
receptors (Akiyama et al., 2000), resulting in the secretion of many pro-inflammatory and 
cytotoxic substances, including reactive oxygen and nitrogen species (El Khoury et al., 
1998), complement (Hoozemans et al., 2002), proteases, glutamate and nitric oxide (NO) 
(Akiyama et al., 2000) that can cause neuronal dysfunction.   
A vicious cycle of progressive inflammation, neuronal loss and Aβ plaque formation 
may occur with the aggregated Aβ (Broytman and Malter, 2004), directly activating microglia 
(Akiyama et al., 2000) and promoting production of cytokines, ROS, NO , etc. (Marx et al., 
1998; Bamberger and Landreth, 2001), while the activated microglia secrete cytokines such 
as interleukins, tumour necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β) 
(Akiyama et al., 2000), that can promote overexpression and deposition of Aβ (Marx et al., 
1998; McGeer and McGeer, 1998; Akiyama et al., 2000).  Interestingly, it has been 
suggested that the immune response may in fact be initiated as a protective mechanism 
(Zilka et al., 2006) as microglial cells and autoreactive Aβ-specific T cells can degrade Aβ 
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(Marx et al., 1998).  However, this mechanism seems to be impaired in AD leading to chronic 
and non-specific inflammation (Marx et al., 1998). 
1.1.3.7 Apoptosis 
It is suggested that apoptosis could be an early instigator of neuronal dysfunction 
(Albrecht et al., 2007) and basis for AD (LeBlanc et al., 1999; Eckert et al., 2003).  This is 
inferred from detection of active caspases in AD brains (Rohn et al., 2002; Rohn et al., 2001) 
and AD lesions (Guo et al., 2004), amplified amyloidogenic generation in neuronal cells 
undergoing apoptosis (Galli et al., 1998), processing of APP by caspase-6 and -8 (Pellegrini 
et al., 1999) or other apoptotic mechanisms (Casoli et al., 2007), regulation of programmed 
cell death by PS2 genes (Vito et al., 1996) and enhanced apoptotic susceptibility of 
mutations in PS1 (Guo et al., 1996; Guo et al., 1997; Keller et al., 1998) and PS2 (Wolozin et 
al., 1996; Araki et al., 2001).  More recently, it has been found that during apoptosis 
caspase-3 cleaves an adaptor protein required for BACE degradation and as a result 
stabilizes BACE leading to increased Aβ secretion (Tesco et al., 2007).  Given the above 
factors, it is possible that AD could be an outcome of increased vulnerability of neurons to 
various apoptotic pathways that may be exacerbated by increased oxidative stress levels 
and mitochondrial defects. 
1.1.3.8 Role of sex and age 
Ageing is associated with an increase in metabolic toxins, with a simultaneous 
decrease in defence mechanisms, making it a vulnerable stage for any disease. In fact, even 
before the discovery of plaques by 19th century German neurologists, Alois Alzheimer and 
Emil Kraepelin, AD was considered as a senility that was part of the natural ageing process 
(Kraepelin, 1910; Zilka and Novak, 2006; Goedert and Ghetti, 2007). Whether sporadic or 
genetic, AD is clearly associated with ageing (reviewed in (Zhu et al., 2007)) including age-
dependent behavioural impairments and changes in levels and species type of Aβ formed in 
the brain, CSF and plasma (Arendash et al., 2001; Kawarabayashi et al., 2001). A primate 
study portrays Aβ neurotoxicity as a pathological response most pronounced in the ageing 
brain of higher order primates (Geula et al., 1998).  
A gender difference is also apparent in AD, with a number of studies reporting a 
higher frequency of AD in women (Andersen et al., 1999; Fratiglioni et al., 1997; Gao et al., 
1998). In mouse studies, females exhibited a higher plaque load (Callahan et al., 2001) while 
males had decreased BACE activity (Schafer et al., 2007). Gender-associated differences 
were also observed with other markers associated with AD. Males had higher metal 
concentrations in various tissues (Rahil-Khazen et al., 2002; Schafer et al., 2007) while 
females produced less mitochondrial oxidants and hence suffered less oxidative damage 
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than males (Vina et al., 2007). Furthermore, a resistance to Aβ-induced mitochondrial 
aggregation that is observed only in young females disappeared with age, whereas the 
males remained susceptible right from the young age (Vina et al., 2007). A recent study 
suggests that these differences may occur due to the interactive and independent regulation 
of AD neuropathology by the sex hormones, oestrogen and progesterone (Carroll et al., 
2007). Supporting this, young female triple-transgenic AD mice showed increasing stress 
levels and reduced responses when continuously trained for cognition tests, in comparison to 
older female triple-transgenic AD mice and age-matched male triple-transgenic AD mice 
(Clinton et al., 2007).   
1.1.3.9 Role of lipids and ApoE 
Cholesterol has a long association with AD (reviewed by Puglielli et al., 2003), with 
mild hypercholesterolemia as an early risk factor (Pappolla et al., 2003).  Thus, AD and 
cerebrovascular disease (CVD) share similar metabolic profiles and risk factors.  Cholesterol, 
its precursor forms and other products of lipid metabolism have been observed to 
accumulate in brains, CSF and plasma of AD patients (Cutler et al., 2004; Wender et al., 
1994; Schonknecht et al., 2002; Lutjohann et al., 2000; Papassotiropoulos et al., 2002; 
Papassotiropoulos et al., 2000) with a correlation between increased cortical levels of free 
cholesterol and disease severity (Cutler et al., 2004).   
The polymorphic genes of AD consist of all the fundamental components of a neuron 
cholesterol shuttle including cholesterol binding lipoproteins (APOA1, APOA4, APOC1, 
APOC2, APOC3, APOD, APOE and LPA), cholesterol transporters (ABCA1, ABCA2), 
lipoprotein receptors (LDLR, LRP1, LRP8 and VLDLR) and cholesterol metabolising 
enzymes (CYP46A1 and CH25H), which clearly depicts that AD mechanisms converge on 
lipid homoeostasis (Carter, 2007).  Cholesterol impacts both Aβ assembly and degradation 
and vice versa (reviewed by Puglielli et al., 2003; Yao and Papadopoulos, 2002; Carter, 
2007; Hirsch-Reinshagen and Wellington, 2007).  Modulation of cholesterolemia in 
transgenic AD models show significant alteration in amyloid pathology (Petanceska et al., 
2003; Sparks et al., 1994).  Additionally, compartmental lipid association of APP pathway 
components has also been observed in numerous studies. Yamazaki et al observed 
remarkable Aβ accumulation coupled with cholesterol levels in late endosomes (Yamazaki et 
al., 2001).  Also, β-secretase, γ-secretase and APP have all been found to associate or 
localize in lipid rafts (Riddell et al., 2001; Hattori et al., 2006; Vetrivel et al., 2004; Vetrivel et 
al., 2005; Ehehalt et al., 2003; Cheng et al., 2007).  Furthermore, levels of ganglioside-1 
(GM-1), a lipid raft marker known to up-regulate γ-secretase activity (Zha et al., 2004), were 
enhanced in cells deficient in PS, the catalytic unit of γ-secretase complex (Grimm et al., 
2006).  
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ApoE is the brain’s chief lipid transporter and one of the best-established AD risk 
factors.  Even though the precise role of ApoE in the pathophysiology still remains vague 
(reviewed by Lambert and Amouyel, 2007), a possibility is that ApoE modulates γ-secretase 
cleavage of APP (Irizarry et al., 2004; Poirier, 2000; Hirsch-Reinshagen and Wellington, 
2007).  Another study indicates independent effects of ApoE on cholesterol metabolism and 
brain Aβ levels (Mann et al., 2004).  There are high serum cholesterol levels in the absence 
of ApoE ε4 allele (Evans et al., 2000) and studies show that the ε4 allele influences AD 
pathogenesis by favouring vascular over parenchymal accumulation of Aβ, resulting in the 
cerebral amyloid angiopathy (CAA) phenotype (Chalmers et al., 2003; Fryer et al., 2005).  
APP processing is influenced by cholesterol/lipoprotein function, atherosclerosis and 
cerebrovascular function and vice versa (reviewed by Carter, 2007).  Hence changes to Aβ 
levels may also be an indirect consequence of the reduced cerebral perfusion induced by 
atherosclerotic changes observed in AD (Carter, 2007).   
1.1.3.10 Other hypotheses 
A few limitations in the Amyloid Cascade Hypothesis and contradicting results in other 
studies have led to the emergence of several other hypotheses: 
 Alternate Amyloid Hypothesis has been proposed by Lee et al according to which the 
aforementioned risk factors amplifies oxidative stress which then leads to increases in Aβ 
and AD by independent pathways (Lee et al., 2006).  This hypothesis does not explain the 
role of Aβ in AD and the authors are unclear whether Aβ is a cause of or a response to AD.   
Myelin Hypothesis explains the anatomical distribution and progressive course of 
AD pathology.  It is proposed that late-stage disintegrating myelin enhances build-up of toxic 
Aβ fibrils that in due course deposit in the brain to form plaques (Bartzokis, 2004).  The brain 
cortex holds the most prolonged development time for oligodendrocytes, which differentiate 
into myelin-producing cells late in the fifth decade of life, hence they may be more prone to 
stresses. Indeed it has been observed that oligodendrocytes are more susceptible than other 
brain cell types to chronic hypoperfusion (Kurumatani et al., 1998), toxic products of 
microglial activation such as nitric oxide (Mitrovic et al., 1995; Sloane et al., 1999), iron 
toxicity (Kress et al., 2002) and excitotoxicity (McDonald et al., 1998).  In addition, 
oligodendrocyte precursors are particularly vulnerable to oxidative damage (Back et al., 
1998; Husain and Juurlink, 1995) which may expose actively myelinating intracortical and 
subcortical regions as well.  The increased susceptibility of oligodendrocytes is due to their 
metabolic demands, unique functions, structure and biochemistry (Bartzokis, 2004; Bauer et 
al., 2002).  This vulnerability is further aggravated with increasing age, as later-differentiating 
cells myelinate increasing numbers of axonal segments (Bartzokis, 2004).  The advancing 
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pattern of myelin breakdown may provide a course through which AD pathology could slowly 
proceed with progressive disruption to signal transmission and synchrony of the extensive 
neural networks underlying normal brain function, including cognition and memory (Bartzokis, 
2004).  
Cell cycle hypothesis proposes that either mitogenic signalling or cell cycle control, 
or both, are unstable in AD neurons (Bowser and Smith, 2002).  Increased chromosome 
number (typical of cells beginning to divide) and increased levels of cell cycle-related 
proteins were found in neurons prior to plaque formation in an APP transgenic mouse model 
(Yang et al., 2006).  The cell-cycle malfunction has been attributed to the failure of gene 
silencing and synaptic plasticity elicited by the abnormal subcellular distribution and 
segregation of origin recognition complex (ORC) proteins in AD (Arendt and Bruckner, 2007).  
Interestingly, Aβ binds to integrins and activates focal adhesion (FA) proteins by mediating 
signal transmission from the extracellular Aβ deposits into the cell (Grace and Busciglio, 
2003).  These Aβ induced integrin/FA signalling pathways are known to mediate cell cycle 
activation and cell death (reviewed by Caltagarone et al., 2007). 
1.1.4 Hurdles in AD research 
The diagnosis of AD is difficult due to its slow progression.  Current AD treatments 
focus on symptoms and fail to target the etiological mechanisms.  The acquisition of brain 
samples for accurate histochemical information in different phases of the disease is 
impossible while the patient is alive.  Hence the disease is studied in various models.  
Experiments in these models are yet again difficult to interpret due to the heterogeneity of the 
disease and the multi-faceted nature of the proteins involved.  Despite these complexities, 
researchers are developing therapeutic strategies that focus on the mechanisms described 
above.  Indeed it is the multifactorial nature of AD itself that provides the basis for the large 
number of therapeutic targets and different strategies. 
1.1.5 AD model systems  
AD research is carried out using a variety of research models that include in vitro 
systems, cell models and transgenic animals for the purpose of drug evaluation, 
development of diagnostics and elucidation of disease mechanisms. 
1.1.5.1 Animal models   
Most transgenic AD animal models are genetically engineered for the over-
expression of an FAD APP mutation or particular fragments of human APP, to ideally show 
age-dependent development of amyloid plaques, tangles, cell death and cognitive 
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deterioration (McGowan et al., 2006; Phinney et al., 2003; Gotz et al., 2007).  Hence they are 
of immense value to gain knowledge about AD mechanisms pertaining to specific genes and 
proteins involved.  For instance, alteration of Aβ40:Aβ42 ratio and enhancement of CAA by 
human apoEε4 was ascertained from an APP transgenic model (Fryer et al., 2005). 
AD animal models that provide information on Aβ deposition and memory impairment 
are most popular in drug testing as these attributes are considered relevant to AD 
pathogenesis.  Mouse models have been used for testing a range of approaches including 
ACE inhibitors (Hemming et al., 2007), immunization (Schenk et al., 1999; Games et al., 
2000; Vehmas et al., 2001; Morgan et al., 2000), environmental enrichment (Berardi et al., 
2007) and imaging (Moreno et al., 2007).  Apart from single, double and triple transgenic 
mice (Duyckaerts et al., 2008), other animal models used in AD research are rabbits 
(Woodruff-Pak et al., 2007), hamsters (Hartig et al., 2007), guinea pigs (Arjona et al., 2002), 
non-human primates (Kulstad et al., 2005), fruit flies (Li et al., 2007; Ganguly et al., 2008) 
and worms (Link, 2006; Smialowska and Baumeister, 2006).   
A difficulty with any model is its relevance to AD. Since animals do not have an 
equivalent to AD, extrapolation is essential (reviewed by Duyckaerts et al., 2008; Duff and 
Suleman, 2004).  Animal models are also very expensive and time-consuming, with years 
being required to reproduce an ageing process.  In addition, animal models are never suited 
to analyses of large numbers of compounds.  Therefore, additional model systems, such as 
those outlined below, are important.   
1.1.5.2 Cell models 
Cell models may be used to dissect molecular mechanisms of AD and are more 
amenable to high-throughput screening.  Owing to the similarity of proteins, biochemical 
pathways and cell biology between humans and unicellular organisms, a number of bacterial 
(Wurth et al., 2002; Kim et al., 2006; Kim and Hecht, 2006) and yeast models (Caine et al., 
2007; von der Haar et al., 2007; Bagriantsev and Liebman, 2006; Treiber et al., 2004) have 
been engineered to study AD.  Of course, mammalian cell culture is also useful and essential 
for the study of AD with a huge choice of cell types, ranging from transformed non-neuronal 
cells (Buckig et al., 2002) to primary neuronal cells (Lee et al., 2006).  However, mammalian 
cell culture is more complex and expensive than that of microbial cells.   
1.1.5.3 In vitro models 
In vitro models are also very useful to dissect molecular mechanisms of AD and to 
perform high throughput screening.  In vitro studies include Aβ peptide fibril formation assays 
(Raman et al., 2005; Yagi et al., 2007; Inouye and Kirschner, 2000), systems mimicking 
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biological fluids  and model membranes (Mobley et al., 2004; Tashima et al., 2004; de 
Planque et al., 2007; Choucair et al., 2007).  Advantages of in vitro models include their high 
simplicity in comparison to animal and cellular models, making them very amenable to 
interpretation, scale up, reproducibility and robotic manipulation.  
In silico modelling of Aβ structure via computational biology is yet another model 
study (Jang et al., 2008).  
1.1.6 AD therapeutics 
Current AD treatments target cognitive decline or failure and may provide minor 
benefits across the array of symptoms (Omerovic et al., 2007; Tariot, 2006).  Nevertheless, 
the approved AD drugs such as the anti-choline esterase inhibitors (e.g. Aricept, Namenda, 
Exelon, etc.) and N-methyl-D-aspartate (NMDA) receptor antagonists (e.g. Memantine) that 
are prescribed in monotherapy or in combination, are expensive, may have adverse 
reactions and most importantly, do not prevent disease progression (reviewed by Raschetti 
et al., 2007; Jelic et al., 2006).  
Research for therapeutic interventions has intensely focussed on the complex 
etiology for more effective treatments (Seabrook et al., 2007).  However, the physiological 
importance of Aβ in normal cellular function (Pearson and Peers, 2006; Grimm et al., 2007; 
Grimm et al., 2005; Selkoe, 2006) raises specific concerns in eliminating Aβ for therapeutic 
purposes.  In fact, the progress of earlier approaches including blockers for Aβ production 
and accumulation, Aβ catabolic accelerators, anti-oxidants, metal chelators, vaccines, 
antibodies against Aβ, etc. have been hampered due to side-effects (reviewed by Selkoe and 
Schenk, 2003; Vardy et al., 2005; Orgogozo et al., 2003).  This may partly be due to the 
adverse effects on the normal functions of Aβ and other proteins involved, thereby upsetting 
cellular homeostasis.  The significance of both trophic and toxic properties of Aβ in 
comparison to each other has been reviewed (Atwood et al., 2003).  Given the physiological 
and pathological importance of Aβ, APP and other cleavage products of APP, the essential 
criteria for safe and effective therapeutics would be to target the selective imbalance while 
permitting the normal functions to remain considerably stable.  At present, some compounds 
that may address the imbalance of APP and its derivatives are reaching clinical assessment. 
1.1.6.1 Therapeutic targets 
AD is complex, as is Aβ, which can be considered the main target for therapeutic 
intervention.  Apart from targeting Aβ itself, many strategies have been devised based on 
other reasonable molecular targets, such as α-, β- and γ- secretases, APP, Apo E and tau 
protein, as well as other mechanisms involved in AD pathogenesis.  While pursuing causal 
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factors, research is also underway into new anti-cholinesterase inhibitors with increased 
potency and additional properties like anti-oxidant activity and receptor affinity (Musial et al., 
2007; Shirey et al., 2008), and also in the better tolerated NMDA agonists for greater 
neuroprotective properties (Chen and Lipton, 2006; Lipton, 2007). 
1.1.7 Web references for AD research updates 
 AD research is moving at a rapid pace, making it difficult to provide a completely up-
to-date review.  The websites listed below continually provide new updates on AD 
developments.   
♦ Alzheimer's Association (http://www.alz.org/) is the prime national voluntary health 
organization of the U.S. devoted to AD research and development and it also 
provides education and support for patients, their families and caregivers. 
♦ Alzheimer Research Forum (http://www.alzforum.org/), founded in 1996, is an 
online scientific community dedicated to develop treatments and preventions for AD.  
It provides regularly updated web resources for researchers and discussion forums 
that promote debate and faster distribution of novel ideas, thus eliminating barriers 
that inhibit multi-disciplinary research and thereby universally contributing to better 
treatments for AD. 
♦  Alzheimer Disease & Frontotemporal Dementia Mutation Database 
(http://www.molgen.ua.ac.be/ADMutations/), launched in September 1999, is a locus-
specific database that gathers all known mutations and non-pathogenic coding 
variations in genes related to AD and frontotemporal dementia (FTD) according to the 
guidelines of the Human Genome Variation Society (Horaitis et al., 2007).  The 
database is systematically updated and includes mutations reported in the literature, 
at scientific meetings and unpublished mutations directly submitted to the database. 
1.2 STRATEGY OF THIS RESEARCH 
As outlined above, our current understanding of the precise cause of AD is 
incomplete due to uncertainties in experimental models and the multi-faceted nature of Aβ.  
Although Aβ is a naturally-occurring protein, an accelerated production of this amyloidogenic 
protein leads to AD via unknown triggering mechanisms. This project aims to elucidate the 
biological effects and toxic mechanisms of intracellular Aβ by investigating the cellular 
responses and interactions of this pleiotrophic protein in the yeast cytosol.  
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1.2.1 Significance of cytosolic Aβ 
The literature portrays two different pools of Aβ in cells: secreted (majority) or 
intracellular (minority) (see Table 1.1). Whether Aβ acts from within cells or from the 
extracellular space to injure cells is a topic of on-going controversy amongst AD researchers 
(see Table 1.3). However, the cytosolic location of Aβ is worthy of strong consideration as 
there are numerous reports of Aβ having a cytoplasmic localization and of this Aβ initiating 
AD (Glabe, 2001; Wirths et al., 2004). Cytoplasmic Aβ has also been found in the eye lenses 
and brains of AD patients (Gouras et al., 2000; Goldstein et al., 2003), CHO cells (Buckig et 
al., 2002), human neuroblastoma cells (Lee et al., 2006) and brains of Aβ transgenic mice 
(Billings et al., 2005).  In addition, there may be a possibility for secreted extracellular Aβ to 
re-enter and damage neuronal cells, while presumably being exposed to the cytosol. 
Mounting evidence from animal models and AD patients implicate intracellular Aβ 
accumulation in disease progression (Tabira et al., 2002; LaFerla et al., 2007). For these 
reasons, Aβ fused to green fluorescent protein (GFP) has been produced in the cytosol of 
the eukaryotic model, yeast to monitor its presence and properties (Caine et al., 2007).  
1.2.2 Yeast as an excellent model for study 
A unicellular model like yeast is advantageous because of its fundamental similarity 
to human cells, and the availability of a wide range of experimental resources in yeast, 
especially for drug discovery (Ma, 2001).  Yeast has already made contributions to 
neurobiology (Walberg, 2000).  In yeast, the aggregation/misfolding of Aβ (Bagriantsev and 
Liebman, 2006; Caine et al., 2007) as well as its cytotoxicity (Bharadwaj et al., in press) has 
been observed, making it possible to embark on studies to look for chemo preventatives of 
these activities. 
1.2.3 Aims of this research 
The main focus of this research has been to decipher the mechanisms of influence exerted 
by Aβ on living cells. The questions addressed are: 
♦ What levels of toxicity does Aβ produce in living cells? 
♦ How does Aβ affect cell metabolism and AD pathogenesis? 
♦ What other cellular factors influence Aβ toxicity? 
♦ What factors influence the aggregation of normal Aβ into pathological plaques? 
♦ How can the toxic influences of the above be inhibited or prevented? 
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More precisely, the objectives can be summarised as:  
1. Study the expression profile of yeast cells in the presence of Aβ, using yeast genome 
microarrays. 
2. Analyse cellular responses and interactions of Aβ using molecular and cell biology 
techniques 
3. Develop in vivo assays to screen compounds that might competitively inhibit Aβ 
binding. 
The identification of cellular pathways affected by Aβ and the development of screening 
assays for inhibitory compounds in simple genetic organisms like yeast can lead to novel 
chemo-preventatives. The ultimate benefit is the amelioration of AD. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Yeast media 
The following media were used to culture the different yeast strains: 
1. YEPD (rich media) Æ 1% yeast extract (Difco), 2% peptone (Difco), 2% glucose 
(dextrose) 
2. YNB (SD minimal media) Æ 0.67% yeast nitrogen base (Difco), 2% glucose.  
3. Synthetic complete media Æ YNB media was supplemented with 20mg/L each of uracil, 
tryptophan, adenine, arginine, methionine, and histidine, 30mg/L each of tyrosine, 
leucine, isoleucine and lysine, 50mg/L phenylalanine, 100mg/L each of glutamic acid and 
aspartic acid, 250mg/L valine, 200mg/L threonine and 400mg/L serine. 
4. Selective media:  
♦ YNB media was supplemented with amino acids as follows: 
i. YNB + H Æ YNB with histidine 
ii. YNB + U Æ YNB with uracil 
iii. YNB + HAT Æ YNB with histidine, adenine and tryptophan 
iv. YNB + HATL Æ YNB with histidine, adenine, tryptophan and leucine 
v. YNB + HATUL Æ YNB with histidine, adenine, tryptophan, uracil and 
leucine 
♦ Amino acids were omitted from synthetic complete media as follows: 
i. Minus Ura Æ synthetic complete media without uracil 
ii. Minus Leu Æ synthetic complete media without leucine 
iii. Minus His Æ synthetic complete media without histidine 
For solid media, 2% agar (Merck) was added. 
2.1.2 Yeast strains 
Yeast strains used in this work are listed in Table 2.1 with source or reference. The table also 
provides information on the genotype of each strain. All yeast strains were either grown in 
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liquid media (with aeration) or on solid media at 30°C. Wild-type yeast strains were 
preferably grown in rich media (YEPD) for all experiments in this study, except in section 4.4, 
where they were grown in minimal media. Recombinant clones with plasmid(s) were grown in 
selective media in the absence of the respective amino acid for the selection of plasmid(s). 
Table 2.1 Yeast strains used in this study 
Strain Genotype Source and 
Reference 
W303-1A MATa leu2-3,112 trp1-1 can1-100 
ura3-1 ade2-1 his3-11,15 
Prof. Ian G Macreadie (CSIRO-Molecular 
and Health Technologies) Reference: 
Caine et al., 2007 
BY4741 MATa his3∆1 leu2∆0 met15∆0 LYS2 
ura3∆0 
Dr. Gabriel Perrone (Dawes Lab, 
University of New South Wales) Original 
reference: Euroscarf (EUROpean 
Saccharoymces Cerevisiae ARchive for 
Functinal analysis) 
BY4743 MATa/MATα his3∆1/his3∆1 
leu2∆0/leu2∆0 met15∆0/MET15 
LYS2/lys2∆0 ura3∆0/ura3∆0 
Dr. Gabriel Perrone (Dawes Lab, 
University of New South Wales) Original 
reference: Euroscarf (EUROpean 
Saccharoymces Cerevisiae ARchive for 
Functinal analysis) 
MW98-8C 
(K. lactis) 
 
MATα uraA arg lys K' Prof. Ian G Macreadie (CSIRO-Molecular 
and Health Technologies) Original 
reference: Macreadie et al., 1991 
ahp1 (AHP1::kanmx derivative of BY4743)  
MATa/MATα his3∆1/his3∆1 
leu2∆0/leu2∆0 met15∆0/MET15 
LYS2/lys2∆0 ura3∆0/ura3∆0 
AHP1::kanmx 
Dr. Gabriel Perrone (Dawes Lab, 
University of New South Wales) Original 
reference: Saccharomyces Genome 
Deletion Project 
p82a* w303-1A hsc82::LEU2 hsp82::LEU2 
HIS3-GPD-HSP82 
Dr. Peter Piper (University of Sheffield, 
Western Bank, UK) Original reference: 
Nathan and Lindquist, 1995  
hsp82E381K* w303-1A hsc82::LEU2 hsp82::LEU2 
HIS3-GPD-hsp82 E381K 
Dr. Peter Piper (University of Sheffield, 
Western Bank, UK) Original reference: 
Nathan and Lindquist, 1995  
* The integrated wild -type (HSP82) or mutant (hsp82) gene for HSP90 is the only functional HSP90 
gene in these strains and is expressed under the control of the constitutively active glyceraldehyde-3-
phosphate dehydrogenase (GPD1) gene promoter and not HSF (Nathan and Lindquist, 1995). 
2.1.3 Bacterial media 
The following media were used to culture bacterial strains: 
1. 1 x YT Æ 0.8% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract and 0.5 % (w/v) 
NaCl 
2. 2 x YT Æ 1.6% (w/v) bacto-tryptone, 1% (w/v) bacto-yeast extract and 0.5 % (w/v) 
NaCl 
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3. SOB Æ 2% (w/v) bacto-tryptone, 1% (w/v) bacto-yeast extract and 0.05% (w/v) NaCl, 
10mM MgCl2. 
4. SOC Æ 20ml of filter sterile 1M glucose per litre of SOB 
2.1.4 Bacterial strains 
Bacterial strains were used only for plasmid amplification and obtained from Prof. Ian G 
Macreadie (CSIRO-Molecular and Health Technologies, Parkville, Australia). Bacteria were 
grown in liquid or on solid media at 37°C. 
The strains used in this study are as follows: 
♦ MC1061 Æ ∆(ara-leu)7697 araD139 galK16 galE15 mcrA0 relA1 rpsL150 spoT1 
mcrB9999 hsdR2 F- 
♦ BL21 (DE3) Æ F- ompT hsdSB (rB- mB-) gal dcm (DE3) 
2.1.5 Plasmids 
The different plasmids used in this study are listed in Table 2.2 with all related information. 
All plasmids encoding Aβ and its mutations were prepared by Sonia Sankovich (CSIRO-
Molecular and Health Technologies, Parkville, Australia) and plasmids encoding HSE 
reporters were gifts of Dr. Dennis Winge (University of Utah, Salt Lake City, UT) and Prof. 
Peter Piper (University of Sheffield, Western Bank, UK). 
2.1.6 Buffers 
♦ 10 x PBS (phosphate buffered saline) Æ 8% (w/v) NaCl, 0.2% (w/v) KCl, 1.44% (w/v) 
Na2HPO4, 0.24% (w/v) KH2PO4, pH 7.4 with HCl 
♦ RNA sample bufferÆ 10% sucrose ,90% Deionised formamide, 0.05% bromophenol 
blue  
♦ 5 x SDS gel loading buffer Æ 200mM Tris, 25% glycerol, 12.5% β-mercaptoethanol, 
5% SDS, 0.2% bromophenol blue 
♦ SDS-PAGE running buffer (NuPAGE MES) Æ 50mM MES, 50mM Tris base, 0.1% 
SDS, 1mM EDTA, pH 7.3 
♦ 1 x Western transfer buffer Æ 20mM Tris base, 160mM glycine, 20% methanol 
♦ Z buffer (Miller, 1972) Æ 60mM Na2HPO4.7H2O, 40mM NaH2PO4, 10mM KCl, 1mM 
MgSO4.7H2O, 40mM β-mercaptoethanol (added only before use in each experiment), 
pH 7.0, stored at room temperature without addition of β-mercaptoethanol. 
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Table 2.2 Plasmids used in this study 
 Name of 
plasmid 
Mutations  
(if any) 
Selective 
marker 
Reference or 
Description 
C-terminal Aβ42 fusion pAS1N.Aβ42GFP  - LEU Caine et al., 2007 
N-terminal Aβ42 fusion 1 pAS1N.GFPAβ42  - LEU Caine et al., 2007 
N-terminal Aβ42 fusion 2 p416.GFPAβ42  - URA Constructed by 
Sonia Sankovich 
(CSIRO-MHT) 
GFP plasmid 1 pAS1N.GFP  - LEU Caine et al., 2007 
GFP plasmid 2 p416.GFP  - URA Constructed by 
Sonia Sankovich 
(CSIRO-MHT) 
Aβ variants pAS1N.GFPAβ40 
pAS1N.GFPAβ28 
p416.GFPAβ16 
 - LEU 
LEU 
URA 
Constructed by 
Sonia Sankovich 
(CSIRO-MHT) 
Single mutants of Aβ42 pAS1N.Aβ42GFP M35V  
M35S 
LEU 
LEU 
University of 
Melbourne 
Double mutants of Aβ42 pAS1N.GFPAβ42 I32N/V36A 
M35R/V36E 
F19S/L34P 
LEU 
LEU 
LEU 
Constructed by 
Sonia Sankovich 
(CSIRO-MHT) 
Histidine mutants of 
Aβ42 
pAS1N.Aβ42GFP H13N  
H13N/H14N 
H13N/H14N/H6N
LEU 
LEU 
LEU 
University of 
Melbourne 
FAD mutants of Aβ42 pAS1N.Aβ42GFP E22Q (Dutch) 
D23N (Iowa) 
LEU 
LEU 
Constructed by 
Sonia Sankovich 
(CSIRO-MHT) 
HSE reporter 1 (HSE)-lacZ  - URA Sorger and 
Pelham, 1987 
Mutant HSE reporter (mt HSE)-lacZ  - URA Sorger and 
Pelham, 1987 
HSE reporter 2 KHSE  - LEU Prof. Peter Piper 
(University of 
Sheffield, Western 
Bank, UK) 
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2.1.7 Other solutions and reagents 
♦ Coomassie stain solution Æ Coomassie blue R-250 in 20% (v/v) ethanol and 10% 
(v/v) glacial acetic acid 
♦ Destain solution Æ 10% (v/v) glacial acetic acid, 20% (v/v) ethanol 
♦ 20 x SSC (stock) Æ 3M NaCl, 0.3M sodium citrate, pH 7.0 
♦ Hybridisation solution mix 1 for (microarray experiment 1) Æ 6 x SSC, 5 x Denhardt's 
solution, 0.5% SDS, 50% deionised formamide 
♦ Hybridisation solution mix 2 for (microarray experiment 2) Æ 400µl filtered new Dig 
Easy Hyb, 8µl tRNA and 11µl Herring Sperm (can be used for 4 microarray reactions) 
♦ Wash solutions for microarrays Æ 1 x SSC + 0.1% SDS, 1 x SSC and 0.1 x SSC 
prepared in double filtered milli Q water. 
♦ Blocking solution for western blots Æ 1% casein in PBS 
♦ 50 x TMB Æ 50mg 3,3’,5,5’-tetramethylbenzidine in 10ml ethanol 
♦ Citrate-EDTA solution Æ 10mM EDTA, 10mM sodium citrate in milliQ water, pH 5.5 
♦ Dextran sulphate solution Æ 1% (w/v) dextran sulphate in Citrate/EDTA solution 
♦ TMB colour reagent for western blots Æ 1 x TMB, 0.0002% H2O2 in 1% dextran 
sulphate solution (prepared fresh for each experiment) 
♦ ONPG reagent Æ 4mg/ml o-nitrophenyl-β-D-galactoside in Z buffer (prepared fresh 
for each experiment) 
♦ Ampicillin Æ 50µg/ml ampicillin in sterile water 
♦ Clioquinol (Sigma-Aldrich) Æ Appropriate amounts of clioquinol were dissolved in 
100% DMSO and stored in foil covered tubes at -20°C for future use 
♦ GSH Æ 0.5M reduced glutathione in ethanol 
♦ DTT Æ 1M di-thiothreitol in sterile water 
♦ Propidium iodide solution Æ 30mM propidium iodide in water 
 
2.2 METHODS 
2.2.1 DNA methods 
2.2.1.1 Preparation of CaCl2 competent bacterial cells for transformation 
Cells were grown overnight in 5ml of 2 x YT at 37°C. This was inoculated into 500ml of 2 x 
YT and grown further at 37°C until they reached a cell density of A600 of 0.3. Cultures were 
then centrifuged at 8,000rpm for 10min. at 4°C. After discarding supernatant, pellet was 
gently resuspended in a small amount of chilled 0.1M CaCl2 and made up to 250ml with the 
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same. The cell suspension was left on ice for 45min. and centrifuged as before. The pellet 
was again resuspended in 12.5ml chilled 0.1M CaCl2. Sterile 80% (v/v) glycerol was added 
by gentle swirling to a final concentration of 10%. The cells were then dispensed in 40-100µl 
aliquots in eppendorf tubes and frozen on dry ice before storage at -80°C. These were 
prepared “in-house”. 
2.2.1.2 Bacterial transformation 
Competent cells were thawed completely on ice for 15min. 4µl aliquots of competent cells 
were incubated on ice with 0.5-2.0µl plasmid DNA for 15-30min. The mixture was heat-
shocked at 42°C for 45 sec. and immediately placed on ice for 5-10min. 200-400µl of SOC 
was added to this and incubated at 37°C for 30-45min. 200µl of cells were finally plated onto 
pre-warmed 1 x YT + ampicillin plates and incubated overnight at 37°C. 
2.2.1.3 Plasmid purification – “Miniprep” 
QIAprep® Spin Miniprep Kit from Qiagen was used for the purification of high copy plasmids. 
The procedure is a modified version of alkaline lysis method of Birnboim and Dolly (1979). 
Bacterial overnight cultures (1-5ml) were lysed under alkaline conditions. The lysate was 
neutralized, adjusted to high-salt binding conditions and loaded onto the QIAprep silica-gel 
membrane for DNA binding. Plasmid DNA was then eluted with sterile water and stored at -
20°C. Details of the procedure can be found in the QIAprep Miniprep® Handbook. 
2.2.1.4 Yeast transformation 
2.2.1.4.1 Method 1 (Long method) 
The protocol was adapted and modified from the high efficiency transformation 
method of Gietz and Schiestl (1995). For 10 transformations, 50ml YEPD media was 
inoculated with 5ml overnight culture and incubated for 4 hours at 30°C. Cells were 
harvested at 2500rpm for 5-10min. at room temperature. After discarding supernatant, pellet 
was washed in 25ml sterile water and centrifuged as before. The pellet was again washed 
with 1ml 0.1M LiAc, centrifuged at 12000rpm for 1min, resuspended in 0.1M LiAc to a final 
volume of 500µl and vortexed. The vortexed mixture was dispensed in 50µl aliquots into 10 
eppendorfs for individual transformations, centrifuged and the supernatant removed. For 
each transformation, the following mix was added in the listed order to the cells: 240µl of 
50% (w/v) PEG, 36µl of 1M LiAc, 25µl of 2mg/ml single-stranded carrier DNA (boiled for 5min 
and quickly chilled on ice) and 50µl of plasmid DNA. The mixture was then vortexed for 1min, 
followed by incubation at 30°C for 30min. The mixture was then heat-shocked at 42°C for 20-
25min. and centrifuged at 8000rpm to remove the “transformation mix”. Pellets were 
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resuspended in 200µl-1ml sterile water, plated onto selective media in 200µl aliquots and 
incubated at 30°C. 
2.2.1.4.1 Method 2 (Short method) 
Method 1 was later replaced by this method, which is a quicker version of the above 
method. For each transformation, 300µl-1ml culture was grown overnight at 30°C in YEPD 
media and harvested the next day at 12000rpm for 1min. Pellet was washed with 500µl-1ml 
sterile water, centrifuged as before, resuspended in 1.5ml of 0.1M LiAc and incubated at 
30°C for 5min. After centrifugation (as before) to remove LiAc, the “transformation mix” was 
added in the following order: 240µl of 50% (w/v) PEG, 36µl of 1M LiAc, 50µl of 2mg/ml 
single-stranded carrier DNA (boiled for 5min and quickly chilled on ice), 5µl of plasmid DNA 
and 20µl of sterile water. The mixture was vortexed for 1min, heat-shocked at 42°C for 
20min. and centrifuged again. Pellets were resuspended in 250µl sterile water, plated onto 
selective media and incubated at 30°C. 
In the case of double transformants, strains were grown in YEPD, transformed with one 
plasmid, grown in selective media and then transformed with the second plasmid. 
2.2.2 Microarray methods 
2.2.2.1 RNA preparation 
2.2.2.1.1 RNA isolation 
Total RNA was isolated from recombinant clones using the Trizol method. Cultures 
were grown overnight in selective media, refreshed the following day with fresh media to 1/5 
of the culture volume and grown until they reached log-phase. Cells were harvested at 
5000rpm for 10min. and resuspended in trizol to 20 x volume of cell pellet. To this cell 
suspension, 0.4-0.6µm glass beads were added to ½ the volume, vortexed for 2min. and 
incubated at 65°C for 3min. 100µl chloroform was added to the above, shaken vigorously by 
hand for 15sec., incubated at room temperature for 5min. and centrifuged at 12000rpm for 
10min. at 4°C. The clear top face was gently transferred to a clean tube and 250µl 
isopropanol was added. The tube was slowly inverted 5-6 times, incubated at room 
temperature for 10min. and centrifuged as before. After discarding the supernatant the pellet 
was washed with cold 75% ethanol and centrifuged as before. The resulting supernatant was 
quickly and carefully discarded and centrifuged again to remove any residual ethanol. For 
every 5ml culture harvested, 100µl DEPC treated water was added to the tube to dissolve 
the RNA.   
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Special care was taken to prevent RNA lysis. All tubes and eppendorfs used were RNase-
free. Any materials used in DNA preparation were avoided as they may contain RNase. All 
solutions were made fresh with DEPC treated water. Glass beads used were heated to 
120°C for 30min. and stored in a cleaned sealed jar. Lids of tubes and eppendorfs were not 
left open to avoid RNase contamination. Pipettes used were rinsed with ethanol and pipette 
tips contained filter plugs.  
2.2.2.1.2 RNA purification 
In order to purify the isolated total RNA, DNase digestion was done using the cleanup 
protocol from Qiagen® RNeasy Minelute kit. The RNA isolated as above was adjusted to 
column binding conditions and loaded onto the RNeasy silica-gel membrane for RNA 
binding. RNA was then eluted with DEPC treated water and stored at -20°C. Details of the 
procedure can be found in the Qiagen® RNeasy Handbook. The amount and purity of the 
cleaned RNA was checked on a spectrophotometer using A260 /A 280 ratio. 
2.2.2.1.3 Native Gel Electrophoresis for RNA 
Degradation of RNA was checked on 1% agarose gel. The RNA sample was mixed 
with an equal volume of RNA sample buffer and heated to 60-65°C for 2-3min. The mixture 
was then cooled to room temperature, loaded onto the gel and run at 100V. After sufficient 
electrophoresis gels were stained in ethidium bromide solution. The bands were visualised 
under UV light and photographed. 
2.2.2.1.4 Ethanol precipitation 
Pure RNA was concentrated by ethanol precipitation using a method adapted from 
Invitrogen manual L1014-02. 3M sodium acetate (pH 5.2) was added up to 0.2 x volume of 
RNA. To this ice cold absolute ethanol was added to 6 x volume of RNA and incubated at -
20°C for 30min. to overnight. After incubation the suspension was centrifuged at 12000rpm 
for 10-20min. at 4°C. The supernatant was removed carefully and discarded. Next, 250µl of 
ice cold 75% ethanol was added and centrifuged 12000rpm for 2min. at 4°C. The 
supernatant was again carefully removed. Sample was air-dried for 10min. and resuspended 
in DEPC treated water. 
2.2.2.2 cDNA synthesis and fluorescent labelling 
This was done using the Invitrogen cDNA synthesis and labelling plus kit (L101505) that 
uses anchored oligo(dT)20 primers, SuperScriptTM III RT, Alexa Fluor® 555- labelled 
nucleotides and Alexa Fluor® 647- labelled nucleotides. Briefly, the method was as follows: 
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Pure total RNA was incubated with the anchored oligo(dT)20 primers at 70°C for 10min., 
placed on ice for 1-2min. and then incubated with buffer, 0.1M DTT, Alexa Fluor®-labelled 
nucleotide mix, RNaseOUT  and SuperScriptTM III RT  at 46°C in the dark for 3 hours. After 
cDNA synthesis, hydrolysis with 0.1M NaOH was performed to degrade the original RNA and 
neutralized with 0.1M HCl. For purification, cDNA was prepared for column binding with 
buffers provided in the kit and eluted with DEPC treated water. The eluate contained purified 
labelled cDNA which was stored at -20°C in amber coloured eppendorf. For details refer the 
kit manual. 
The Alexa Fluor®-labelled nucleotide mix used for each RNA sample is shown in Table 3.1. 
2.2.2.3 Microarray sample preparation 
Fluorescently labelled cDNA samples were dried in speedivac for 20min. until 10µl remained. 
The dye-swapped samples (i.e. samples to be hybridised on the same array slide) were 
combined and dried in speedivac until 5µl remained (~10min.). To this, 88µl of hybridisation 
solution mix was added, heated at 65°C for 5min. and cooled to room temperature in a dark 
box. For experiment 1, the hybridisation solution mix 1 was pre-warmed to 42°C before 
adding to sample. For experiment 2, hybridisation solution mix 2 was used without pre-
warming. 
2.2.2.4 Microarray slide preparation and blocking 
Microarray slides were baked for 4-5 hours at 80°C and stored in a slide box until used. To 
prepare the slides for hybridisation, they were washed (in the listed order) for each 
experiment: 
Experiment 1 Æ in 1x SSC + 0.1 % SDS, 1 x SSC, 0.1% SSC and twice with milli Q water – 
all 5min. each 
Experiment 2 Æ in boiling 0.1% STS for 5min., 5% ethanol for 1min. at room temperature 
and twice with milli Q water for 1min. each  
While washing, special care was taken to prevent drying of slides. To keep the slides wet, 
they were constantly agitated. All washing solutions were filtered and stored in very clean 
bottles. 
2.2.2.5 Microarray hybridisation  
Arrays of experiment 1 were hybridised using an automated incubation system (Advalytix) 
that incorporates fluid handling technology based on surface acoustic waves; whereas arrays 
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of experiment 2 were hybridised in a normal manual hybridisation chamber. The procedures 
were as follows:  
Experiment 1 Æ The cover slips were cleaned in milli Q water and isopropanol prior to use. 
The array slide and cover slip were affixed in the hybridisation chamber according to manual 
instructions.  Then 79µl of the prepared sample was carefully loaded. 
Experiment 2 Æ The cover slips were cleaned in milli Q water and isopropanol prior to use. 
Slide boxes were used as hybridisation chambers. The bottom of the boxes was lined with 
tissues soaked in hybridisation solution mix to create the required humidity. The array slides 
were placed horizontally across the box on the edges of the slide dividers. 79µl of the 
prepared sample was carefully loaded on to the slide onto which the cover slip was slowly 
lowered without air bubbles.  
Hybridisation was carried out at 37°C overnight (at least 16 hours). 
2.2.2.6 Post-hybridisation processing 
 After hybridisation, slides were washed in different solutions in foil covered 50ml falcon 
tubes. All solutions were pre-warmed to 50°C to prevent the precipitation of SDS on the array 
slides. First, the arrays were immersed in 1x SSC +0.1% SDS solution for cover slip removal. 
Care was taken to remove the cover slip gently with forceps. The slides were then washed in 
1 x SSC + 0.1% SDS solution twice for 15min. and once for 20min.  Final wash was done in 
1 x SSC for 5-8 times (15min.each). For experiment 1, the slides were further washed in 
filtered milli Q water (2-3 times). After washing, slides were dried by placing in falcon tubes 
and centrifuging at 800rpm for 8min. Any traces of moisture that were left on the slide, were 
dried off very gently using clean compressed air from an air-gun. Finally the bottom of the 
slide was cleaned with isopropanol to remove any dust or smudges.  
2.2.2.7 Scanning and Image analysis 
The dried array slides were fed into the array scanner. The exposure of both channels 
(532nm and 635nm) was optimized and the PMT gain was set initially at 650 with 100% 
power in both channels. The slides were scanned and observed for their channel signal ratio 
(count ratio) in the histogram. To prevent dye bias, the PMT gain was increased or 
decreased appropriately so as to obtain a count ratio of 1. On obtaining a count ratio of 1, the 
settings were saved. All array slides were then scanned with the same settings, to generate 
images in TIFF file format.  
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Image analysis was performed using Gene Pix Pro 6.0. The corresponding GAL file (Gene 
Pix Array List) was loaded and the scanned image was overlaid with the microarray grid. 
After appropriately overlaying all blocks and spots in the entire array, good and bad quality 
spots were flagged manually according to background interference, expression and intensity. 
The background was adjusted using morphological background subtraction to obtain 
accurate data. The individual settings for each slide thus furnished were locked and saved 
separately as Gene Pix Settings (.gps files). Slides were analysed in their individual settings 
to generate results i.e. Gene Pix Results (.gpr files).  
2.2.2.8 Statistical Analysis of data from microarrays (using LIMMA) 
The microarray results were statistically analysed using the LIMMA (Linear Models for 
MicroArray) software developed by Gordon Smyth and James Wettenhall (Wettenhall and 
Smyth, 2004; Smyth, 2005). More specifically, the graphical user interface version of LIMMA 
i.e. limmaGUI was used. The software was run in R statistical computing environment. The 
analysis was as follows. For each slide, RNA target files and spot-types files were created in 
tab-delimited format following the guidelines in the manual. The limmaGUI package was 
loaded in R environment and a working directory (containing the .gpr, GAL, RNA target and 
spot-type files) was chosen. Normalisation was done using the parameters “normexp” 
background correction (Ritchie et al., 2007), spot quality weighting and “print-tip loess” 
normalisation within arrays (Smyth and Speed, 2003). The quality of array signals (see 
appendix II) before and after normalisation was assessed using MA plots, M box plots and 
Image Array plots. Differentially expressed (DE) genes in each comparison were computed 
by duplicate correction (Smyth et al., 2005) and robust regression analysis. Benjamini-
Hochberg method (Benjamini and Hochberg, 1995) was used to estimate false discovery rate 
and to adjust P values for multiple testing. The entire list of significant DE genes (significant 
DE list) and an HTML report were generated for each experiment. The specific details of 
parameters and terms used here are detailed in the cited references. 
Various control spots included by the manufacturer on the microarray slide were: empty 
spots, Arabidopsis controls, calibration controls, utility controls, ratio controls and negative 
controls. This experiment did not require the use of these controls and hence, all signals from 
control spots were used to assess the degree of false positives. 
2.2.2.9 Functional analysis – GO and FunSpec 
Functional analysis was done using the GOminer software 
(http://discover.nci.nih.gov/gominer/) at the University of Melbourne (Courtesy: Dr. Victoria 
Perreau) and FunSpec (Robinson et al, 2002), a web-based cluster 
(http://funspec.med.utoronto.ca/). The GOminer allowed comparison against genes in the 
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user-specified background list, while FunSpec compares across genes in the entire yeast 
genome. 
GOminer Æ Gene lists loaded were a “background list” consisting of all genes in the GAL file 
and a “changed list” consisting of top 100 genes in the significant DE list. All database 
sources of S. cerevisiae were interrogated at “level 3 evidence code” (a parameter in 
GOminer). GO summary lists based on the molecular function, biological process and 
cellular component were generated for each microarray experiment and saved as tab-
delimited files. 
FunSpec Æ The most significant (top 100) DE genes were analysed with a P value threshold 
of 0.01 and without Bonferroni correction. The results generated were saved as tab-delimited 
files. 
2.2.2.10 Pathway analysis 
Pathway analysis was done primarily through literature survey of the yeast cellular pathways 
to find genes involved, followed by correlation with the DE gene lists. ‘Pathway Studio’ 
software from Ariadne Genomics was used to analyse how the genes in each pathway were 
affected in each experiment. Medscan reader incorporated in Pathway Studio was used to 
read the literature and specific pathways were generated using this information. These 
pathways were then manually curated by consulting the SGD database 
(http://www.yeastgenome.org/) and other scientific literature. The differential expression (DE) 
data of each experiment was imported into Pathway Studio to visualize specific up- and 
down- regulation of genes in each pathway. The intensity of colour corresponded to the 
intensity of differential expression of the given gene. 
2.2.3 Assays 
2.2.3.1 β-galactosidase filter assay 
A dry nitrocellulose filter was overlaid onto selective agar using sterile forceps. Recombinant 
clones were streaked onto the filter on the media and incubated overnight at 30°C. The 
following day, the filter was removed from the media, labelled using a ball-point pen, floated 
(colony side up) in an aluminium foil boat on a thin layer of liquid nitrogen for 5min. and then 
thawed at room temperature. A petri dish was prepared for the reaction with #1 Whatman 
filter paper, 5ml Z buffer and 70µl of 2-10% X-gal .The nitrocellulose filter was overlaid on the 
filter paper with colonies facing up. The petri dish was closed and sealed with paraffin tape to 
create a humidified chamber. This was incubated at 30°C until colour development.  
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2.2.3.2 HSR assay 
Heat shock response (HSR) was measured with respect to the heat shock factor activity. 
Recombinant clones contained a lacZ reporter under the control of heat shock element (i.e. 
HSE-lacZ and KHSE). The lacZ coded β-Galactosidase activity was determined by a 
modification of the method of Guarente (1983). 5ml yeast cultures were grown overnight in 
selective media at 30°C. Cell density (A600 nm) was recorded, and cells were harvested at 
4°C by centrifugation for 1min. at 17, 500 g. The cells were resuspended in 1ml of chilled Z 
buffer and permeabilised at 28°C for 15–30min. with 0.15ml chloroform and 0.05ml of 0.1% 
SDS. The permeabilised cells were then incubated in the presence of 0.2ml of ONPG 
(4mg/ml), and the reaction was stopped by addition of 0.5ml of 1M Na2CO3. The released o-
nitrophenol (ONP) was measured spectrophotometrically at 420 nm. The ONPG-hydrolysing 
activity was determined using the formula A420 nm/ (A600nm x v x t), where A420 nm represents 
the degree of color development during the incubation with ONPG, A600 nm represents the 
density of culture used, v is the volume of lysate used in each reaction, and t is the time 
elapsed during the reaction. Specific activities are reported in Miller units (1000 x A420 
nm/A600 nm of culture per milliliter of culture per minute of reaction) (Miller, 1972). 
2.2.3.3 Flow cytometry 
Flow cytometric analysis was carried out by Mehrnoush Lotfi-Miri (CSIRO-Molecular and 
Health Technologies, Parkville, Australia) in Beckman Coulter EPIC flow cytometer and 
FACSCalibur, BD Biosciences. Data was analysed using CellQuest analysis software.  
200µl of overnight cultures grown in selective media at 30°C were inoculated into 2ml fresh 
media and grown further for 2-4 hours. After sufficient incubation, cells were harvested at 
12,000 rpm for 2min. and resuspended in 2ml of 1 X PBS. 500µl of the suspension was 
transferred into flow cytometry tube containing 5µl of propidium iodide (PI) solution. The cell 
populations were gated on a forward and side scatter dot plot to analyse PI staining. 25,000 
cells were analysed in each sample. The percentage of cell death was estimated in the 
population of PI-positive cells while the percentage of cells exhibiting GFP fluorescence was 
estimated in the population of PI-negative (live) cells.  
2.2.3.4 Inductively Coupled Plasma Mass Spectroscopy (ICP-MS) 
At log-phase, cultures grown in minimal media were treated with appropriate compounds at 
30°C. After overnight incubation (16-20 hours), cultures were harvested at 5,000rpm for 
10min., washed twice with sterile water and centrifuged as before. Cell pellets were weighed 
and thoroughly dried in a speedivac. Dry weights of pellets were recorded and sent for ICP-
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MS analysis. Metal concentrations were estimated after acid digestion of the pellets followed 
by ICP-MS analysis by Mitchell Paul at University of Newcastle. New South Wales, Australia.  
2.2.4 Protein methods 
2.2.4.1 Preparation of cell extract 
10-20ml overnight cultures were grown at 30°C, harvested at 5000rpm for 10min., washed 
twice with 2ml 1 x PBS and centrifuged at 12,000rpm for 2min. After discarding supernatant 
pellets were weighed and resuspended in 3 x pellet volume of Y-PER® reagent (Yeast 
Protein Extraction Reagent) and 1 x Complete Protease Inhibitor (Roche). To this mixture, 
0.5-0.6µm glass beads were added up to ⅓ of the total volume. This was then vortexed for 
4min. with intermittent cooling on ice. The lysate was transferred to eppendorf tubes without 
aspirating beads and centrifuged as before. The supernatant was transferred into another 
eppendorf tube, labelled as S and kept aside on ice. The pellet was washed with 1 x PBS (to 
prevent carry over) and centrifuged as before. The washed pellet was resuspended in ½ the 
initial volume of 200mM Na2CO3 and placed on a spinning wheel for 20min. at 4°C. 4M urea 
was added to this mix up to ½ the initial volume and again placed on the spinning wheel for 
4°C for 20min. Finally the mix was centrifuged and the supernatant fraction was transferred 
into another eppendorf. This was labelled as P1, while the pellet fraction was labelled as P2 
and both were placed on ice or stored at -20°C.  
2.2.4.2 SDS-PAGE (Sodium Dodecyl Sulphate – PolyAcrylamide Gel Electrophoresis) 
First, the cell lysate fractions were prepared as follows: 5 x SDS gel loading buffer was 
added to the S and P1 fractions to give 1 x concentration and 2 x SDS gel loading buffer was 
added to the P2 fraction up to the initial volume. All three fractions were boiled for 30min. at 
100°C. After boiling, all fractions were centrifuged at 12000rpm for 2min. and supernatants 
were transferred to another eppendorf. 
Next, equal amounts of the prepared fractions were loaded on to 4-20% polyacrylamide 
gradient gels (NuPage) and run at 100-150V for 60-90min. in NuPage MES running buffer. 
Pre-stained molecular weight standards (Benchmark - Invitrogen) were loaded in each gel. 
After electrophoresis the gels were stained with Coomassie blue stain for 1 hour at room 
temperature. The gels were then placed in de-staining solution until background was clear 
and scanned. 
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2.2.4.3 Western Blot 
The proteins were electro transferred from the SDS-PAGE Gel onto nitrocellulose membrane 
(100 V, 1 hour),  blocked with 1% casein in PBS for 1 hour and reacted overnight with the 
primary antibody [mouse anti-GFP monoclonal antibody, MAB2510 (Chemicon 
International)]. The membrane was washed thrice with 1 x PBS for 2min. each and reacted 1 
hour with secondary antibody [horseradish peroxidase conjugated to goat anti-mouse IgG 
(BioRad)]. Primary and secondary antibodies were diluted in the same blocking agent. Next, 
the membrane was washed twice with 1 x PBS and once with citrate-EDTA solution to 
change pH to 5.5. TMB colouring reagent was added and reacted until the bands were 
visualised. The membrane was washed for 5min. in water, dried in the dark between paper 
towels and scanned.  
2.2.5 Other methods 
2.2.5.1 Densitometry analysis 
The protein bands on the western blot were quantitated using Gel-pro (Kodak). All the bands 
in each lane and any degradation products present were included in the analysis. The 
amount of protein was expressed in arbitrary OD units.    
2.2.5.2 Fluorescent microscopy 
1ml overnight cultures grown in selective media at 30°C were inoculated into 10ml selective 
media and grown further for 2-4 hours. A drop of the culture was mounted on a microscopic 
slide, covered with a cover slip and sealed. Cells were observed under oil immersion 
objective of the fluorescent microscope in white light and under blue filter and photographed. 
2.2.5.3 Statistical analysis of assay data 
Mean and SEM were calculated from all assay data and plotted on a graph. Significant levels 
of HSR were determined with a confidence interval of 95% by one-way ANOVA followed by 
Bonferroni test comparing all pairs of samples. 
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CHAPTER 3 
STUDY OF CELLULAR RESPONSES TO Aβ  
A century after its discovery, Alzheimer’s disease (AD) remains the most significant 
disease burden of ageing societies. Knowledge of the precise causes of AD is fundamental 
to rational preventative approaches and treatment. However, our current understanding is 
incomplete due to uncertainties in experimental models and the multi-faceted nature of β-
amyloid (Aβ), a protein that is considered to be the causative agent associated with AD.  This 
study queries the underlying principles and mechanisms by which Aβ affects neuronal 
dysfunction at a molecular level by identifying molecular and biochemical pathways affected 
by Aβ in yeast. Due to the fundamental homology of this unicellular organism to human cells, 
and the availability of a huge range of experimental resources in yeast, this study has chosen 
yeast to produce cytosolic Aβ. Our site of expression of Aβ is the cytosol, whereas native Aβ 
derives from the amyloid precursor protein (APP), which is secreted into the endoplasmic 
reticulum, processed, and eventually cleaved by proteases to liberate Aβ. Regardless of this 
difference, we consider that our cytosolic location is worthy of strong consideration due to the 
reasons discussed in the earlier chapter (section 1.2.1). 
With rapid advances in biotechnology, high-throughput studies have permitted 
analysis of genomic and proteomic profiles thereby identifying particular pathways that may 
be affected.  These include microarray analysis of neuronal cells treated with Aβ (Martinez 
and Pascual, 2007; Kim et al., 2003) and proteomic analysis of brain tissues from AD animal 
models by 2D gel electrophoresis (Sizova et al., 2007).  Using a similar approach, the gene 
expression profile of yeast producing intracellular Aβ has been studied using two-colour 
microarrays to allow comparisons of cells producing Aβ and normal states. Two common 
statistical designs for microarray experiments (see appendix I) are the dye-swap (direct) and 
the loop design (indirect), both of which have been utilised here. An overview of the 
sequence of experiments and analyses used in this chapter is presented in Fig.3.1. 
3.1 MICROARRAY ANALYSIS OF YEAST PRODUCING Aβ 
 The production of native Aβ in the yeast cytoplasm was not detectable, possibly due 
to its rapid turnover in yeast (Caine et al., 2007).  However, Aβ fused to green fluorescent 
protein (GFP) has been stably produced in yeast cells (Caine et al., 2007). Two types of Aβ42 
fusions have been produced in yeast cells, the C-terminal fusion, pAS1N.Aβ42GFP, and the 
N-terminal Aβ fusion, pAS1N.GFPAβ42 (Caine et al., 2007). The significance of these two 
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fusions is the different pathogenic importance of residues in the N- and C-terminals of Aβ 
that may be exposed for interactions in the C-terminal and N-terminal fusions, respectively.  
 
Extraction of total RNA from yeast producing 
GFP and Aβ-GFP or GFP-Aβ
Reverse transcription of RNA into cDNAs
Fluorescent labelling of cDNA with Alexa 
Fluor-555 (Cy3) or Alexa Fluor-647 (Cy5) dyes
Combining differentially labelled cDNAs for 
direct comparison
Hybridisation onto microarrays
STEP 1 
WET-LAB EXPERIMENTS
Quantification of microarray signals by Image 
Analysis
Statistical analysis to find significant differentially 
expressed (DE) genes
Gene Ontology (GO) and FunSpec analysis to find 
functional enrichment
Transcription factor (TF) analysis for pathway 
identification
Pathway analysis to comprehend the effect of Aβ
STEP 2 
BIOINFORMATICS
 
Fig.3.1 Schematic outline of experiments and analyses performed in this study. The 
sequence in which each step was done is shown. 
  
For the microarray analysis of yeast producing intracellular Aβ, several batches of 
yeast cells (BY4743) transformed with pAS1N.GFP, pAS1N.Aβ42GFP, pAS1N.GFPAβ42 and 
pAS1N.GFPAβ28 were grown and harvested at exponential phase for total RNA extraction. 
Extracted RNA was treated with DNase and tested for purity and integrity (Fig.3.2).  
Pure RNA samples of each cell line were pooled before cDNA synthesis, fluorescent 
labelling and hybridisation onto microarrays (Table 3.1). The RNA extractions and 
hybridisations of experiment 1 were conducted by Dr. Peter Iliades. 
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Fig.3.2 Image of native agarose gel loaded with total RNA extracted and purified from 
BY4743 yeast transformed with pAS1N.GFP, pAS1N.Aβ42GFP, pAS1N.GFPAβ42 and 
pAS1N.GFPAβ28 after electrophoresis. The given image is representative of several batches 
of RNA analysed. Distinct and clear bands of 18S and 28S ribosomal RNA with no DNA 
contamination are visible. 
 
Lane 1: RNA from BY4743 [pAS1N.GFP] 
Lane 2: RNA from BY4743 [pAS1N.GFP] 
Lane 3: RNA from BY4743 [pAS1N.Aβ42GFP] 
Lane 4: RNA from BY4743 [pAS1N.Aβ42GFP] 
Lane 5: RNA from BY4743 [pAS1N.GFPAβ42] 
Lane 6: RNA from BY4743 [pAS1N.GFPAβ42] 
Lane 7: RNA from BY4743 [pAS1N.GFPAβ28] 
Lane 8: RNA from BY4743 [pAS1N.GFPAβ28] 
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Table 3.1 Fluorescent labelling of cDNAs hybridised on arrays. Dye incorporated in the 
cDNA from cells producing the respective foreign protein is indicated. Each shaded set is a 
dye-swap pair. 
Experiment Alexa Fluor-555 
(green) 
Alexa Fluor-647 
(red) 
Slide Number 
1 
 
GFP Aβ42GFP 38 
Aβ42GFP GFP 39 
2 
GFP GFPAβ42 189728 
GFPAβ42 GFP 189913 
2 
GFPAβ28 GFP 189912 
GFP GFPAβ28 189910 
2 
GFPAβ28 GFPAβ42 189911 
GFPAβ42 GFPAβ28 189909 
  
 
INDIRECT COMPARISON
(experiment 2)
pAS1N.GFP
pAS1N.GFPAβ28
pAS1N.GFPAβ42
DIRECT COMPARISON
(experiment 1)
pAS1N.GFP pAS1N.Aβ42GFP
 
Fig. 3.3 Design scheme of microarray experiments used in this study. Arrows represent 
competitive hybridisation of the samples on array slide. The arrowhead points to Alexa Fluor-
647-labelled cDNA, hence a double-headed arrow indicates a dye-swap. 
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The experimental design is schematically represented in Fig. 3.3. The two 
comparisons done were: 
♦ Experiment 1 Æ direct comparison of pAS1N.Aβ42GFP versus pAS1N.GFP transformants  
and 
♦ Experiment 2 Æ indirect comparison of pAS1N.GFPAβ42 transformants versus pAS1N.GFP 
transformants (via loop design),  
where pAS1N.GFP transformants were used as a control (i.e. normal) that 
represented the non-disease state. A dye swap was included in each set of comparisons 
(Table 3.1) as a duplicate and to rule out any errors that may arise due to dye-affinity. The 
purpose of the loop design was to obtain reliable signals of pAS1N.GFP transformants and 
pAS1N.GFPAβ42 transformants. The pAS1N.GFPAβ28 transformants were the common 
reference (Fig.3.3).  
After hybridisation, all the arrays were scanned and images were analysed using 
Gene Pix Pro 6.0 to generate the primary data. The background was adjusted using 
morphological background subtraction to obtain accurate data. Further data processing was 
done using LIMMA statistical package (Wettenhall and Smyth, 2004; Smyth, 2005). To adjust 
for any bias that may arise from variation in technology, the data from each array was 
normalised using the parameters “normexp” background correction (Ritchie et al., 2007), 
spot quality weighting and “print-tip loess” normalisation within arrays (Smyth and Speed, 
2003). The quality of array signals (see appendix II) before and after normalisation was 
assessed using various plots. These plots allow identification of differences in scale between 
arrays within an experiment, data-skewing, reliability of data from arrays and effects of 
normalisation.  
Fig.3.4 and Fig.3.5 present the MA plots (see appendix II) of each array used in 
experiment 1 and 2, respectively. MA plots of both arrays in experiment 1 illustrate that A 
values (see appendix II) spanned a broad range, with greater density around lower values, 
and the bulk of M values (see appendix II) were less than the range of A values. This 
indicates a good distribution of log intensities and log differential expressions of the spots. 
Blanks or empty spots were mostly in the lower end of M and A values denoting a relatively 
low background. By contrast, MA plots of arrays in experiment 2 revealed broader scattering 
in M values than the arrays in experiment 1. Slide 189913, in particular, exhibited a broad 
scatter of M values across all levels of A and hence was excluded from the indirect 
comparison. It is notable that any skewing that existed in the array signals was rectified by 
the normalisation process in both experiments. 
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(A) 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
Fig. 3.4 MA plots of individual arrays of experiment 1 – before and after normalisation. (A) 
Slide 38 had Alexa Fluor-555 labelled cDNA from BY4743 [pAS1N.GFP] and Alexa Fluor-
647 labelled cDNA from BY4743 [pAS1N.Aβ42GFP]. (B) Slide 39 had Alexa Fluor-647 
labelled cDNA from BY4743 [pAS1N.GFP] and Alexa Fluor-555 labelled cDNA from BY4743 
[pAS1N.Aβ42GFP]. The normalisation method used was “print-tip loess” within arrays only. 
Key to the colour coded spots are: gene – black, blank/empty – yellow, Arabidopsis controls 
– pink, calibration controls – blue, utility controls – brown, ratio controls – red and negative 
controls – orange. 
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(C) (D) 
 
 
 
 
 
Fig. 3.5* MA plots of individual arrays of experiment 2 – before and after normalisation. (A) Slide 189728 had Alexa Fluor-555 labelled 
cDNA from BY4743 [pAS1N.GFP] and Alexa Fluor-647 labelled cDNA from BY4743 [pAS1N.GFPAβ42]. (B) Slide 189913 had Alexa Fluor-
647 labelled cDNA from BY4743 [pAS1N.GFP] and Alexa Fluor-555 labelled cDNA from BY4743 [pAS1N. GFPAβ42]. (C) Slide 189912 had 
Alexa Fluor-555 labelled cDNA from BY4743 [pAS1N.GFPAβ28] and Alexa Fluor-647 labelled cDNA from BY4743 [pAS1N.GFP]. (D) Slide 
189910 had Alexa Fluor-647 labelled cDNA from BY4743 [pAS1N.GFPAβ28] and Alexa Fluor-555 labelled cDNA from BY4743 
[pAS1N.GFP]. The normalisation method used was “print-tip loess” within arrays only. Key to the colour coded spots are: gene – black, 
blank/empty – yellow, Arabidopsis controls – pink, calibration controls – blue, utility controls – brown, ratio controls – red and negative 
controls – orange.  
                                                 
* Continued on next page 
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(E)  
 
 
 
 
 (F) 
 
 
 
 
Fig. 3.5 MA plots of individual arrays of experiment 2 – before and after normalisation (continued 
from previous page). (E) Slide 189911 had Alexa Fluor-555 labelled cDNA from BY4743 
[pAS1N.GFPAβ28] and Alexa Fluor-647 labelled cDNA from BY4743 [pAS1N.GFPAβ42]. (F) Slide 
189909 had Alexa Fluor-647 labelled cDNA from BY4743 [pAS1N.GFPAβ28] and Alexa Fluor-
555 labelled cDNA from BY4743 [pAS1N.GFPAβ42]. The normalisation method used was “print-
tip loess” within arrays only.  
Fig.3.6 and Fig.3.7 present M box plots of arrays included in the analysis of experiment 1 
and 2, respectively. The M box plots revealed that normalisation eliminated the differences 
between arrays within an experiment. Image array plots that enable judgement of spatial 
variation and artefacts in arrays and print-tip group MA plots of the arrays have been included in 
the CD attached (see back cover of thesis). 
Finally, the differentially expressed (DE) genes in each comparison were computed for 
significance by duplicate correction (Smyth et al., 2005) and robust regression analysis in 
LIMMA (Smyth, 2004). The Benjamini-Hochberg method (Benjamini and Hochberg, 1995) was 
used to estimate false discovery rate and to adjust P values for multiple testing. The entire list of 
significant DE genes and an HTML report of the two experiments are included in the attached 
CD. 
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Fig. 3.6 M box plots of all arrays included in analysis of experiment 1 – before and after normalisation. Slide 38 had Alexa Fluor-555 
labelled cDNA from BY4743 [pAS1N.GFP] and Alexa Fluor-647 labelled cDNA from BY4743 [pAS1N.Aβ42GFP]. Slide 39 had Alexa Fluor-
647 labelled cDNA from BY4743 [pAS1N.GFP] and Alexa Fluor-555 labelled cDNA from BY4743 [pAS1N.Aβ42GFP]. The normalisation 
method used was “print-tip loess” within arrays only. 
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Fig. 3.7 M box plots of all arrays included in analysis of experiment 2 – before and after 
normalisation. Slide 189728 had Alexa Fluor-555 labelled cDNA from BY4743 [pAS1N.GFP] and 
Alexa Fluor-647 labelled cDNA from BY4743 [pAS1N.GFPAβ42]. Slide 189912 had Alexa Fluor-
555 labelled cDNA from BY4743 [pAS1N.GFPAβ28] and Alexa Fluor-647 labelled cDNA from 
BY4743 [pAS1N.GFP]. Slide 189910 had Alexa Fluor-647 labelled cDNA from BY4743 
[pAS1N.GFPAβ28] and Alexa Fluor-555 labelled cDNA from BY4743 [pAS1N.GFP]. Slide 189911 
had Alexa Fluor-555 labelled cDNA from BY4743 [pAS1N.GFPAβ28] and Alexa Fluor-647 
labelled cDNA from BY4743 [pAS1N.GFPAβ42]. Slide 189909 had Alexa Fluor-647 labelled 
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cDNA from BY4743 [pAS1N.GFPAβ28] and Alexa Fluor-555 labelled cDNA from BY4743 
[pAS1N.GFPAβ42]. The normalisation method used was “print-tip loess” within arrays only. Note: 
Slide 189913 was excluded from the analysis. 
3.2 GENE ONTOLOGY FUNCTIONAL ANALYSIS  
Gene ontology (GO) consists of three structured and controlled vocabularies that ascribe 
GO annotations to every gene in every organism based on the molecular function, biological 
process and cellular component of the gene products. Consequently, genes that are functionally 
associated with each other would be clustered in the same GO category. Thus, a GO analysis of 
a list of significant DE genes would reveal functional groups that are over-represented in the list. 
To identify functional groups affected by Aβ fused to GFP, the 100 most significant DE 
genes obtained from each of the two comparisons were analysed for their GO annotations 
based on the biological process (Table 3.2 and 3.5), molecular function (Table 3.3 and 3.6) and 
cellular component (Table 3.4 and 3.7) of the gene products. The P values represent the 
probability that the intersection of a given list with any given functional category occurs by 
chance. The tables show results from the GO analysis at a P value cut-off of 0.05 for experiment 
1 and 0.1 for experiment 2. A less stringent cut-off was applied to experiment 2 owing to the 
broader scatter observed in the plots (Fig.3.5). The entire lists of all the GO analyses are 
included in the attached CD. 
According to the results shown in Table 3.2, the biological processes affected by 
Aβ42GFP seemed to be RNA mediated transposition, protein misfolding, responses to different 
kinds of stresses (heat, osmotic and oxidative) and stimuli (unfolded protein, abiotic and protein) 
and effects on cell division and kinase pathways. Table 3.3 revealed signs of activity of enzymes 
involved in oxidation-reduction reactions, production of DNA, RNA and peptides, isomerisation of 
proteins, and some chaperone regulation and Hsp binding; while Table 3.4 indicated 
retrotransposon and proteasome genes. Comparing these results with the effects of Aβ42GFP, 
there were slight variations as well as consistencies. Table 3.5 largely indicated effects on cell 
division, cellular morphogenesis and biogenesis of cellular organelles, in particular, the ribosome 
and its components. Indications for a stress or stimuli response were small within P<0.1. 
However, similar indications were higher above the 0.1 P value (see entire list in CD). The 
molecular functions affected by GFPAβ42 were chaperone regulation, ubiquitination, RNA 
activity, transcription and translation, as observed from Table 3.6. The cellular components 
affected by GFPAβ42 seemed to be too broad to comprehend (Table 3.7).  Another functional 
analysis tool (FunSpec) was used to confirm differences observed between the two Aβ fusions. 
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Table 3.2 GO analysis based on biological process of top 100 DE genes in experiment 1. The P 
value cut-off was 0.05. ‘Total genes’ indicate the total number of genes in a given GO category. 
‘Changed genes’ are the number of genes in the given category that are altered by Aβ42GFP.  
Total 
Genes  
Changed 
Genes 
P-Value  GO Term 
(Biological Process)  
69 10 0.0001 transposition, RNA-mediated 
77 10 0.0001 transposition 
81 7 0.0002 protein folding 
9 3 0.0003 protein refolding 
464 17 0.0006 response to stress 
726 21 0.0026 response to stimulus 
48 4 0.0061 cell surface receptor linked signal transduction 
26 3 0.0071 pheromone-dependent signal transduction during 
conjugation with cellular fusion 
10 2 0.0098 budding cell apical bud growth 
11 2 0.0118 MAPKKK cascade during osmolarity sensing 
32 3 0.0127 G-protein coupled receptor protein signaling pathway 
1 1 0.0154 chaperone cofactor-dependent protein folding 
1 1 0.0154 Post-translational protein folding 
1 1 0.0154 nicotinamide riboside metabolic process 
1 1 0.0154 glucose catabolic process to butanediol 
13 2 0.0164 branched chain family amino acid biosynthetic process 
107 5 0.0241 response to abiotic stimulus 
73 4 0.0256 response to osmotic stress 
17 2 0.0275 response to unfolded protein 
17 2 0.0275 response to protein stimulus 
2 1 0.0306 unfolded protein response, positive regulation of target 
gene transcription 
2 1 0.0306 age-dependent response to reactive oxygen species 
during chronological cell aging 
2 1 0.0306 age-dependent response to reactive oxygen species 
2 1 0.0306 mitochondrial DNA metabolic process 
2 1 0.0306 activation of MAPKK activity during osmolarity sensing 
2 1 0.0306 positive regulation of gene-specific transcription 
20 2 0.0373 osmosensory signaling pathway 
20 2 0.0373 glycolysis 
20 2 0.0373 MAPKKK cascade 
20 2 0.0373 serine family amino acid metabolic process 
3 1 0.0456 activation of MAPKK activity 
3 1 0.0456 homoserine biosynthetic process 
23 2 0.0482 protein kinase cascade 
23 2 0.0482 response to heat 
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Table 3.3* GO analysis based on molecular function of top 100 DE genes in experiment 1. The 
P value cut-off was 0.05. ‘Total genes’ indicate the total number of genes in given GO category. 
‘Changed genes’ are the number of genes in the given category that are altered by Aβ42GFP. 
Total 
Genes 
Changed 
Genes 
P-Value  GO Term 
(Molecular Function) 
40 4 0.0031 RNA-directed DNA polymerase activity 
21 3 0.0038 oxidoreductase activity, acting on the aldehyde or oxo 
group of donors 
290 11 0.0046 RNA binding 
143 7 0.0062 peptidase activity 
55 4 0.0099 DNA-directed DNA polymerase activity 
56 4 0.0105 isomerase activity 
87 5 0.0106 ribonuclease activity 
1 1 0.0154 nicotinamide riboside kinase activity 
1 1 0.0154 (R,R)-butanediol dehydrogenase activity 
1 1 0.0154 alpha-keto ester reductase activity 
1 1 0.0154 alpha-keto amide reductase activity 
1 1 0.0154 3-hydroxyanthranilate 3,4-dioxygenase activity 
1 1 0.0154 phosphoribosyl-AMP cyclohydrolase activity 
1 1 0.0154 phosphoglycerate kinase activity 
1 1 0.0154 C-8 sterol isomerase activity 
1 1 0.0154 threo-3-hydroxyaspartate ammonia-lyase activity 
1 1 0.0154 ATP-dependent 3' to 5' DNA helicase activity 
1 1 0.0154 histidinol dehydrogenase activity 
1 1 0.0154 serine racemase activity 
1 1 0.0154 aspartate-semialdehyde dehydrogenase activity 
1 1 0.0154 adenylosuccinate synthase activity 
1 1 0.0154 manganese superoxide dismutase activity 
1 1 0.0154 trans-aconitate 3-methyltransferase activity 
1 1 0.0154 chaperone inhibitor activity 
13 2 0.0164 peptidyl-prolyl cis-trans isomerase activity 
262 9 0.0187 oxidoreductase activity 
17 2 0.0275 oxidoreductase activity, acting on the aldehyde or oxo 
group of donors, NAD or NADP as acceptor 
2 1 0.0306 Hsp90 protein binding 
2 1 0.0306 SAM domain binding 
2 1 0.0306 racemase and epimerase activity, acting on amino acids 
and derivatives 
2 1 0.0306 superoxide dismutase activity 
2 1 0.0306 oxidoreductase activity, acting on superoxide radicals as 
acceptor 
Table 3.3 GO analysis based on molecular function of top 100 DE genes in experiment 1 
(continued from previous page). The P value cut-off was 0.05. ‘Total genes’ indicate the total 
                                                 
* Continued on next page 
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number of genes in the given GO category. ‘Changed genes’ are the number of genes in the 
given category that are altered by Aβ42GFP.  
Total 
Genes 
Changed 
Genes 
P-Value  GO Term 
(Molecular Function) 
2 1 0.0306 phosphoribosyl-ATP diphosphatase activity 
2 1 0.0306 3' to 5' DNA helicase activity 
2 1 0.0306 2-isopropylmalate synthase activity 
18 2 0.0306 lipase activity 
2 1 0.0306 Hsp70 protein binding 
2 1 0.0306 branched-chain-amino-acid transaminase activity 
2 1 0.0306 importin-alpha export receptor activity 
20 2 0.0373 adenyl nucleotide binding 
1944 38 0.042 catalytic activity 
3 1 0.0456 DNA strand annealing activity 
3 1 0.0456 dioxygenase activity 
3 1 0.0456 oxidoreductase activity, acting on single donors with 
incorporation of molecular oxygen, incorporation of two 
atoms of oxygen 
3 1 0.0456 oxidoreductase activity, acting on single donors with 
incorporation of molecular oxygen 
3 1 0.0456 glyceraldehyde-3-phosphate dehydrogenase activity 
3 1 0.0456 glyceraldehyde-3-phosphate dehydrogenase 
(phosphorylating) activity 
3 1 0.0456 heat shock protein binding 
3 1 0.0456 chaperone activator activity 
 
Table 3.4 GO analysis based on cellular component of top 100 DE genes in experiment 1. The 
P value cut-off was 0.05. ‘Total genes’ indicate the total number of genes in the given GO 
category. ‘Changed genes’ are the number of genes in the given category that are altered by 
Aβ42GFP. 
Total 
Genes 
Changed 
Genes 
P-Value  GO Term 
(Cellular Component) 
68 10 0.0001 retrotransposon nucleocapsid 
15 2 0.0217 proteasome core complex (sensu Eukaryota) 
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Table 3.5* GO analysis based on biological process of top 100 DE genes in experiment 2. The P 
value cut-off was 0.1. ‘Total genes’ indicate the total number of genes in the given GO category. 
‘Changed genes’ are the number of genes in the given category that are altered by GFPAβ42. 
Total 
Genes 
Changed 
Genes 
P-Value  GO Term 
(Biological Process) 
1202 34 0.0008 organelle organization and biogenesis 
2061 49 0.0017 cellular component organization and biogenesis 
16 3 0.0022 rRNA modification 
31 3 0.015 mitochondrial genome maintenance 
315 11 0.0166 ribonucleoprotein complex biogenesis and assembly 
1 1 0.0169 asparagine biosynthetic process from oxaloacetate 
1 1 0.0169 aspartate biosynthetic process 
1 1 0.0169 oxaloacetate metabolic process 
1 1 0.0169 dicarboxylic acid catabolic process 
13 2 0.0196 ribosomal small subunit assembly and maintenance 
64 4 0.0226 RNA modification 
248 9 0.0237 ribosome biogenesis and assembly 
37 3 0.0241 autophagy 
102 5 0.0288 actin cytoskeleton organization and biogenesis 
2 1 0.0336 proline catabolic process to glutamate 
2 1 0.0336 aspartate catabolic process 
2 1 0.0336 aspartate metabolic process 
2 1 0.0336 actin cortical patch localization 
43 3 0.0357 processing of 20S pre-rRNA 
269 9 0.0374 telomere maintenance 
269 9 0.0374 telomere organization and biogenesis 
113 5 0.042 establishment and/or maintenance of cell polarity 
113 5 0.042 establishment and/or maintenance of cell polarity (sensu 
Fungi) 
79 4 0.0443 35S primary transcript processing 
47 3 0.0447 G1/S transition of mitotic cell cycle 
3 1 0.05 asparagine biosynthetic process 
3 1 0.05 rRNA pseudouridine synthesis 
3 1 0.05 cytokinesis, actomyosin structure organization and 
biogenesis 
245 8 0.0546 cellular structure morphogenesis 
245 8 0.0546 cell morphogenesis 
245 8 0.0546 anatomical structure development 
245 8 0.0546 anatomical structure morphogenesis 
 
                                                 
* Continued on next page 
 53
Table 3.5 GO analysis based on biological process of top 100 DE genes in experiment 2 
(continued from previous page). The P value cut-off was 0.1. ‘Total genes’ indicate the total 
number of genes in the given GO category. ‘Changed genes’ are the number of genes in the 
given category that are altered by GFPAβ42. 
Total 
Genes 
Changed 
Genes 
P-Value  GO Term 
(Biological Process) 
779 19 0.0604 developmental process 
24 2 0.0616 regulation of exit from mitosis 
167 6 0.063 rRNA processing 
4 1 0.0661 vacuolar protein processing or maturation (CVT pathway) 
4 1 0.0661 proline catabolic process 
4 1 0.0661 spindle orientation checkpoint 
4 1 0.0661 organic acid catabolic process 
25 2 0.0662 amino acid catabolic process 
25 2 0.0662 ribosomal small subunit biogenesis and assembly 
350 10 0.0705 RNA processing 
131 5 0.0705 protein-RNA complex assembly 
26 2 0.071 chitin- and beta-glucan-containing cell wall biogenesis 
26 2 0.071 cell wall biogenesis 
177 6 0.0787 rRNA metabolic process 
553 14 0.0805 chromosome organization and biogenesis (sensu 
Eukaryota) 
28 2 0.0808 nitrogen compound catabolic process 
28 2 0.0808 amine catabolic process 
5 1 0.0819 protein urmylation 
5 1 0.0819 microautophagy 
5 1 0.0819 response to copper ion 
558 14 0.0853 chromosome organization and biogenesis 
63 3 0.0905 ribosome assembly 
101 4 0.0913 establishment of cell polarity (sensu Fungi) 
101 4 0.0913 establishment of cell polarity 
64 3 0.0938 protein targeting to vacuole 
324 9 0.0962 cell division 
6 1 0.0975 regulation of glycogen biosynthetic process 
6 1 0.0975 response to xenobiotic stimulus 
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Table 3.6 GO analysis based on molecular function of top 100 DE genes in experiment 2. The P 
value cut-off was 0.1. ‘Total genes’ indicate the total number of genes in the given GO category. 
‘Changed genes’ are the number of genes in the given category that are altered by GFPAβ42. 
Total 
Genes 
Changed 
Genes 
P-Value  GO Term 
(Molecular Function) 
11 2 0.0141 chaperone regulator activity 
1 1 0.0169 alpha-keto ester reductase activity 
1 1 0.0169 alpha-keto amide reductase activity 
1 1 0.0169 ubiquitin activating enzyme activity 
1 1 0.0169 deoxycytidyl transferase activity 
1 1 0.0169 proline dehydrogenase activity 
1 1 0.0169 rRNA (adenine-N6,N6-)-dimethyltransferase activity 
1 1 0.0169 rRNA (adenine) methyltransferase activity 
1 1 0.0169 chorismate mutase activity 
1 1 0.0169 APG12 conjugating enzyme activity 
2 1 0.0336 RNA cap binding 
2 1 0.0336 aspartate transaminase activity 
42 3 0.0336 transcription factor binding 
558 15 0.0465 nucleic acid binding 
21 2 0.0484 histone binding 
3 1 0.05 endopeptidase inhibitor activity 
3 1 0.05 cyclin-dependent protein kinase inhibitor activity 
3 1 0.05 peptidyltransferase activity 
22 2 0.0527 enzyme inhibitor activity 
4 1 0.0661 adenyl-nucleotide exchange factor activity 
4 1 0.0661 rRNA methyltransferase activity 
4 1 0.0661 protease inhibitor activity 
25 2 0.0662 snoRNA binding 
28 2 0.0808 translation initiation factor activity 
60 3 0.0808 transcription factor activity 
5 1 0.0819 alpha-1,3-mannosyltransferase activity 
182 6 0.0873 enzyme regulator activity 
321 9 0.0921 transcription regulator activity 
6 1 0.0975 transferase activity, transferring amino-acyl groups 
6 1 0.0975 glutathione peroxidase activity 
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Table 3.7 GO analysis based on cellular component of top 100 DE genes in experiment 2. The 
P value cut-off was 0.1. ‘Total genes’ indicate the total number of genes in the given GO 
category. ‘Changed genes’ are the number of genes in the given category that are altered by 
GFPAβ42. 
Total 
Genes 
Changed 
Genes 
P-Value  GO Term 
(Cellular Component) 
518 16 0.0124 ribonucleoprotein complex 
57 4 0.0154 small nucleolar ribonucleoprotein complex 
734 20 0.0191 organelle lumen 
734 20 0.0191 membrane-enclosed lumen 
1803 40 0.0235 nucleus 
524 15 0.0288 nuclear lumen 
924 23 0.0316 intracellular non-membrane-bound organelle 
924 23 0.0316 non-membrane-bound organelle 
2 1 0.0336 mitochondrial chromosome 
2 1 0.0336 nuclear cap binding complex 
226 8 0.0367 nucleolus 
44 3 0.0378 mitochondrial large ribosomal subunit 
44 3 0.0378 organellar large ribosomal subunit 
81 4 0.0478 mitochondrial ribosome 
81 4 0.0478 organellar ribosome 
3 1 0.05 RecQ helicase-Topo III complex 
4523 82 0.0595 intracellular 
992 23 0.064 nuclear part 
4 1 0.0661 AP-3 adaptor complex 
129 5 0.0669 transcription factor complex 
5 1 0.0819 Rpd3S complex 
31 2 0.0962 clathrin-coated vesicle 
103 4 0.0965 nucleolar part 
6 1 0.0975 90S preribosome 
6 1 0.0975 signal recognition particle, endoplasmic reticulum targeting 
6 1 0.0975 signal recognition particle 
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3.3 ‘FUNSPEC’ ANALYSIS 
 FunSpec is a web-based cluster that locates “Functional Specification” of genes enriched 
in the list of DE genes that is submitted for analysis (Robinson et al, 2002). The output obtained 
is a summary of functional classes, cellular localizations and protein complexes. In contrast to 
the GO miner software, FunSpec interrogates the input list of genes across different databases 
and published datasets. 
The top 100 DE genes were re-analysed using FunSpec with a P value threshold of 0.01 
for both comparisons. The P values represent the probability that the intersection of a given list 
with any given functional category occurs by chance. Table 3.8 and 3.9 present all the 
categories in experiment 1 and 2 for which the same probability of functional enrichment is lower 
than the P value threshold in an individual test. Significant DE genes from Aβ42GFP yielded hits 
in the MIPS and GO classifications, while DE genes for GFPAβ42 yielded only GO annotations. 
FunSpec analysis further emphasized the most significant pathways that were being affected by 
the respective Aβ proteins, but none were found to be common in both comparisons. Aβ42GFP 
indicated activation of stress responses, molecular chaperones and heat shock proteins. There 
were also indications of ribosomal and proteasomal activities (Table 3.8). GFPAβ42, on the other 
hand, seemed to trigger a response to metals, particularly copper (Table 3.9). 
3.4 TRANSCRIPTION FACTOR ANALYSIS 
In order to isolate the particular cellular pathways that are being affected by the Aβ42 
fusions, transcription factor (TF) analysis was performed on the DE genes, using only the top 
100 hits. The online query tools in Yeastract database (Teixeira et al., 2006) was used for this 
purpose. The results generated were edited and compiled to display the required information 
(Table 3.10 and 3.11). The SGD database was also consulted to verify the gene descriptions.  
The results obtained were striking, as pathways common to both Aβ fusions were 
apparent. There is a huge indication of oxidative stress with Yap1, Msn2, Msn4 and Skn7 being 
largely affected. Moreover, the involvement of Hsf1 and Rpn4 were suggestive of a heat shock 
response and proteasome activity. Table 3.10 and 3.11 displays only those TFs that had the 
majority of targets in the list of DE genes; the complete list of results can be found in the 
attached CD. 
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Table 3.8* FunSpec analysis of top 100 DE genes in experiment 1. Categories for which the 
probability of enrichment by chance is lower than P=0.01 in an individual test are displayed. ‘k’ is 
the number of genes from the input list in the given category and ‘f’ is the total number of genes 
in the given category. 
MIPS Functional Classification 
Category p-value DE genes in Category k f 
stress response 2.33E-06 SSA1 TIP1 SSE2 HSP30 CPR1 HSP12 
NSR1 HSP104 AHP1 SNZ1 STI1 HSP82  
12 175 
rRNA transcription 7.93E-05 NOP1 NSR1 DBP7 DRS1 RRB1 DBP2 
RPA190 NOP4  
8 109 
rRNA processing 1.56E-04 NOP1 NSR1 DBP7 DRS1 DBP2 NOP4  6 63 
protein folding and 
stabilization 
9.76E-04 SSA1 CPR1 SBA1 SSA2 CPR6  5 59 
amino acid degradation 
(catabolism) 
1.05E-03 GCV1 BAT1 BNA1 SRY1  4 35 
cytoplasmic and nuclear 
degradation 
1.77E-03 UMP1 NAS6 PRE3 UFD4 PRE5 PRE6  6 99 
other control of cellular 
organization 
3.40E-03 RRB1 NOC2  2 7 
MIPS Phenotypes 
Category p-value DE genes in Category k f 
other stress response 
defects 
5.74E-03 UMP1 HSP30  2 9 
conditional phenotypes 8.89E-03 SSE2 HSP30 NOP1 CPR1 REF2 NSR1 
PRE3 SBA1 DBP7 DRS1 HSP104 DBP2 
NOP4 HSP82  
14 535 
MIPS Subcellular Localization 
Category p-value DE genes in Category k f 
nuclear envelope 2.75E-04 UMP1 NAS6 PRE3 PRE5 PRE6  5 45 
nucleolus 4.53E-04 NOP1 NSR1 DRS1 RRB1 NOP4  5 50 
cytoplasm 9.13E-03 SSA1 SSE2 PGK1 PWP2 ARO3 CPR1 
TDH1 UFD4 SSA2 HSP104 AHP1 CPR6 
PGM2 HSP82 SRO7  
15 593 
MIPS Protein Complexes 
Category p-value DE genes in Category k f 
20S proteasome 3.33E-05 UMP1 PRE3 PRE5 PRE6  4 15 
26S proteasome 9.30E-05 UMP1 NAS6 PRE3 PRE5 PRE6  5 36 
proteasome 9.30E-05 UMP1 NAS6 PRE3 PRE5 PRE6  5 36 
rRNA splicing 8.77E-04 NOP1 NSR1 DRS1  3 15 
MIPS Protein Classes 
Category p-value DE genes in Category k f 
molecular chaperones 7.25E-05 SSA1 SSE2 HSP12 SSA2 HSP104 
HSP82  
6 55 
other ATPases 3.80E-04 SSA1 SSA2 HSP104 HSP82  4 27 
HSP70 family 8.77E-04 SSA1 SSE2 SSA2  3 15 
cyclophilins 3.40E-03 CPR1 CPR6  2 7 
Peptidyl-Prolyl-Isomerases 8.62E-03 CPR1 CPR6  2 11 
DnaK subfamily 8.62E-03 SSA1 SSA2  2 11 
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 Table 3.8* FunSpec analysis of top 100 DE genes in experiment 1 (continued from previous 
page). Categories for which the probability of enrichment by chance is lower than P=0.01 in an 
individual test are displayed. ‘k’ is the number of genes from the input list in the given category 
and ‘f’ is the total number of genes in the given category. 
GO Molecular Function 
Category p-value DE genes in Category k f 
heat shock protein [GO:0003773] 1.44E-09 SSA1 SSE2 HSP30 HSP12 SSA2 
HSP104 HSP82  
7 18 
chaperone [GO:0003754] 9.79E-09 SSA1 SSE2 UMP1 HSP30 HSP12 
SBA1 SSA2 HSP104 STI1 HSP82  
10 66 
RNA helicase [GO:0003724] 1.58E-03 DBP8 DBP7 DRS1 DBP2  4 39 
RNA binding [GO:0003723] 1.59E-03 PWP2 NOP1 REF2 SAD1 NSR1 
DBP8 DBP7 DRS1 DBP2 NOP4  
10 253 
RNA dependent 
adenosinetriphosphatase 
[GO:0008186] 
4.03E-03 DBP8 DBP7 DRS1  3 25 
ATP dependent RNA helicase 
[GO:0004004] 
4.03E-03 DBP8 DBP7 DRS1  3 25 
proteasome endopeptidase 
[GO:0004299] 
6.80E-03 PRE3 PRE5 PRE6  3 30 
threonine endopeptidase 
[GO:0004298] 
6.80E-03 PRE3 PRE5 PRE6  3 30 
co-chaperone [GO:0003767] 8.62E-03 SBA1 HSP104  2 11 
GO Biological Process 
Category p-value DE genes in Category k f 
protein folding [GO:0006457] 2.26E-09 SSA1 SSE2 HSP30 SBA1 SSA2 
HSP104 CPR6 STI1 HSP82  
9 42 
ribosome biogenesis 
[GO:0007046] 
2.31E-04 PWP2 NOP1 NSR1 DBP8 DBP7 
DRS1 RRB1 NOP4  
8 127 
transcription from Pol I promoter 
[GO:0006360] 
2.86E-04 PWP2 NOP1 NSR1 DBP8 DBP7 
DRS1 RPA190 NOP4  
8 131 
rRNA processing [GO:0006364] 3.05E-04 PWP2 NOP1 NSR1 DBP8 DBP7 
DRS1 NOP4  
7 100 
ribosome biogenesis and assembly 
[GO:0042254] 
1.33E-03 PWP2 NOP1 NSR1 DBP8 DBP7 
DRS1 RRB1 NOP4  
8 165 
35S primary transcript processing 
[GO:0006365] 
2.48E-03 NOP1 DBP8 DBP7 DRS1  4 44 
RNA processing [GO:0006396] 3.09E-03 PWP2 NOP1 REF2 SAD1 PRP18 
NSR1 DBP8 DBP7 DRS1 NOP4  
10 277 
ribosomal subunit assembly 
[GO:0042257] 
3.42E-03 NOP1 NSR1 DBP7 DRS1  4 48 
ribosome assembly [GO:0042255] 3.97E-03 NOP1 NSR1 DBP7 DRS1  4 50 
histone deacetylation 
[GO:0016575] 
4.50E-03 CPR1 STB2  2 8 
RNA metabolism [GO:0016070] 6.99E-03 PWP2 NOP1 REF2 SAD1 PRP18 
NSR1 DBP8 DBP7 DRS1 NOP4  
10 311 
protein amino acid deacetylation 
[GO:0006476] 
8.62E-03 CPR1 STB2  2 11 
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 Table 3.8 FunSpec analysis of top 100 DE genes in experiment 1 (continued from previous 
page). Categories for which the probability of enrichment by chance is lower than P=0.01 in an 
individual test are displayed. ‘k’ is the number of genes from the input list in the given category 
and ‘f’ is the total number of genes in the given category. 
GO Cellular Component 
Category p-value DE genes in Category k f 
nucleolus [GO:0005730] 7.71E-06 PWP2 NOP1 NSR1 DBP8 DBP7 DRS1 
RRB1 RPA190 NOP4 NOG1  
10 133 
20S core proteasome 
[GO:0005839] 
3.33E-05 UMP1 PRE3 PRE5 PRE6  4 15 
26S proteasome [GO:0005837] 2.47E-04 UMP1 NAS6 PRE3 PRE5 PRE6  5 44 
cytosol [GO:0005829] 6.83E-03 UMP1 PGK1 TMT1 NAS6 PRE3 TDH1 PGM2 
PRE5 PRE6 SRO7  
10 310 
Table 3.9 FunSpec analysis of top 100 DE genes in experiment 2. Categories for which the 
probability of enrichment by chance is lower than P=0.01 in an individual test are displayed. ‘k’ is 
the number of genes from the input list in the given category and ‘f’ is the total number of genes 
in the given category. 
GO Molecular Function 
Category p-value DE genes in Category k f 
copper binding 
[GO:0005507] 
6.90E-04 CUP1-1 CUP1-2  2 3 
heavy metal binding 
[GO:0005505] 
1.37E-03 CUP1-1 CUP1-2  2 4 
GO Biological Process 
Category p-value DE genes in Category k f 
response to copper 
[GO:0046688] 
6.90E-04 CUP1-1 CUP1-2  2 3 
rRNA modification 
[GO:0000154] 
1.69E-03 NOP10 DIM1 RRP9  3 16 
rRNA metabolism 
[GO:0016072] 
2.03E-03 NOP10 DIM1 RRP9  3 17 
response to heavy metal 
[GO:0009412] 
3.35E-03 CUP1-1 CUP1-2  2 6 
response to toxin 
[GO:0009636] 
4.64E-03 CUP1-1 CUP1-2  2 7 
regulation of mitosis 
[GO:0007088] 
9.54E-03 CDC15 CDC55 BUB2  3 29 
GO Cellular Component 
Category p-value DE genes in Category k f 
nucleus [GO:0005634] 3.93E-03 
 
TAF5 SNU23 YCG1 NUG1 LSM5 NOP10 
NVJ1 SRP21 UBA1 SIC1 BDF1 ZDS2 
BUD22 RNA14 YMR144W SGS1 ELP6 
NOP15 SPP2 REV1 PIP2 RDR1 ULP1 
CBC2 DIM1 RRP9  
26 1007
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Table 3.10* TF analysis of top 100 DE genes in experiment 1. Analysis was based on documented regulations supported by direct, indirect 
or undefined evidences. ‘P1’ is the percentage of DE genes relative to the total number of genes in the input list and ‘P2’ is the percentage 
of DE genes relative to the total number of genes regulated by the given TF. 
P1 P2 TF Description GO Biological process 
48.4 % 3.0 % Yap1p Basic leucine zipper (bZIP) transcription factor required for 
oxidative stress tolerance; mediates pleiotropic drug and 
metal resistance; localized to the nucleus in response to the 
presence of oxidants 
response to singlet oxygen, response to heat, response to 
metal ion, response to drug, regulation of transcription 
from RNA polymerase II promoter in response to oxidative 
stress, response to arsenic 
28.4 % 3.8 % Aft1p Transcription factor involved in iron utilization and 
homeostasis; binds the consensus site PyPuCACCCPu and 
activates the expression of target genes in response to 
changes in iron availability 
high affinity iron ion transport, positive regulation of 
transcription from RNA polymerase II promoter 
26.3 % 2.2 % Met4p Leucine-zipper transcriptional activator, responsible for the 
regulation of the sulfur amino acid pathway, requires 
different combinations of the auxiliary factors Cbf1p, 
Met28p, Met31p and Met32p 
sulfur amino acid metabolic process, positive regulation of 
transcription from RNA polymerase II promoter, response 
to arsenic, response to cadmium ion 
24.2 % 4.3 % Hsf1p Trimeric heat shock transcription factor, activates multiple 
genes in response to stresses that include hyperthermia; 
recognizes variable heat shock elements (HSEs) consisting 
of inverted NGAAN repeats; posttranslationally regulated 
regulation of transcription from RNA polymerase II 
promoter in response to stress, response to heat, spindle 
pole body duplication 
22.1 % 4.7 % Msn4p Transcriptional activator related to Msn2p; activated in 
stress conditions, which results in translocation from the 
cytoplasm to the nucleus; binds DNA at stress response 
elements of responsive genes, inducing gene expression 
replicative cell ageing, age-dependent response to 
oxidative stress during chronological cell ageing,  
response to stress, response to osmotic stress, response 
to oxidative stress, heat acclimation, cellular response to 
glucose starvation, regulation of transcription from RNA 
polymerase II promoter in response to stress, response to 
freezing, response to hydrostatic pressure 
22.1 % 4.1 % Msn2p Transcriptional activator related to Msn4p; activated in 
stress conditions, which results in translocation from the 
cytoplasm to the nucleus; binds DNA at stress response 
elements of responsive genes, inducing gene expression 
replicative cell aging, age-dependent response to 
oxidative stress during chronological cell aging,  response 
to stress, response to osmotic stress, response to 
oxidative stress, heat acclimation, cellular response to 
glucose starvation, regulation of transcription from RNA 
polymerase II promoter in response to stress, response to 
freezing, response to hydrostatic pressure 
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Table 3.10* TF analysis of top 100 DE genes in experiment 1 (continued from previous page). 
P1 P2 TF Description GO Biological process 
21.1 % 2.5 % Rpn4p Transcription factor that stimulates expression of 
proteasome genes; Rpn4p levels are in turn regulated by the 
26S proteasome in a negative feedback control mechanism; 
RPN4 is transcriptionally regulated by various stress 
responses 
G2/M transition of mitotic cell cycle, telomere 
maintenance, positive regulation of protein catabolic 
process, positive regulation of DNA repair, positive 
regulation of transcription, response to arsenic 
21.1 % 4.1 % Gcn4p Transcriptional activator of amino acid biosynthetic genes in 
response to amino acid starvation; expression is tightly 
regulated at both the transcriptional and translational levels 
regulation of transcription from RNA polymerase II 
promoter, unfolded protein response, positive regulation of 
target gene transcription, amino acid biosynthetic process 
18.9 % 1.8 % Sok2p Nuclear protein that plays a regulatory role in the cyclic AMP 
(cAMP)-dependent protein kinase (PKA) signal transduction 
pathway; negatively regulates pseudohyphal differentiation; 
homologous to several transcription factors 
pseudohyphal growth 
16.8 % 3.1 % Sfp1p Transcription factor that controls expression of many 
ribosome biogenesis genes in response to nutrients and 
stress, regulates G2/M transitions during mitotic cell cycle 
and DNA-damage response, involved in cell size modulation 
transcription from RNA polymerase III promoter, regulation 
of cell size, ribosome biogenesis and assembly 
16.8 % 3.7 % Pdr1p Zinc cluster protein that is a master regulator involved in 
recruiting other zinc cluster proteins to pleiotropic drug 
response elements (PDREs) to fine tune the regulation of 
multidrug resistance genes 
regulation of transcription from RNA polymerase II 
promoter, response to drug 
15.8 % 4.9 % Yhp1p One of two homeobox transcriptional repressors (see also 
Yox1p), that bind to Mcm1p and to early cell cycle box 
(ECB) elements of cell cycle regulated genes, thereby 
restricting ECB-mediated transcription to the M/G1 interval 
G1/S-specific transcription in mitotic cell cycle, negative 
regulation of transcription from RNA polymerase II 
promoter, regulation of progression through mitotic cell 
cycle, regulation of meiosis 
15.8 % 3.2 % Yox1p Homeodomain-containing transcriptional repressor, binds to 
Mcm1p and to early cell cycle boxes (ECBs) in the 
promoters of cell cycle-regulated genes expressed in M/G1 
phase; expression is cell cycle-regulated; potential Cdc28p 
substrate 
G1/S-specific transcription in mitotic cell cycle, negative 
regulation of transcription from RNA polymerase II 
promoter, regulation of progression through mitotic cell 
cycle 
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Table 3.10* TF analysis of top 100 DE genes in experiment 1 (continued from previous page). 
P1 P2 TF Description GO Biological process 
15.8 % 4.3 % Skn7p Nuclear response regulator and transcription factor, part of a 
branched two-component signaling system; required for 
optimal induction of heat-shock genes in response to 
oxidative stress; involved in osmoregulation 
response to singlet oxygen, transcription, response to 
osmotic stress, response to oxidative stress, regulation of 
cell size 
15.8 % 2.1 % Ste12p Transcription factor that is activated by a MAP kinase 
signaling cascade, activates genes involved in mating or 
pseudohyphal/invasive growth pathways; cooperates with 
Tec1p transcription factor to regulate genes specific for 
invasive growth 
conjugation with cellular fusion, invasive growth (sensu 
Saccharomyces), pseudohyphal growth, positive 
regulation of transcription from RNA polymerase II 
promoter by pheromones 
13.7 % 2.1 % Ino4p Transcription factor required for derepression of inositol-
choline-regulated genes involved in phospholipid synthesis; 
forms a complex, with Ino2p, that binds the inositol-choline-
responsive element through a basic helix-loop-helix domain 
phospholipid biosynthetic process, positive regulation of 
transcription from RNA polymerase II promoter 
13.7 % 2.6 % Abf1p DNA binding protein with possible chromatin-reorganizing 
activity involved in transcriptional activation, gene silencing, 
and DNA replication and repair 
negative regulation of transcription from RNA polymerase 
II promoter, nucleotide-excision repair, DNA damage 
recognition, DNA replication, chromatin remodeling, 
chromatin silencing at silent mating-type cassette, positive 
regulation of transcription from RNA polymerase II 
promoter 
13.7 % 6.7 % Cst6p Basic leucine zipper (bZIP) transcription factor of the 
ATF/CREB family, activates transcription of genes involved 
in utilization of non-optimal carbon sources; involved in 
telomere maintenance 
telomere maintenance, DNA metabolic process, 
transcription initiation from RNA polymerase II promoter 
12.6 % 2.3 % Swi4p DNA binding component of the SBF complex (Swi4p-Swi6p), 
a transcriptional activator that in concert with MBF (Mbp1-
Swi6p) regulates late G1-specific transcription of targets 
including cyclins and genes required for DNA synthesis and 
repair 
G1/S transition of mitotic cell cycle, transcription 
12.6 % 4.1 % Adr1p Carbon source-responsive zinc-finger transcription factor, 
required for transcription of the glucose-repressed gene 
ADH2, of peroxisomal protein genes, and of genes required 
for ethanol, glycerol, and fatty acid utilization 
negative regulation of transcription from RNA polymerase 
II promoter by glucose, regulation of carbohydrate 
metabolic process, transcription, peroxisome organization 
and biogenesis 
                                                 
* Continued on next page 
 63
Table 3.10 TF analysis of top 100 DE genes in experiment 1 (continued from previous page). 
P1 P2 TF Description GO Biological process 
12.6 % 2.7 % Mbp1p Transcription factor involved in regulation of cell cycle 
progression from G1 to S phase, forms a complex with 
Swi6p that binds to MluI cell cycle box regulatory element in 
promoters of DNA synthesis genes 
regulation of progression through cell cycle, DNA 
replication 
12.6 % 3.5 % Stb5p Activator of multidrug resistance genes, forms a heterodimer 
with Pdr1p; contains a Zn(II)2Cys6 zinc finger domain that 
interacts with a PDRE (pleotropic drug resistance element) 
in vitro; binds Sin3p in a two-hybrid assay 
transcription, response to xenobiotic stimulus, response to 
drug 
12.6 % 1.6 % Arr1p Transcriptional activator of the bZIP family, required for 
transcription of genes involved in resistance to arsenic 
compounds 
positive regulation of transcription from RNA polymerase II 
promoter, response to arsenic 
11.6 % 6.6 % Sko1p Basic leucine zipper (bZIP) transcription factor of the 
ATF/CREB family, forms a complex with Tup1p and Ssn6p 
to both activate and repress transcription; cytosolic and 
nuclear protein involved in osmotic and oxidative stress 
responses 
negative regulation of transcription from RNA polymerase 
II promoter 
11.6 % 4.7 % Gcr1p Transcriptional activator of genes involved in glycolysis; 
DNA-binding protein that interacts and functions with the 
transcriptional activator Gcr2p 
positive regulation of glycolysis, positive regulation of 
transcription from RNA polymerase II promoter 
10.5 % 2.9 % Rox1p Heme-dependent repressor of hypoxic genes; contains an 
HMG domain that is responsible for DNA bending activity 
negative regulation of transcription from RNA polymerase 
II promoter 
9.5 % 4.0 % Pdr3p Transcriptional activator of the pleiotropic drug resistance 
network, regulates expression of ATP-binding cassette 
(ABC) transporters through binding to cis-acting sites known 
as PDREs (PDR responsive elements) 
regulation of transcription from RNA polymerase II 
promoter, response to drug, positive regulation of 
transcription, DNA-dependent 
9.5 % 1.7 % Tec1p Transcription factor required for full Ty1 expression, Ty1-
mediated gene activation, and haploid invasive and diploid 
pseudohyphal growth; TEA/ATTS DNA-binding domain 
family member 
invasive growth (sensu Saccharomyces), pseudohyphal 
growth, positive regulation of transcription from RNA 
polymerase II promoter 
9.5 % 6.2 % Ino2p Component of the heteromeric Ino2p/Ino4p basic helix-loop-
helix transcription activator that binds inositol/choline-
responsive elements (ICREs), required for derepression of 
phospholipid biosynthetic genes in response to inositol 
depletion 
phospholipid biosynthetic process, positive regulation of 
transcription from RNA polymerase II promoter 
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Table 3.11* TF analysis of top 100 DE genes in experiment 2. Analysis was based on documented regulations supported by direct, indirect 
or undefined evidences. ‘P1’ is the percentage of DE genes relative to the total number of genes in the input list and ‘P2’ is the percentage 
of DE genes relative to the total number of genes regulated by the given TF. 
P1 P2 TF Description GO Biological process 
27.6 % 1.7 % Yap1p Basic leucine zipper (bZIP) transcription factor required for 
oxidative stress tolerance; mediates pleiotropic drug and 
metal resistance; localized to the nucleus in response to 
the presence of oxidants 
response to singlet oxygen, response to heat, response to 
metal ion, response to drug, regulation of transcription 
from RNA polymerase II promoter in response to oxidative 
stress, response to arsenic 
19.4 % 1.6 % Met4p Lecine-zipper transcriptional activator, responsible for the 
regulation of the sulfur amino acid pathway, requires 
different combinations of the auxiliary factors Cbf1p, 
Met28p, Met31p and Met32p 
sulfur amino acid metabolic process, positive regulation of 
transcription from RNA polymerase II promoter, response 
to arsenic, response to cadmium ion 
12.2 % 1.5 % Rpn4p Transcription factor that stimulates expression of 
proteasome genes; Rpn4p levels are in turn regulated by 
the 26S proteasome in a negative feedback control 
mechanism; RPN4 is transcriptionally regulated by various 
stress responses 
G2/M transition of mitotic cell cycle, telomere 
maintenance, positive regulation of protein catabolic 
process, positive regulation of DNA repair, positive 
regulation of transcription, response to arsenic 
11.2 % 1.1 % Sok2p Nuclear protein that plays a regulatory role in the cyclic 
AMP (cAMP)-dependent protein kinase (PKA) signal 
transduction pathway; negatively regulates pseudohyphal 
differentiation; homologous to several transcription factors 
pseudohyphal growth 
11.2 % 1.5 % Rap1p DNA-binding protein involved in either activation or 
repression of transcription, depending on binding site 
context; also binds telomere sequences and plays a role in 
telomeric position effect (silencing) and telomere structure 
chromatin silencing, chromatin silencing at telomere, 
transcription from RNA polymerase II promoter, telomere 
maintenance via telomerase, protection from non-
homologous end joining at telomere 
10.2 % 1.4 % Ste12p Transcription factor that is activated by a MAP kinase 
signaling cascade, activates genes involved in mating or 
pseudohyphal/invasive growth pathways; cooperates with 
Tec1p transcription factor to regulate genes specific for 
invasive growth 
conjugation with cellular fusion, invasive growth (sensu 
Saccharomyces), pseudohyphal growth, positive 
regulation of transcription from RNA polymerase II 
promoter by pheromones 
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Table 3.11* TF analysis of top 100 DE genes in experiment 2 (continued from previous page). 
P1 P2 TF Description GO Biological process 
10.2 % 1.7 % Ino4p Transcription factor required for derepression of inositol-
choline-regulated genes involved in phospholipid synthesis; 
forms a complex, with Ino2p, that binds the inositol-choline-
responsive element through a basic helix-loop-helix domain 
phospholipid biosynthetic process, positive regulation of 
transcription from RNA polymerase II promoter 
10.2 % 2.0 % Gcn4p Transcriptional activator of amino acid biosynthetic genes in 
response to amino acid starvation; expression is tightly 
regulated at both the transcriptional and translational levels 
regulation of transcription from RNA polymerase II 
promoter, unfolded protein response, positive regulation of 
target gene transcription, amino acid biosynthetic process 
9.2 % 2.3 % Cad1p AP-1-like bZIP transcriptional activator involved in multiple 
stress responses, iron metabolism, and pleiotropic drug 
resistance; controls a set of genes involved in stabilizing 
proteins, binds consensus sequence TTACTAA; 5' UTR 
contains uORFs 
positive regulation of transcription from RNA polymerase II 
promoter, response to cadmium ion 
9.2 % 1.7 % Swi4p DNA binding component of the SBF complex (Swi4p-
Swi6p), a transcriptional activator that in concert with MBF 
(Mbp1-Swi6p) regulates late G1-specific transcription of 
targets including cyclins and genes required for DNA 
synthesis and repair 
G1/S transition of mitotic cell cycle, transcription 
9.2 % 1.8 % Msn2p Transcriptional activator related to Msn4p; activated in 
stress conditions, which results in translocation from the 
cytoplasm to the nucleus; binds DNA at stress response 
elements of responsive genes, inducing gene expression 
replicative cell ageing, age-dependent response to 
oxidative stress during chronological cell ageing,  
response to stress, response to osmotic stress, response 
to oxidative stress, heat acclimation, cellular response to 
glucose starvation, regulation of transcription from RNA 
polymerase II, promoter in response to stress, response to 
freezing, response to hydrostatic pressure 
9.2 % 1.2 % Arr1p Transcriptional activator of the bZIP family, required for 
transcription of genes involved in resistance to arsenic 
compounds 
positive regulation of transcription from RNA polymerase II 
promoter, response to arsenic 
8.2 % 1.5 % Tec1p Transcription factor required for full Ty1 expression, Ty1-
mediated gene activation, and haploid invasive and diploid 
pseudohyphal growth; TEA/ATTS DNA-binding domain 
family member 
invasive growth (sensu Saccharomyces), pseudohyphal 
growth, positive regulation of transcription from RNA 
polymerase II promoter 
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Table 3.11* TF analysis of top 100 DE genes in experiment 2 (continued from previous page). 
P1 P2 TF Description GO Biological process 
8.2 % 1.6 % Leu3p Zinc-finger transcription factor that regulates genes involved 
in branched chain amino acid biosynthesis and ammonia 
assimilation; positively regulated by alpha-isopropylmalate, 
an intermediate in leucine biosynthesis 
regulation of transcription from RNA polymerase II 
promoter, leucine biosynthetic process 
8.2 % 1.6 % Abf1p DNA binding protein with possible chromatin-reorganizing 
activity involved in transcriptional activation, gene silencing, 
and DNA replication and repair 
negative regulation of transcription from RNA 
polymerase II promoter, nucleotide-excision repair, 
DNA damage recognition, DNA replication, chromatin 
remodeling, chromatin silencing at silent mating-type 
cassette, positive regulation of transcription from RNA 
polymerase II promoter 
7.1 % 2.4 % Mga1p Protein similar to heat shock transcription factor; multicopy 
suppressor of pseudohyphal growth defects of ammonium 
permease mutants 
filamentous growth 
7.1 % 2.0 % Rox1p Heme-dependent repressor of hypoxic genes; contains an 
HMG domain that is responsible for DNA bending activity 
negative regulation of transcription from RNA 
polymerase II promoter 
7.1 % 1.0 % Aft1p Transcription factor involved in iron utilization and 
homeostasis; binds the consensus site PyPuCACCCPu and 
activates the expression of target genes in response to 
changes in iron availability 
high affinity iron ion transport, positive regulation of 
transcription from RNA polymerase II promoter 
6.1 % 1.7 % Yap5p basic leucine zipper (bZIP) transcription factor G1/S-specific transcription in mitotic cell cycle, positive 
regulation of transcription from RNA polymerase II 
promoter 
6.1 % 1.8 % Stb5p Activator of multidrug resistance genes, forms a heterodimer 
with Pdr1p; contains a Zn(II)2Cys6 zinc finger domain that 
interacts with a PDRE (pleotropic drug resistance element) in 
vitro; binds Sin3p in a two-hybrid assay 
transcription, response to xenobiotic stimulus, 
response to drug 
6.1 % 2.8 % Yap6p Putative basic leucine zipper (bZIP) transcription factor; 
overexpression increases sodium and lithium tolerance 
positive regulation of transcription from RNA 
polymerase II promoter 
6.1 % 1.1 % Hsf1p Trimeric heat shock transcription factor, activates multiple 
genes in response to stresses that include hyperthermia; 
recognizes variable heat shock elements (HSEs) consisting 
of inverted NGAAN repeats; posttranslationally regulated 
regulation of transcription from RNA polymerase II 
promoter, response to stress, response to heat, spindle 
pole body duplication 
                                                 
* Continued on next page 
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Table 3.11* TF analysis of top 100 DE genes in experiment 2 (continued from previous page). 
P1 P2 TF Description GO Biological process 
6.1 % 1.4 % Pdr1p Zinc cluster protein that is a master regulator involved in 
recruiting other zinc cluster proteins to pleiotropic drug 
response elements (PDREs) to fine tune the regulation of 
multidrug resistance genes 
regulation of transcription from RNA polymerase II 
promoter, response to drug 
6.1 % 1.2 % Sfp1p Transcription factor that controls expression of many 
ribosome biogenesis genes in response to nutrients and 
stress, regulates G2/M transitions during mitotic cell cycle 
and DNA-damage response, involved in cell size modulation 
transcription from RNA polymerase III promoter, 
regulation of cell size, ribosome biogenesis and 
assembly 
5.1 % 1.9 % Stp2p Transcription factor, activated by proteolytic processing in 
response to signals from the SPS sensor system for external 
amino acids; activates transcription of amino acid permease 
genes 
positive regulation of transcription from RNA 
polymerase II promoter 
5.1 % 2.0 % Hcm1p Forkhead transcription factor that drives S-phase specific 
expression of genes involved in chromosome segregation, 
spindle dynamics, and budding; suppressor of calmodulin 
mutants with specific SPB assembly defects; telomere 
maintenance role 
G1/S-specific transcription in mitotic cell cycle, S-
phase-specific transcription in mitotic cell cycle, 
telomere maintenance, regulation of transcription from 
RNA polymerase II promoter, spindle pole body 
organization and biogenesis 
5.1 % 1.8 % Cin5p Basic leucine zipper transcriptional factor of the yAP-1 family 
that mediates pleiotropic drug resistance and salt tolerance; 
localizes constitutively to the nucleus 
regulation of transcription from RNA polymerase II 
promoter, response to salt stress, response to drug 
5.1 % 1.1 % Yox1p Homeodomain-containing transcriptional repressor, binds to 
Mcm1p and to early cell cycle boxes (ECBs) in the promoters 
of cell cycle-regulated genes expressed in M/G1 phase; 
expression is cell cycle-regulated; potential Cdc28p substrate 
G1/S-specific transcription in mitotic cell cycle, 
negative regulation of transcription from RNA 
polymerase II promoter, regulation of progression 
through mitotic cell cycle 
5.1 % 2.3 % Hac1p bZIP transcription factor (ATF/CREB1 homolog) that 
regulates the unfolded protein response, via UPRE binding, 
and membrane biogenesis; ER stress-induced splicing 
pathway utilizing Ire1p, Trl1p and Ada5p facilitates efficient 
Hac1p synthesis 
regulation of transcription from RNA polymerase II 
promoter, phospholipid metabolic process, unfolded 
protein response, positive regulation of target gene 
transcription, positive regulation of transcription, DNA-
dependent 
                                                 
* Continued on next page 
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Table 3.11 TF analysis of top 100 DE genes in experiment 2 (continued from previous page). 
P1 P2 TF Description GO Biological process 
5.1 % 2.6 % Fkh1p Forkhead family transcription factor with a minor role in the 
expression of G2/M phase genes; negatively regulates 
transcriptional elongation; positive role in chromatin silencing 
at HML and HMR; regulates donor preference during 
switching 
G2/M-specific transcription in mitotic cell cycle, RNA 
elongation from RNA polymerase II promoter, 
transcription termination from RNA polymerase II 
promoter, pseudohyphal growth, donor selection, 
chromatin silencing at silent mating-type cassette, 
negative regulation of progression through cell cycle, 
positive regulation of progression through cell cycle 
5.1 % 1.6 % Cbf1p Helix-loop-helix protein that binds the motif CACRTG, which 
is present at several sites including MET gene promoters and 
centromere DNA element I (CDEI); required for nucleosome 
positioning at this motif; targets Isw1p to DNA 
chromatin assembly or disassembly, chromosome 
segregation, methionine biosynthetic process,  
negative regulation of transcription, response to drug, 
positive regulation of gene-specific transcription 
5.1 % 3.6 % Dal82p Positive regulator of allophanate inducible genes; binds a 
dodecanucleotide sequence upstream of all genes that are 
induced by allophanate; contains an UISALL DNA-binding, a 
transcriptional activation, and a coiled-coil domain 
allantoin catabolic process, transcription initiation from 
RNA polymerase II promoter  
5.1 % 1.7 % Fhl1p Transcriptional activator with similarity to DNA-binding 
domain of Drosophila forkhead but unable to bind DNA in 
vitro; required for rRNA processing; isolated as a suppressor 
of splicing factor prp4 
rRNA processing, transcription from RNA polymerase 
II promoter, transcription from RNA polymerase III 
promoter 
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3.5 PATHWAY ANALYSIS 
 Pathway analysis was done primarily through literature survey of the yeast cellular 
pathways to find genes involved, followed by correlation with the DE genes identified in yeast 
producing Aβ. Secondarily, ‘Pathway Studio’ software was used to analyse how the genes in 
each pathway were affected by the Aβ fusions. 
 
Fig.3.8 Overview of genes targeted by HSF (Hahn et al., 2004). The HSF constellation 
comprised mainly of heat shock proteins (HSPs) and also genes involved in ubiquitination and 
proteolysis, vesicular transport, cell wall organization, small molecule transport, carbohydrate 
metabolism, energy generation, signal transduction and oxidative stress mechanisms. 
 
Evaluation of the Hsf1 pathway revealed that it had a large constellation of target genes 
(Fig.3.8), of which most were affected by both types of Aβ42 (see list of DE genes in CD or 
Tables 3.8 and 3.9). Apart from molecular chaperones, Hsf1 regulates many genes involved in a 
wide variety of cellular processes like ubiquitination and proteolysis, vesicular transport, cell wall 
organization, small molecule transport, carbohydrate metabolism, energy generation, signal 
transduction and oxidative stress mechanisms. Fig.3.9 details the comprehensive involvement of 
Hsf1 in various diseases and cell processes and also illustrates the associations with small 
molecules, protein functional classes and complexes. 
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Disease 
 
Fig.3.9 Comprehensive involvement of Hsf1. Pathway was compiled using Pathway Studio and the information it contained. Key to 
symbols used in pathway is shown on the right. 
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Pathway Studio was also used to examine the copper pathway. The pathway was 
compiled and curated using the information from SGD and literature research (Fig.3.10). 
Furthermore, to investigate the cellular response elicited by Aβ42GFP and GFPAβ42, the 
differential expression of genes involved in the copper pathway in the presence of Aβ42GFP and 
GFPAβ42 were individually analysed (Fig.3.11).  Up-regulation of Mac1, Cup1, Cup2, Cox17 and 
Cox23 and down-regulation of Ace1, Ace2 and Ctr3 was common to both Aβ fusions. Iron 
reductases and transporters that require copper for their function e.g. Atx1, Fet4, Fre1, Fre2, 
Fre6 and Fre7, were observed to be up-regulated in both profiles. Interestingly, there were 
differences in the expression of Hsf1, Sod1 and Ctr1 between Aβ42GFP and GFPAβ42 profiles. 
3.6 DISCUSSION 
 Experimental design: The increased scatter in the plots of Fig.3.5 indicates higher 
background and weaker binding of DNA in experiment 2, which may introduce greater false 
positives in the analysis. The variation in DNA binding could be due to the difference in 
hybridisation procedures that consequently affect the quality of signals from the two 
experiments. Arrays of experiment 1 were hybridised using an automated incubation system 
(Advalytix) that incorporates fluid handling technology based on surface acoustic waves; 
whereas arrays of experiment 2 were hybridised in a manual hybridisation chamber. Slide 
189913 that had Alexa Fluor-647 labelled cDNA from BY4743 [pAS1N.GFP] and Alexa Fluor-
555 labelled cDNA from BY4743 [pAS1N.GFPAβ42] showed a high background, making it 
impossible to identify truly significant genes that may be affected by GFPAβ42.  Hence, if array 
data from experiment 2 were to be analysed by direct comparison, results would not be as 
reliable as those from experiment 1. To overcome this, an indirect comparison was designed to 
include only good quality arrays and exclude ones that exhibited poor signals (e.g. slide 
189913). 
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Fig.3.10 Copper Pathway including all genes involved in regulation and transport of copper. Pathway was compiled using Pathway Studio 
and curated using information from SGD and literature search. Key to symbols used in pathway is shown on the left. 
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(B) 
 
 
 
 
 
 
 
 
Fig.3.11 Differential expression profile of genes in copper pathway: (A) in the presence of 
Aβ42GFP (B) in the presence of GFPAβ42. Green indicates down-regulation and red indicates up-
regulation of the given genes. The intensity of colour corresponds to the intensity of differential 
expression of the given gene. Grey colour indicates no effect on the given gene. 
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Intracellular Aβ42 fused to GFP induces oxidative stress on cells: Previous studies have 
shown that Aβ fused to GFP causes GFP misfolding in Escherichia coli (Wurth et al., 2002); 
whereas Aβ fused to mitochondrial release factor (MRF) caused its oligomerisation in yeast 
(Bagriantsev and Liebman, 2006). In this study, Aβ42 fused to GFP seems to produce oxidative 
stress in the yeast cell. Using the GO analysis, there are indications of a defence against 
oxidative stress being induced (Tables 3.2 and 3.3) by both types of Aβ, evidence of which 
become more obvious in the TF (Tables 3.10 and 3.11) and pathway analysis (Fig.3.11). Yap1, 
Skn7, Msn2, Msn4, Sod1 and Ahp1 are some of the prominent genes of the oxidative stress 
response pathway that are being induced by Aβ. Oxidative stress may be one of the earliest 
events in the development of AD, ahead of Aβ accumulation and other cytopathological changes 
(Pratico et al., 2001; Odetti et al., 1998; Nunomura et al., 2000; Nunomura et al., 2001). In vitro, 
Aβ is known to be involved in the generation of reactive oxygen species (ROS) (Adlard and 
Bush, 2006). ROS are generated through a number of different pathways of which the prominent 
sources in AD include direct interaction of Aβ with redox-active metals like Fe and Cu via Fenton 
or Fenton-like reactions (Barnham et al., 2004) mediated by biologic reducing agents (Opazo et 
al., 2002). Mechanisms underlying the metal-mediated oxidative stress have been further 
explored in the following chapter (chapter 4.4). 
Aβ may induce a heat shock response in cells: Signs of protein misfolding are evident in 
the GO analysis (Table 3.2) of Aβ42GFP. Evidence of oxidative stress has been observed for 
both Aβ42GFP and GFPAβ42 as described above. Hence, an induction of heat shock response 
(HSR) by Aβ could be expected as both ROS and protein misfolding are known inducers of HSR 
(Lee et al., 2000; Trotter et al., 2002). Furthermore, chaperone regulation in the GO analysis of 
Aβ42GFP and GFPAβ42 (Tables 3.3 and 3.6) and proteasomal activity in Aβ42GFP (Table 3.4) 
were noticed. These are further indications of HSR as Rpn4 and chaperones form part of the 
HSF constellation (Fig.3.8). An up-regulation of Hsf1 is also noticed in GFPAβ42 (Fig.3.11B). In 
addition, TF analysis demonstrates that 24.2% of the DE genes in Aβ42GFP and 6.1% of the DE 
genes in GFPAβ42 are regulated by Hsf1. Literature shows that nearly 3% (165 genes) of the 
yeast genome can be targeted by Hsf (Hahn et al., 2004; Yamamoto et al., 2005). These include 
not only heat shock proteins (HSPs), but also genes involved in a wide range of cellular 
processes, including ubiquitination and proteolysis, vesicular transport, cell wall organization, 
small molecule transport, carbohydrate metabolism, energy generation, signal transduction and 
oxidative stress mechanisms (Hahn et al., 2004; Yamamoto et al., 2005). Hence, it is likely that 
some of these genes are induced to abrogate the stress induced on the cells by Aβ. Several 
studies have shown that HSPs are more abundant in brains of people with AD. Hsp70, Hsp72 
and Grp78 (also known as HspA5) levels were significantly increased in AD brains and in AD 
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plaques (Hamos et al., 1991; Smith et al., 2005; Wilhelmus et al., 2006). The induction of HSR in 
cells by intracellular Aβ was further explored using Aβ variants and different yeast strains (see 
chapter 4.1). 
Intracellular Aβ may reduce intracellular copper availability to other metallo-proteins: The 
induction of Mac1 (Fig.3.11) and repression of Ace1 and Ace2 (Fig.3.11) are suggestive of 
reduced levels of copper in the cell. Since Aβ is known to be a metallo-protein with increased 
affinity for Cu (relative to other metals) (reviewed in Donnelly et al., 2007), intracellular Cu may 
be bound to Aβ, thus reducing its availability to other copper binding proteins. For example, most 
iron transporters and reductases require Cu for their proper function (Askwith et al., 1994, 
Spizzo et al., 1997, Casamayor et al., 1995, Georgatsou et al., 1997). This may explain the 
induction of Fet4, Fre1, Fre2 and Fre3. Induction of copper chaperones like Atx1, Cox11, Cox17 
and Ccs1 are also observed in both Aβ fusions. Collectively, these suggest reduced availability 
of intracellular copper. The role of copper in Aβ toxicity has been further investigated in the 
following chapter (chapter 4.4). 
Using the hints from the genomic profile described above, some of the biological effects of Aβ 
were further studied in yeast through in vivo assays. However, confirmation of the differential 
expression of genes via Northern blot or real-time PCR is required. Further bioinformatics could 
also reveal other Aβ interactions. For instance, differential expressions of genes involved in 
pathways of oxidative stress, MAPK signalling and cell cycle would be useful to discern the 
mechanisms of Aβ toxicity and identify differential interactions of the C and N terminals of Aβ. 
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CHAPTER 4 
STUDY OF TOXICITY MECHANISMS AND INTERACTIONS OF Aβ 
As outlined in chapter 1, a plethora of hypotheses on the cause of AD and a range of 
assays to measure outcomes in different treatments have evolved. Although Aβ is a 
naturally-occurring protein, an accelerated production of this amyloidogenic protein leads to 
AD via unknown triggering mechanisms. Identification of factors that influence Aβ toxicity 
would help us understand how Aβ affects cell metabolism and AD pathogenesis, and thus 
develop strategies to overcome the Aβ directed toxicity. Some of the pathways affected by 
intracellular Aβ in yeast were identified in the previous chapter (chapter 3). In this study, 
those pathways are analysed using in vivo assays to reveal the mechanisms involved in the 
toxicity and interactions of intracellular Aβ. 
Since this study utilises Aβ fused to GFP (a green fluorescent protein), protein 
expression was indicated by the fluorescence of recombinant cells. Previous studies in our 
lab have indicated maximal proportion of fluorescent cells and optimal protein expression at 
the log phase of cell growth. Furthermore, stationary cells seemed to lose fluorescence. 
Hence, most of the assays in this study were performed on log phase cells. But some assays 
(e.g. HSR assays) were performed on both log phase and stationary phase cells. A slight 
growth reduction of 5% has also been observed in cells expressing Aβ fused to GFP (Caine 
et al., 2007). 
4.1 INVESTIGATING THE STRESS RESPONSE TO Aβ AND ITS MECHANISMS 
The heat shock response (HSR) is a stress defence pathway required both in stress 
and normal conditions. The HSR is highly conserved from humans to yeast and consists of a 
large set of molecular chaperones that, upon stimulation, bind to partially unfolded or 
misfolded proteins to prevent aggregation. This is either by facilitating proper conformational 
refolding or directing them to degradation (reviewed in Calabrese et al., 2007). A HSR is 
triggered by the enhanced binding of the conformationally active heat shock transcription 
factor (HSF) to arrays of 5-bp sequences (nGAAn) called heat shock elements (HSE), 
present upstream of all heat shock genes (Xiao et al., 1991; Wu, 1995; Hahn et al., 2004; 
Giardina and Lis, 1995) (see Fig.4.1).  
The HSR is primarily modulated by the activity of HSF rather than by its 
concentration. In yeast, HSF is constitutively expressed (Jakobsen and Pelham, 1988) and a 
second factor like protein misfolding or ROS can stimulate its activity to cause HSR (Lee et 
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al., 2000; Trotter et al., 2002). In AD, since there is an involvement of ROS and protein 
misfolding associated with Aβ, an induction of HSR by Aβ could be expected. In the previous 
chapter, the genomic profiling of yeast producing intracellular Aβ revealed an upregulation of 
heat shock genes, that is, genes with upstream HSEs. This study investigates the induction 
of HSR by various intracellular Aβ species and analyses the probable causes. 
 
HSF oxidative stress, aberrant protein folding, temperature change, etc.
HSE HSP  
Fig.4.1 Induction of heat shock response (HSR) – schematic representation 
 
4.1.1 β-galactosidase filter assay 
To investigate whether wild-type Aβ (Aβ42) caused HSR, the URA- LEU+ yeast 
(BY4743) transformants producing GFP, Aβ42GFP and GFPAβ42 (Caine et al., 2007)  were 
further transformed with a reporter plasmid that selectively allowed growth of positive 
transformants in the absence of uracil and leucine. The reporter plasmid encodes the yeast 
heat shock element (HSE) fused to a downstream β-galactosidase (lacZ) gene (Sorger and 
Pelham, 1987). Both N-terminal and C-terminal fusions of Aβ were assayed to evaluate the 
presence of any differential effects. 
When the heat shock reporter plasmid was present in cells where GFP was 
produced, levels of β-galactosidase were low (faint green) (Fig.4.2). In contrast, cells 
producing GFPAβ42 and Aβ42GFP showed higher β-galactosidase activity (dark blue-green) 
(Fig.4.2). The mediation of this effect specifically through the HSE was demonstrated via a 
control construct wherein the HSE was mutated (mt HSE). All yeast transformants with mt 
HSE showed negligible β-galactosidase activity (no colour change) (Fig.4.2). 
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HSE HSE
HSE mt HSE
mt HSEmt HSE
GFP
GFP-Aβ42 Aβ42-GFP
 
Fig. 4.2 HSR induced in BY4743 [pAS1N.GFP], BY4743 [pAS1N.GFPAβ42] and BY4743 
[pAS1N.Aβ42GFP] – all containing either the HSE-lacZ or the mt HSE-lacZ reporters. ‘HSE’ 
denote cells containing the wild-type heat shock reporter plasmid (HSE-lacZ) and ‘mt HSE’ 
denote cells containing the control reporter plasmid in which the HSE was mutated (mt HSE-
lacZ). The change in colour indicates a positive reaction i.e. HSF-directed β-galactosidase 
activity. The protocol used for this assay is described in chapter 2 (see section 2.2.3.1) 
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4.1.2 HSR assay of yeast expressing wild-type Aβ 
In order to quantitate the level of HSR observed above, the β-galactosidase activity in 
the yeast transformants was measured (Fig.4.3). Yeast cells (BY4743) producing GFPAβ42 
and Aβ42GFP had high levels of β-galactosidase activity that were very significant 
(P<0.0001), compared to the low levels in GFP expressing cells. β-galactosidase activity in 
all yeast transformants with a mutated HSE were at very low levels compared to GFP and 
Aβ42/GFP fusions containing the wild-type HSE (Fig.4.3). 
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Fig. 4.3 Quantification of HSR induced in BY4743 [pAS1N.GFP], BY4743 [pAS1N.GFPAβ42] 
and BY4743 [pAS1N.Aβ42GFP] (n≥3). Every recombinant clone contained either the HSE-
lacZ or the mt HSE-lacZ reporters. Overnight cultures grown at 30°C were assayed for the 
HSF-directed β-galactosidase activity. Error bars in graph represent standard error of mean 
(SEM). 
 
4.1.3 HSR assay of yeast expressing different Aβ species 
To investigate whether the HSR varied in the presence of different Aβ species, the 
wild-type HSE reporter was transformed into yeast cells (W303-1A) producing Aβ42GFP, 
GFPAβ42, GFPAβ40, GFPAβ28 and GFPAβ16, where Aβ28 and Aβ16 are recombinantly 
truncated to contain residues 1-28 and 1-16 respectively. β-galactosidase activity was 
significantly higher (P<0.001) in cells producing Aβ42GFP, GFPAβ42 and GFPAβ40 compared 
to GFP producing cells (Fig.4.3), whereas cells producing GFPAβ28 (Fig.4.4) and GFPAβ16 
(Fig.4.5) showed no significant difference (P>0.05) from that of GFP producing cells. It is also 
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noteworthy that cells expressing Aβ42GFP showed significantly less (P<0.001) β-
galactosidase levels compared to GFPAβ42 (Fig.4.4).  
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Fig. 4.4 HSR induced in W303-1A [pAS1N.GFP], W303-1A [pAS1N.Aβ42GFP], W303-1A 
[pAS1N.GFPAβ42], W303-1A [pAS1N.GFPAβ40] & W303-1A [pAS1N.GFPAβ28] (n=6). Every 
recombinant clone was further transformed with the HSE-lacZ reporter. Overnight cultures 
grown at 30°C were assayed for the HSF-directed β-galactosidase activity. Error bars in 
graph represent standard error of mean (SEM). 
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Fig. 4.5 HSR induced in W303-1A [p416.GFP], W303-1A [p416.GFPAβ42] and W303-1A 
[p416.GFPAβ16] (n=3). Every recombinant clone was further transformed with the KHSE 
reporter (see Table 2.2). Overnight cultures grown at 30°C were assayed for HSF-directed β-
galactosidase activity. Error bars in graph represent standard error of mean (SEM). 
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4.1.4 Flow cytometry analysis of yeast expressing different Aβ species 
Incorrect folding of Aβ can interfere with folding of the GFP tag attached to it, thereby 
quenching its fluorescence (Wurth et al., 2002). The protein folding status of GFP, GFPAβ42, 
GFPAβ28 and GFPAβ16 produced in yeast was determined using flow cytometry in the mid-
log phase of growth. Analysis showed that the percentage of live cells fluorescing green was 
significantly lower (P<0.001) in cells producing GFPAβ42 compared to GFP producing cells, 
whereas cells producing GFPAβ16 showed no difference from GFP producing cells (P>0.05) 
(Fig.4.6). Cells producing GFPAβ28 had a marked increase in fluorescence compared with 
GFPAβ42 (P<0.001), but not as high as cells with GFP or GFPAβ16 (P<0.01) (Fig.4.6). 
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Fig. 4.6 Green fluorescence in yeast cells (W303-1A) producing GFP, GFPAβ42, GFPAβ28 
and GFPAβ16 (n=3). Cultures were initiated at the same cell density (A600 nm) and grown at 
30°C. At mid-log phase, the percentage of dead cells and live fluorescing cells were 
analysed using flow cytometry. Error bars in graph represent standard error of mean (SEM). 
 
4.1.5 HSR assay of yeast expressing mutated GFP and wild-type Aβ 
To establish the effect of aberrant protein folding on HSR, mutated GFP was 
introduced into yeast cells. The plasmid producing this mutated GFP was constructed by 
Sonia Sankovich (CSIRO-MHT). It had three amino acid substitutions around the fluorophore 
and was designed to remove the fluorescence of GFP, but interestingly, they caused GFP to 
become misfolded and insoluble in the SDS-PAGE analyses done by Sonia (unpublished 
results). As a consequence of the changes, a significantly higher (P<0.001) HSR was 
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observed in cells producing the mutated GFP (GFPmt) compared to cells with wild-type GFP 
(Fig.4.7).  
When wild-type Aβ was fused to the mutated GFP (GFPmt-Aβ42), the HSR was 
significantly higher (P<0.01) than when the other recombinant proteins were produced i.e. 
above GFP, GFP-Aβ42 and mutated GFP alone (Fig.4.7) with little adverse effect on growth 
(Fig.4.7 - inset). This result indicates that Aβ42 has an additional effect that goes beyond 
protein folding. This effect could be due to Aβ42-induced ROS activity. 
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Fig. 4.7 HSR induced in BY4743 [pAS1N.GFP], BY4743 [pAS1N.GFPAβ42], BY4743 
[pAS1N.GFPmt] and BY4743 [pAS1N.GFPmt-Aβ42] (n≥5) – Cell density is shown in inset. 
Every recombinant clone was further transformed with the HSE-lacZ reporter. Overnight 
cultures grown at 30°C were assayed for the HSF-directed β-galactosidase activity. Error 
bars in graph represent standard error of mean (SEM). 
 
4.1.6 HSR assay of yeast after treatment with antioxidants 
To study the role of ROS in HSR, yeast double-transformants producing GFP, 
Aβ42GFP and GFPAβ42 and the HSE reporter were treated with increasing amounts of the 
anti-oxidant, ascorbic acid. Cells were treated during the mid-log phase of growth before 
assaying for β-galactosidase levels. Cells producing both GFPAβ42 and Aβ42GFP showed a 
decline in β-galactosidase activity, while GFP producing cells showed a slight drop (Fig.4.8). 
One interpretation of this result could be that ascorbic acid may have been reducing levels of 
ROS in cells producing Aβ42GFP and GFPAβ42. 
To determine the specificity of this effect and also to check if ascorbic acid affected β-
galactosidase activity, wild-type yeast that constitutively produced β-galactosidase (K. lactis) 
were similarly treated. Analysis showed that ascorbic acid treated K. lactis cells showed a 
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similar decline in β-galactosidase activity (Fig.4.9). Likewise, treatments with increasing 
amounts of other antioxidants such as DTT and GSH also showed a decline in the β-
galactosidase activity of K. lactis (Fig.4.10). 
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Fig. 4.8 HSR levels induced in BY4743 [pAS1N.GFP], BY4743 [pAS1N.Aβ42GFP] and 
BY4743 [pAS1N.GFPAβ42] with ascorbic acid treatment (n=1). Every recombinant clone was 
further transformed with the HSE-lacZ reporter. Cultures were grown overnight at 30°C in 
selective media, refreshed the following day and grown further to reach similar cell density 
(A600 nm). At mid-log phase, each culture was treated with increasing amounts of ascorbic 
acid and grown for 2 hours at 30°C. The HSF-directed β-galactosidase activity was 
measured after 2 hours. 
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Fig. 4.9 β-galactosidase levels in K. lactis following ascorbic acid treatment (n=3). Cultures 
were grown overnight at 30°C in selective media, refreshed the following day and grown 
further to reach similar cell density (A600 nm). At mid-log phase, each culture was treated with 
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increasing amounts of ascorbic acid and grown for 2 hours at 30°C. β-galactosidase activity 
was measured after 2 hours. Error bars in graph represent standard error of mean (SEM). 
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Fig. 4.10 β-galactosidase levels in K. lactis following treatment with (A) DTT (n=1) and (B) 
GSH (n=1). Cultures were grown overnight at 30°C in selective media, refreshed the 
following day and grown further to reach similar cell density (A600 nm). At mid-log phase, 
each culture was treated with increasing amounts of DTT or GSH and grown for 2 hours at 
30°C. β-galactosidase activity was measured after 2 hours. 
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4.1.7 HSR assay of ahp1 mutant yeast expressing wild-type Aβ 
To further explore the effect of oxidative stress on HSR, Ahp1 knock-out yeast 
mutants of BY4743 were doubly-transformed with pAS1N.GFP, pAS1N.Aβ42GFP and 
pAS1N.GFPAβ42 and an HSE reporter. Analysis showed that in comparison with wild-type 
yeast (BY4743) producing GFP, the background HSR levels were significantly raised 
(P<0.05) in ahp1 mutant cells producing GFP (Fig.4.11). Aβ production in these mutants 
further enhanced HSR levels significantly (P<0.001), irrespective of the fusion form of Aβ42 
(Fig.4.11). 
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Fig. 4.11 HSR induced in ahp1 and BY4743 strains transformed with pAS1N.GFP, 
pAS1N.Aβ42GFP and pAS1N.GFPAβ42 and further transformed with the HSE-lacZ reporter 
(n=3). Overnight cultures grown at 30°C were assayed for the HSF-directed β-galactosidase 
activity. Error bars in graph represent standard error of mean (SEM). 
 
4.1.8 Discussion 
HSR is specifically induced by toxic species of intracellular Aβ: Utilizing the 
mechanism of HSR induction, preliminary experiments were conducted with an HSE-lacZ 
reporter system. An increase in β-galactosidase activity dependent on a functional HSE was 
observed in each of the transformants producing Aβ42 fused to GFP (Fig.4.2), indicating that 
an HSR is elicited in all cells producing Aβ42. This specific increase was found to be 
statistically significant in subsequent analysis (Fig.4.3). The low-level HSR seen in cells 
expressing GFP only may be due to basal levels of ROS in cells and probably to foreign 
protein expression. Whilst cells producing both N-terminally fused Aβ (GFPAβ42) and C-
terminally fused Aβ (Aβ42GFP) showed significantly greater HSR than GFP producing cells, 
the levels for GFPAβ42 cells were much higher than for Aβ42GFP cells (Fig.4.4), probably 
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owing to the hydrophobic nature of the C-terminus of GFPAβ42 that is unbound to GFP and 
hence exposed to improper interactions. Aβ fused to the N-terminus and C-terminus of GFP 
has previously been shown to have differential properties (Caine et al., 2007). This 
demonstrates that the HSR assay can detect effects from minor changes to Aβ with great 
sensitivity. Additional experiments show that HSR levels decline as the C-terminus of Aβ is 
truncated, with reduced HSR in GFPAβ40, the lesser amyloidogenic species (reviewed by 
Jarrett et al., 1993), and almost no HSR in the species, GFPAβ1-28 and GFPAβ1-16 (Fig.4.4 
and Fig.4.5). The lack of toxicity and proper folding of these Aβ species correlated with an 
increased number of fluorescing cells in GFPAβ1-28 and GFPAβ1-16 producing cell lines 
compared to the wild-type GFPAβ42 producing cells (Fig.4.6), determined by flow cytometry. 
This confirms that it is the toxic form of Aβ that stresses the yeast cells, thereby eliciting 
HSR. Increasing evidence points to the presence of HSR in AD. Rapid induction of Hsp70 
has been reported in neuronal cells secreting intracellular Aβ42 (Magrane et al., 2004). An 
inverse relationship between aggregated tau and levels of Hsp70 and Hsp90 has also been 
observed in a tau transgenic mouse as well as AD brains (Dou et al., 2003). Several studies 
have shown the co-localisation and abundance of HSPs in human AD brains. HSP70, 
HSP72 and GRP78 (also known as HSPA5) levels were significantly increased in AD brains 
and in extracellular AD plaques (Hamos et al., 1991; Smith et al., 2005; Wilhelmus et al., 
2006). The recognition that yeast responds specifically to Aβ42 with HSR further confirms that 
Aβ42 is a deleterious entity. Hence, estimation of HSR can be regarded as a measure of the 
toxicity/stress caused by Aβ and can be easily be developed into a high-throughput assay. 
Aberrant protein folding and oxidative stress are both toxicity factors of Aβ: The non-
toxic species, Aβ1-28 and Aβ1-16 were found to be significantly more fluorescent than Aβ42 
when fused to GFP (Fig.4.6), indicating that these proteins fold correctly and thereby do not 
alter the folding and fluorescence of the attached reporter. In the absence of protein 
misfolding, Aβ remained non-toxic and no HSR was produced (Fig.4.4 and Fig. 4.5). 
Although Aβ17-21 is the central hydrophobic cluster (Wurth et al., 2002) that is located in the 
transmembrane domain of APP, the C-terminal region from residues 28-42 is considered to 
be more hydrophobic and crucial for the nucleation of fibre formation (reviewed by Jarrett et 
al., 1993). This could explain why a difference in fluorescence was apparent for Aβ1-28 
compared with Aβ1-16 and GFP (Fig.4.6). The role of protein misfolding and oxidative stress in 
HSR was further probed using the control protein, GFP. A misfolded GFP mutant induced a 
substantial increase in HSR compared with wild-type GFP (Fig.4.7), validating abnormal 
protein folding as a contributing factor in the cause of HSR. Wild-type GFP was also 
produced in yeast cells that were oxidatively stressed due to the absence of Ahp1, a 
reductase that protects against oxidative damage [Lee et al., 1999]. GFP in these cells 
exhibited a higher HSR than in normal cells (Fig.4.11). Consistent with earlier observations, 
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these results confirm that protein misfolding and oxidative stress can induce HSR. A further 
rise in HSR levels was seen in the presence of Aβ42 in both oxidatively stressed cells and 
cells expressing mutated GFP (Fig.4.7 and Fig.4.11). Former studies showed that Aβ fused 
to GFP causes GFP misfolding in Escherichia coli (Wurth et al., 2002) and yeast  (Caine et 
al., 2007), while Aβ fused to mitochondrial release factor (MRF) caused its oligomerization in 
yeast (Bagriantsev and Liebman 2006). Aβ is also known to be involved in the generation of 
reactive oxygen species (ROS) (reviewed by Adlard and Bush, 2006). Taken together, the 
data suggest that the HSR induction by Aβ is attributable to both aberrant protein folding and 
oxidative stress. 
Antioxidants affect β-galactosidase activity: Attempts to rescue the Aβ toxicity with an 
antioxidant (ascorbic acid) showed decreasing HSR with increasing amounts of the 
antioxidant (Fig.4.8). This may indicate that generation of ROS is the cause of Aβ toxicity. 
However, a more comprehensive analysis of wild-type yeast strains that naturally show 
constitutive levels of β-galactosidase clarified that the anti-oxidants were affecting the 
enzyme activity itself (Fig.4.9 and 4.10). This was a surprising and a novel discovery. Assays 
utilising β-galactosidase are popular as a robust reporter assay and there have been no 
reports of the enzyme being affected by reducing agents, despite it being routinely used in 
conjunction with antioxidants. 
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4.2 ASSAYING THE TOXICITY OF SPECIFIC Aβ MUTANTS  
The literature highlights several amino acid residues in Aβ as the basis of the 
characteristic properties of Aβ. An E. coli model that studied Aβ-GFP identified variants of 
Aβ42 with reduced aggregation tendencies (Wurth et al., 2002). An M35V change in Aβ42 was 
found to have enhanced toxicity (Ciccotosto et al., 2004). Several studies report involvement 
of three histidine residues in the N-terminal hydrophilic region of Aβ in primary metal binding 
(Miura et al., 2000; Barnham et al., 2004; Stellato et al., 2006). FAD mutations that occur in 
Aβ are known to initiate an earlier onset of disease. 
In this study, the HSR assay has been used to elucidate the factors and mechanisms 
of in vivo Aβ toxicity in some of these known mutants and also to simultaneously evaluate the 
sensitivity and specificity of the assay. 
4.2.1 Fluorescence of Aβ double mutants 
Previous studies have shown that incorrect folding of Aβ can interfere with folding of 
the GFP tag attached to it, thereby quenching its fluorescence (Kim et al., 2006; Wurth et al., 
2002) and altering the cell phenotype (Caine et al., 2007). Aβ42 fused to GFP also showed 
different protein folding in yeast (Caine et al., 2007) and in E. coli (Wurth et al., 2002). 
Hence, to detect the occurrence of any changes in the folding of Aβ42 mutants, some of the 
mutations identified in the E. coli model (Wurth et al., 2002) were expressed in yeast.  
Yeast (W303-1A) were transformed with pAS1N.GFP, pAS1N.GFPAβ42 and mutants 
of pAS1N.GFPAβ42 with two changes each in Aβ42 (i.e. F19S/L34P, M35R/V36E and 
I32N/V36A)* and analysed using fluorescent microscopy. Microscopy revealed that all strains 
with double changes in Aβ42 exhibited a uniform fluorescence throughout the cell in contrast 
to the punctate phenotype of cells producing Aβ42GFP and GFPAβ42) (Fig.4.12).   
On quantitating the percentage of live cells fluorescing green via flow cytometry, all 
the mutants showed a 20% increase (P<0.001) in fluorescence compared to those cells with 
wild-type GFPAβ42 (Fig.4.12). Yet, the fluorescence of all cells with double changes in Aβ 
were notably less (P<0.001) than those with GFP (Fig.4.13). The percentage of dead cells 
was insignificant in all the cell lines. 
                                                 
* The numbering of amino acid residues is from the start of Aβ and not GFP. 
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Fig. 4.12 Fluorescence microscopy images of yeast (W303-1A) producing GFP, GFPAβ42 
and mutants of GFPAβ42 with the changes, F19S/L34P, M35R/V36E and I32N/V36A within 
Aβ. Overnight cultures were refreshed and grown further for 2-4 hours before observing 
under the microscope. 
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Fig. 4.13 Green fluorescence in yeast (W303-1A) transformed with pAS1N.GFP, 
pAS1N.GFPAβ42 and mutants of pAS1N.GFPAβ42 with two changes each in Aβ42 (i.e. 
F19S/L34P, M35R/V36E and I32N/V36A) (n=3). Cultures were initiated at the same cell 
density (A600 nm) and grown at 30°C. At mid-log phase, the percentage of dead cells and live 
fluorescing cells were analysed using flow cytometry. Error bars in graph represent standard 
error of mean (SEM). 
 
4.2.2 HSR assay with Aβ double mutants 
To investigate the differential HSR levels caused by these more fluorescent Aβ 
double mutants, the HSE reporter was transformed into yeast cells producing the 
recombinant proteins and analysed for HSR levels. A significant decrease (P<0.001) in 
stress levels was observed in all mutants of Aβ42 (i.e. F19S/L34P, M35R/V36E and 
I32N/V36A) compared to wild-type Aβ (GFPAβ42) (Fig.4.14). But the HSR of all mutants 
remained significantly above GFP (Fig.4.14). 
4.2.3 Protein analysis of Aβ double mutants 
To examine the protein folding in the Aβ double mutants, western blot analyses were 
performed. The mutant GFP-Aβ42 F19S/L34P showed higher amounts of soluble protein in 
the supernatant (S) and in the pellet (P1 solubilised in Na2CO3 and urea) than the wild-type 
Aβ42 (GFP-Aβ42) (Fig. 4.16, panels A and C); whereas the insoluble protein fraction (P2) 
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remained at similar levels in both mutant and wild-type (Fig.4.16, panels A and C). 
Interestingly, the mutants GFP-Aβ42 M35R/V36E and GFP-Aβ42 I32N/V36A showed similar 
amounts of protein in the supernatant (S) fraction and less in the pellet fractions P1 and P2 
than the wild-type Aβ42 (GFP-Aβ42) (Fig.4.16, panels B and D). All bands, including 
degradation products were included in the densitometry analysis. The protein fractionation 
was verified by Coomassie staining (Fig.4.15).  
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Fig. 4.14 HSR induced in yeast (W303-1A) doubly transformed with the plasmid-borne HSF 
reporter and plasmids directing synthesis of pAS1N.GFP, pAS1N.GFPAβ42 and mutants of 
pAS1N.GFPAβ42 with two changes each in Aβ42 (i.e. F19S/L34P, M35R/V36E and 
I32N/V36A) (n=5). Cultures were grown overnight at 30°C and the HSF directed β-
galactosidase activity was determined. Error bars in graph represent standard error of mean 
(SEM). 
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Fig. 4.15 Protein fractionation by SDS-PAGE of (A) lysates of W303-1A yeast cells 
producing GFPAβ42 and GFPAβ42 F19S/L34P (B) lysates of W303-1A yeast cells producing 
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GFPAβ42, GFPAβ42 I32N/V36A and GFPAβ42 M35R/V36E. (A) and (B) were two different 
experiments and the amount of cells lysed were equal only between cell lines within each 
experiment. 
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Fig. 4.16 (A) Western blots of lysates of W303-1A yeast cells producing GFPAβ42 or 
GFPAβ42 F19S/L34P probed with antibody to GFP. (B) Western blots of lysates of W303-1A 
yeast cells producing GFPAβ42, GFPAβ42 M35R/V36E or GFPAβ42 I32N/V36A probed with 
antibody to GFP. (C) Densitometric quantitation corresponding to panel A expressed as 
arbitrary OD units. (D) Densitometric quantitation corresponding to panel B expressed as 
arbitrary OD units. Antibody to GFP was used for detection. Markers denote size in kDa. 
Lanes are S: soluble supernatant fraction, P1: pellet fraction solubilised in Na2CO3 and urea, 
P2: pellet fraction insoluble in Na2CO3 and urea. 
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4.2.4 Fluorescence of Aβ single mutants 
Increased toxicity of an M35V change in Aβ in a neuronal cell assay has been 
previously established (Ciccotosto et al., 2004). In order to detect the possible changes in 
folding of this particular mutant when expressed in yeast, the percentage of live cells 
fluorescing green in W303-1A cells producing GFP and M35V mutants of GFPAβ42 was 
assayed via flow cytometry. As shown in Fig.4.17, the GFPAβ42 M35V mutant showed 10% 
reduction in fluorescence (P<0.001) from wild-type Aβ (GFPAβ42) and another mutant 
(GFPAβ42 M35S). It is notable that the fluorescence of the M35S mutant did not differ from 
wild-type Aβ (P>0.05). The percentage of dead cells remained the same across all the cells, 
irrespective of the type of protein produced. 
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Fig. 4.17 GFP fluorescence in yeast W303-1A transformed with pAS1N.GFP, 
pAS1N.Aβ42GFP and mutants of pAS1N.Aβ42GFP with changes M35V or M35S within Aβ 
(n=3). Cultures were initiated at the same cell density (A600 nm) and grown at 30°C. At mid-log 
phase, the percentage of dead cells and live fluorescing cells were analysed using flow 
cytometry and plotted. Error bars in graph represent standard error of mean (SEM). 
 
4.2.5 HSR assay with Aβ single mutants 
The HSE reporter was transformed into yeast (W303-1A) producing mutant forms of 
Aβ42GFP that had the changes M35V and M35S and analysed for HSR levels. Fig.4.18 
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shows HSR levels increased significantly in cells producing the M35V mutant form of 
Aβ42GFP compared to the wild-type Aβ42GFP (P<0.01) and M35S mutant form of Aβ42GFP 
(P<0.001). This observation supports the decreased fluorescence (Fig.4.17) and increased 
toxicity (Ciccotosto et al., 2004) observed with the M35V mutant form. The M35S mutant 
form of Aβ42GFP displayed no variation (P>0.05) in HSR from the wild-type Aβ42GFP 
(Fig.4.17). 
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Fig. 4.18 HSR induced in yeast (W303-1A) transformed with pAS1N.GFP, pAS1N.Aβ42GFP 
and mutants of pAS1N.Aβ42GFP with M35V or M35S changes within Aβ (n=3). Cultures were 
grown overnight at 30°C and the HSF directed β-galactosidase activity was determined. Error 
bars in graph represent standard error of mean (SEM). 
 
4.2.6 HSR assay with Histidine mutants 
Studies report involvement of three histidine residues present in the N-terminal 
hydrophilic region of Aβ, in primary metal binding (Miura et al., 2000; Barnham et al., 2004; 
Stellato et al., 2006). To investigate any variation of toxicity between metal bound and free 
Aβ, the metal binding sites of Aβ42GFP were mutated differentially (H13N, H13N/H14N and 
H6N/H13N/H14N). These mutants were transformed into yeast cells (BY4743), further 
transformed with the HSE reporter and analysed for HSR levels. It was observed that HSR 
produced by all the histidine mutant forms of Aβ42GFP was significantly higher (P<0.001) 
than that of GFP, but interestingly not different (P>0.05) from the wild-type Aβ42GFP 
(Fig.4.19). 
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Fig. 4.19 HSR induced in yeast (BY4743) transformed with pAS1N.GFP, pAS1N.Aβ42GFP 
and mutants of pAS1N.Aβ42GFP with mutations of histidine residues in Aβ i.e. H13N, 
H13N/H14N and H6N/H13N/H14N (n≥5). Cultures were grown overnight at 30°C and the 
HSF directed β-galactosidase activity was determined. Error bars in graph represent 
standard error or mean (SEM). 
 
4.2.7 HSR assay in FAD mutants 
Some of the FAD mutations occur in Aβ and initiate an earlier onset of disease. 
Amongst the FAD mutations, the Dutch (E22Q) and Iowa (D23N) were reproduced in the 
pAS1N.Aβ42GFP constructs and transformed into the W303-1A yeast strain. The yeast strain 
was then further transformed with the HSE reporter. Considerably higher (P<0.001) stress 
levels were generated by cells producing the Dutch and Iowa mutant forms of Aβ42GFP and 
wild-type Aβ42GFP as compared to cells producing GFP. However, no difference (P>0.05) 
was observed between the mutant forms and wild-type form of Aβ42GFP (Fig.4.20). 
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Fig. 4.20 HSR in yeast (W303-1A) transformed with pAS1N.GFP, pAS1N.Aβ42GFP and the 
FAD mutant forms of pAS1N.Aβ42GFP containing Dutch (E22Q) and Iowa (D23N) mutations 
within Aβ (n=4). Cultures were grown overnight at 30°C and the HSF directed β-
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galactosidase activity was determined. Error bars in graph represent standard error of mean 
(SEM). 
4.2.8 Discussion 
 Mutations of Aβ residues responsible for protein aggregation reduce the stress on 
cells: Several amino acid residues in Aβ affect its tendency to aggregate or form fibrils. The 
hydrophobic residues at positions 19, 34 and 35 in the Aβ42 sequence are known to affect 
folding and assembly of Aβ [reviewed by (Wurth et al., 2002). Though single mutations at 
these points prevented Aβ misfolding to a certain degree, a double mutation (F19S/L34P) 
entirely rescued the misfolding in E. coli (Wurth et al., 2002). Yeast expressing the same Aβ 
double mutant, F19S/L34P, exhibit uniform fluorescence similar to that seen in GFP 
producing cells (Fig.4.12). However, quantitative analysis reveals that, though a relative 
improvement in folding (Fig.4.13) and protein solubility (Fig.4.16, panels A and C) is 
observed in the Aβ double mutant compared to the wild-type Aβ, there was incomplete 
rescue. Fluorescence levels in the Aβ mutant were still lower than GFP (Fig.4.13). In 
agreement with this observation, the HSR levels in the F19S/L34P mutant were substantially 
lower than the wild-type form (Fig.4.14). Other Aβ double mutants, M35R/V36E and 
I32N/V36A, also show rises in fluorescence and a drop in HSR levels similar to that of the 
F19S/L34P mutant (Fig.4.13 and 4.14). Though there is a slight difference in fluorescence 
and HSR levels between the F19S/L34P mutant and the M35R/V36E and I32N/V36A 
mutants, the difference was not statistically significant. Nevertheless, M35R/V36E and 
I32N/V36A mutants were distinctly insoluble compared with wild-type Aβ (Fig.4.16, panels B 
and D). Supporting this contention, data from the E. coli study showed decreased 
fluorescence with M35R/V36E and I32N/V36A mutants compared to the F19S/L34P mutant 
(Wurth et al., 2002). Consistent with the observations from E. coli and other studies, the HSR 
data clearly indicate that mutations of Aβ residues that are responsible for protein 
aggregation reduce the stress on cells.  
Mutations of Aβ residues that amplify toxicity increase the stress on cells: The 
methionine residue at position 35 in the Aβ42 sequence has been reported to play a key role 
in Aβ toxicity via oxidative stress (Varadarajan et al., 1999; Varadarajan et al., 2001; 
Butterfield, 2002). A novel Aβ mutant, M35V, was shown to have increased toxicity due to 
Cu2+ binding, H2O2 generation and higher affinity for the lipid bilayer (Ciccotosto et al., 2004). 
Complementing these observations, the M35V mutant showed remarkably high HSR levels 
compared with the wild-type Aβ (Fig.4.18) and caused a corresponding drop in GFP 
fluorescence (Fig.4.17) when fused to GFP and expressed in yeast. This validates that 
amplified Aβ toxicity, as seen with other systems, elicits a high stress on yeast cells as well. 
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HSR detects hydrophobicity as one mode of Aβ toxicity: On further analysis of the 
above mutants, it may be inferred that mutations causing an increased HSR are ones that 
render Aβ more hydrophobic. For example, with the more toxic Aβ mutant, M35V, a 
hydrophobic residue (methionine) is replaced by another hydrophobic residue (valine). 
Conversely, in the less toxic Aβ mutant, F19S/L34P, hydrophobic residues (phenylalanine 
and leucine) are replaced by polar amino acids (serine and proline). Accordingly it may be 
assumed that, apart from protein misfolding and oxidative stress, HSR detects 
hydrophobicity of Aβ as a degree of its toxicity. This may explain why the histidine mutants 
(Fig.4.19) and FAD mutants (4.20) did not show any significant variation in HSR from the 
wild-type Aβ. There is no net change in the hydrophobicity in the histidine and FAD mutants 
used in this study since all mutations were replacements of one polar residue by another. In 
fact, hydrophobicity is an underlying cause of protein misfolding and oxidative stress. 
Misfolded proteins have exposed hydrophobic side chains, which in turn can cause oxidative 
stress through improper interactions and generation of ROS. Complementing this 
perspective, a recent study has shown that hydrophobic stretches in the Aβ sequence are 
sufficient to promote aggregation (Kim and Hecht, 2006). 
 The yeast HSR assay can be used as a reliable and robust screen for AD 
therapeutics against Aβ: Yeast assays are advantageous over other model systems due to 
the functional homology of yeast to human cells and the availability of a huge range of 
experimental resources in yeast, especially for drug discovery (Ma, 2001). An E. coli study 
has shown that Aβ fused to GFP caused GFP misfolding, thereby abolishing its fluorescence 
completely (Wurth et al., 2002). In contrast, yeast producing GFP fused to either end of Aβ 
show a green fluorescence and allows the detection of Aβ in vivo in specific punctate 
patches (Caine et al., 2007). This may be because yeast contains an environment permitting 
correct, or at least sufficient, folding of Aβ with GFP for fluorescence to be observed. Using 
yeast, Liebman and  colleagues have observed that Aβ fused to a reporter enzyme, MRF, 
could cause loss of function of the reporter, depending on the degree of oligomerization 
induced by Aβ (Bagriantsev and Liebman, 2006). The increased or decreased toxicity of 
previously known variants (Fig.4.4 and 4.5) and mutants (Fig.4.14 and 4.18) of Aβ has been 
accurately reproduced by the yeast HSR assay making it a robust and reliable assay to 
screen for AD therapeutics. The advantages and limitations of the HSR assay have been 
discussed in detail in Chapter 5. 
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4.3 ANALYSING PROTECTIVE ACTIVITY OF HSR AGAINST Aβ TOXICITY 
HSR not only offers thermotolerance to cells, but is also known to protect against 
ischaemia, oxidation and other damaging agents and conditions that can alter protein 
conformation (Sanchez et al., 1992; Liu and Chang, 2008). This conferral of cross-tolerance, 
i.e. protection by one form of stress against impairment by another form of stress, is brought 
about by the amplified production of HSPs that occur during HSR. HSPs also modulate 
apoptosis and prevent inflammation (Chen et al., 2007; Didelot et al., 2006). Hence, it is 
likely that an enhanced HSR can be protective for cells producing Aβ. The increased HSR 
that is already seen in Aβ-producing cells (chapter 4.1) may, in fact, be an attempt of the cell 
to protect itself from the toxicity of Aβ.  
In this study, the prospect of cellular protection against Aβ toxicity was tested using a 
mutant that overactivates HSR. In these mutants, the HSF repressor, Hsp90, has been 
mutated to constitutively overactivate HSR in the absence of stress (Harris et al., 2001). 
Complementing this approach, a food-fraction that can induce HSR was identified using the 
“yeast Aβ HSR" assay and screened for its impact on Aβ toxicity.  
4.3.1 Growth of yeast heat shock mutants expressing Aβ 
Mutating the HSF repressor, Hsp90, leads to the overactivation of HSR in the 
absence of stress and hence leads to an increased stress tolerance (Harris et al., 2001). In 
yeast, Hsp90 exists in two isoforms, encoded by the genes HSC82 and HSP82 (Borkovich et 
al., 1989). So to achieve constitutive overactivation of HSR, a yeast heat shock mutant, 
hsp82E381K, which displays a strong HSR even at a normal temperature (Harris et al., 
2001), was used. The mutant Hsp90 gene was under the control of the constitutively active 
glyceraldehyde-3-phosphate dehydrogenase (GPD1) gene promoter and not HSF. Isogenic 
wild-type yeast i.e. p82a, also have Hsp82 under the control of the constitutive GPD1 
promoter as its sole functional Hsp90 protein (see Table 2.1). 
 
Both the mutant and isogenic wild-type were transformed to uracil prototrophy with 
the plasmids p416.GFP and p416.GFPAβ42 for this experiment. To evaluate the possible 
protection of HSR against Aβ toxicity, cultures of the heat shock mutant and wild-type cells 
producing GFP and GFPAβ42 were initiated at the same cell density (A600 nm), grown for 3 
hours and assessed for their relative growth. The heat shock mutants grew to significantly 
higher (P<0.05) densities than the wild-type cells irrespective of the recombinant protein 
produced in them (Fig.4.21). Slightly reduced growth of cells producing Aβ was consistently 
seen in both wild-type and heat shock mutant strains compared to the cells producing GFP, 
but this difference was not statistically significant. 
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Fig. 4.21 Growth of wild-type (wt) strain p82a and heat shock mutant (HS mt) hsp82E381K 
transformed with p416.GFP and p416.GFPAβ42 (n=6). The integrated HSP82 gene and 
mutant hsp82 gene were the only functional Hsp90 genes in p82a and hsp82E381K, 
respectively, and were expressed under the control of the constitutively active GPD1 gene 
promoter and not HSF. Cultures were initiated at the same cell density (A600 nm) and grown for 
3 hours. Error bars in graph represent standard error of mean (SEM). 
 
4.3.2 Flow cytometry analysis of yeast heat shock mutants expressing Aβ 
In order to assess the effect of enhanced HSR on the folding of GFPAβ which can be 
measured as the percentage of fluorescence, the heat shock mutant and wild-type cells 
producing GFP and GFPAβ42 were subjected to flow cytometry analysis at mid-log phase of 
growth. The percentage of green fluorescing live cells in the heat shock mutant producing 
GFPAβ42 was double (P<0.05) that of wild-type cells producing the same protein; whereas 
the 10% greater fluorescence seen in the heat shock mutant producing GFP compared to 
wild-type producing GFP was not statistically significant (P>0.05) (Fig.4.22). The better 
growth of HS mutant cells was again demonstrated by a decreased percentage of dead cells 
in the population of mutant cells compared to the population of wild-type cells producing the 
same protein (Fig.4.22). 
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Fig. 4.22 Green fluorescence in wild-type (wt) strain p82a and heat shock mutant (HS mt) 
hsp82E381K transformed with p416.GFP and p416.GFPAβ42 (n=6). The integrated HSP82 
gene and mutant hsp82 gene were the only functional Hsp90 genes in p82a and 
hsp82E381K, respectively, and were expressed under the control of the constitutively active 
GPD1 gene promoter and not HSF. Cultures were initiated at the same cell density (A600 nm) 
and grown at 30°C. At mid-log phase, the percentage of dead cells and live cells exhibiting 
fluorescence was determined by flow cytometry. Error bars in graph represent standard error 
of mean (SEM). 
 
4.3.3 Screening for protective compounds using yeast assays 
Yeast wild-type strains (BY4743) doubly-transformed with the plasmid-borne HSF 
reporter and with the plasmids directing synthesis of GFP and GFPAβ42 were used as a 
primary screen for identifying prospective AD compounds. Amongst a library of food 
fractions, one promising fraction (a complex mixture) was identified by Mehrnoush Lotfi-Miri 
(CSIRO-MHT) using the “yeast Aβ flow cytometry” assay. The assay demonstrated a 
consistent rise in the percentage of green fluorescing live Aβ cells when treated with 
increasing amounts of P0206 (0.5 to 2 mg/ml) with negligible adverse effects on growth 
(Fig.4.23). The “yeast Aβ HSR” assay revealed that compound P0206 induced a significant 
HSR (i.e. almost double the baseline level) in cells producing both GFP and GFPAβ42 
(Fig.4.24). The food fraction P0206 is currently under investigation (commercial in 
confidence). 
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Fig. 4.23 Green fluorescence in yeast (BY4743) transformed with pAS1N-GFPAβ42 following 
treatment with a food fraction, P0206 (n=2). Cultures were initiated at the same cell density 
(A600 nm) and grown at 30°C for 2 hours. Increasing amounts of P0206 were added to each 
culture and grown for a further 2 hours after which the percentage of dead cells and live 
fluorescing cells were determined using flow cytometry. Error bars in graph represent 
standard deviation from mean (SD). 
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Fig. 4.24 HSR induced in yeast (BY4743) transformed with pAS1N.GFP and 
pAS1N.GFPAβ42 following treatment with food compound P0206 (n=2) – growth density is 
shown in inset. Error bars in graph represent standard deviation from mean (SD). 
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4.3.4 Discussion 
 HSR offers protection against Aβ toxicity: Since HSR is known to confer cross-
tolerance, the possibility that HSR protects against Aβ toxicity was explored in yeast 
exhibiting HSR overactivation. Though HSR is collectively mediated by the constitutively 
expressed and inducible HSPs, Hsp90 suppresses the activity of the heat shock transcription 
factor HSF in yeast (Duina et al., 1998) and in humans (Zou et al., 1998). Hence, defective 
Hsp90 results in an amplified stress resistance due to a high constitutive level of expression 
of HSPs in the absence of heat shock stress (Duina et al., 1998; Harris et al., 2001). Such 
cells with enhanced HSR (HS mt) showed better growth than normal cells (GFP in Fig.4.21). 
The improved growth of the HS mutant cells was not affected even when the cells produced 
Aβ (GFPAβ42 in Fig.4.21) indicating that HSR could overcome the toxicity of Aβ. This may be 
due to the enhanced ability to turn-over damaged cell components and proteins in these 
cells. Cells with GFPAβ42 exhibited increased fluorescence (Fig.4.22) offering evidence of 
better Aβ folding in the presence of elevated HSR. This could be due to the ability of HSPs to 
prevent and/or repair partial protein denaturation by facilitating protein refolding (Hartl, 1991; 
Gething and Sambrook, 1992). The molecular chaperones, that are part of the HSPs, bind to 
newly synthesized or misfolded proteins and regulate their conformation and transport across 
membranes or through organelles (Guerra et al., 2005). The protection against Aβ provided 
by HSR is further confirmed by the increased HSR and corresponding increase in Aβ folding 
caused by compound P0206 (Fig.4.23 and Fig.4.24). HSR can thus be beneficial to Aβ (more 
precisely GFPAβ42) by aiding its proper folding and thereby eliminating its toxicity. 
 HSR inherently produced by Aβ may not be sufficient for protection: GFPAβ causes 
HSR in yeast cells due to its toxicity (see section 4.1.8). HSP induction by Aβ has been 
observed in neuronal cultures and in human brains (Table 4.1). Despite a HSR induction, Aβ 
remains toxic and impairs the brain, leading to disease progression. The obvious question 
would be “why is HSR not able to protect against this toxicity?” This could be explained by 
the following facts. First, the HSR is attenuated shortly after the induction of HSPs, making it 
a transient, not a sustained, stress response (Guerra et al., 2005). Second, the presence of a 
high molar excess of misfolded protein, such as might occur during disease, may exceed the 
capacity of the inherently produced HSR. Thus, in the disease scenario, the HSR produced 
as a consequence of Aβ toxicity may be insufficient to provide complete defense. 
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Table 4.1 Association of HSPs with AD components 
Type of 
association 
AD 
component
Associated HSP References 
 
 
Co-localisation 
 
Aβ 
Hsp20, Hsp27, 
HspB2 (Hsp22), 
Hsp28, Hsp72, 
Hsp78, Hsp90, 
GRP78 (HspA5), 
αβ-crystallin 
(Wilhelmus et al., 2006; Kakimura 
et al., 2002; Renkawek et al., 
1994; Shinohara et al., 1993; 
Hamos et al., 1991) 
Tau Hsp27 (Nemes et al., 2004) 
Induction by AD 
component 
Aβ Hsp70 (Magrane et al., 2004) 
 
 
Protection by 
HSP 
 
Aβ 
Hsp20, Hsp27, 
HspB2 (Hsp22), 
Hsp70, Hsp90, 
αβ-crystallin 
(Kumar et al., 2007; Wilhelmus et 
al., 2006; Evans et al., 2006; 
Raman et al., 2005) 
Tau Hsp70, Hsp90 (Petrucelli et al., 2004; Dou et al., 
2003) 
 HSR may be a more efficient therapeutic target for AD than the target of other AD 
drugs: It is well-known that HSR offers protection against a variety of noxious conditions like 
ischemia and oxidation (Sanchez et al., 1992), ER stress (Liu and Chang, 2008), endotoxin 
lethality (Chu et al., 1997; Hotchkiss et al., 1993; Ribeiro et al., 1994) , phospholipase-C-
induced lung damage (Villar et al., 1994), inflammatory damage and prevention (Simon et al., 
1995; Snyder et al., 1992; Heneka et al., 2000) and apoptosis. Nearly 3% (165 genes) of the 
yeast genome can be targeted by HSF (Hahn et al., 2004; Yamamoto et al., 2005; 
Muchowski and Wacker, 2005). This array of proteins comprises not only heat shock proteins 
(HSPs), but also proteins involved in a wide range of cellular processes (see Appendix III), 
including ubiquitination and proteolysis, vesicular transport, cell wall organization, small 
molecule transport, carbohydrate metabolism, energy generation, signal transduction and 
oxidative stress mechanisms (Hahn et al., 2004; Yamamoto et al., 2005). HSR with its 
multiple mechanisms can, thus, readily provide an effective abrogation or alleviation of the 
multiple effects produced by the pleiotrophic Aβ. HSPs have already demonstrated protection 
in Parkinson’s disease (Flower et al., 2005; Auluck et al. 2002), Huntington’s disease 
(Wacker et al., 2004), other polyglutamine diseases (Schaffar et al., 2004; Cummings et al., 
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2001; Muchowski et al., 2000; Warrick et al., 1999) and amyotrophic lateral sclerosis (Kieran 
et al., 2004). HSPs are also reported to rescue toxicity of intracellular Aβ (Magrane et al., 
2004) and maintain tau solubility by suppressing tau aggregates (Dou et al., 2003). The 
molecular basis for efficient protection of Aβ toxicity may be due to the ability of HS 
chaperones to modulate the earliest abnormal protein interactions that activate pathogenic 
pathways (Muchowski and Wacker, 2005). Other mechanisms of HSR protection could be 
selective proteolysis, protein sequestration and blockage of downstream signaling pathways 
that lead to dysfunction and apoptosis (Muchowski and Wacker, 2005). A recent review 
(Malyshev and Manukhina, 2005) has proposed 7 mechanisms by which stress proteins can 
provide neuroprotection in AD: restriction of apoptosis, restriction of NO overproduction, 
disaggregation of Aβ aggregates, acceleration of Aβ elimination from intercellular space, 
restriction of tau-protein hyperphosphorylation, protection from glutamate toxicity and 
restriction of intracellular Aβ toxicity. Several approaches are being pursued to develop HSR-
based therapeutics for AD (Chaudhuri and Paul, 2006), however, identification of HSPs that 
are more beneficial for AD is important. Some of the HSPs known to prevent protein toxicity 
and their mechanisms have been summarized in Fig.4.25. It is possible to study deletion 
mutants in yeast to identify which proteins involved in the HSR may be most protective in 
dealing with the damaging effects of Aβ. The further use of yeast with constitutive and/or 
inducible Aβ production may lead to a new understanding of AD and new ways of reducing 
Aβ-induced damage. 
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Fig. 4.25 HSPs known to prevent Aβ toxicity and their mechanisms of inhibition (adapted 
from Muchowski and Wacker, 2005) ER: endoplasmic reticulum, ERAD: endoplasmic 
reticulum-associated degradation, HSP: heat shock protein, LAMP: lysosomal-associated 
membrane protein, ROS: reactive oxygen species, TF: transcription factor. 
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4.4 ANALYSING THE INTERACTIONS OF METALS AND CLIOQUINOL  
Protein aggregation and oxidative stress as seen in AD are both associated with metal 
ions. AD plaques are often described as metal sinks due to their extremely high metal content. 
Evidence exists for significant Zn, Cu and Fe dyshomeostasis in AD brains (reviewed by Atwood 
et al., 1999), with the ions known to induce Aβ aggregation at various pH levels (Miura et al., 
2000; Barnham et al., 2004).  Conversely, studies that quantified metal levels in brains, CSF and 
blood of AD patients have produced inconsistent results (reviewed by Cuajungco and Faget, 
2003).  Metal imbalance in brains also occurs as a consequence of normal ageing (Takahashi et 
al., 2001) which in turn aggravates the oxidative damage. However, it still remains controversial 
as to whether AD may be associated with higher or lower levels of Cu (reviewed by Macreadie, 
2007). 
Since biometal depletion has been shown to solubilize Aβ from post-mortem brain 
tissues (Cherny et al., 1999), metal chelators may hold great promise as therapeutics.  
Compounds in this category include clioquinol (discussed below), desferrioxamine (Smith et al., 
2007), bis(thiosemicarbazonato) complexes (Donnelly et al., 2007), 8-hydroxyquinoline (8HQ), 
neocuproine (NC), 1,10-phenanthroline and pyrrolidine dithiocarbamate (PDTC) (Caragounis et 
al., 2007). 
 Clioquinol (CQ) or 5-chloro-7-iodo-quinolin-8-ol (Fig.4.26) is a member of the 
hydroxyquinoline family of drugs that has long been used as an antibiotic, specifically as an 
antifungal and antiprotozoal agent.  This lipophilic drug has also demonstrated its efficacy in 
animal models of Parkinson’s (Kaur et al., 2003) and Huntington’s diseases (Nguyen et al., 
2005).  Recent animal model studies and pilot clinical trials suggest a promising role in AD 
treatment.  Phase 2 clinical trials show halting cognitive decline with good drug tolerance 
(Ritchie et al., 2003), while an open clinical trial has exhibited marked decrease in other AD 
markers like tau protein and growth-associated protein (GAP43) in the third week of treatment 
(Regland et al., 2001).   
 
  
 Fig.4.26 Chemical structure of clioquinol (5-chloro-7-iodo-quinolin-8-ol) 
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CQ was banned world-wide following an epidemic of sub-acute myelo-optic neuropathy 
(SMON) in CQ users in Japan (Tsubaki et al., 1971; Meade, 1975). Some countries now use the 
drug with vitamin B12 (vit B12) supplementation.  CQ alters vitamin B12 homeostasis due to its 
strong chelation of the vitamin B12 cofactor, cobalt (Yassin et al., 2000).  Another study indicates 
that the phenomenon of CQ mediated toxicity in SMON appears to be Zn-specific (Arbiser et al. 
1998).  Interestingly, the actual in vivo mechanism of CQ remains unknown.  The toxicity of CQ 
certainly warrants detailed investigation.  
The potential of CQ as an AD therapeutic has led to the development of a second 
generation of CQ analogs.  One such compound, PBT2 is reported by Prana Biotechnology 
Limited to have successfully completed a Phase 2a trial in AD patients (Prana Biotechnology 
Limited, 2008).  The trial assessed the safety, tolerability and effects of PBT2 on the mechanism 
and progression of AD, including biomarkers and measures of cognition.  The conclusions are 
due to be released in the first quarter of 2008.  There also appears to be a prospect for using CQ 
and its family of drugs as in vivo imaging agents in AD diagnostics (Opazo et al., 2006). The 
emerging significance of clioquinol (CQ) in the treatment of AD and other neurodegenerative 
diseases emphasizes the importance of further study into its cellular and toxicity mechanisms. 
This study focuses on analysing the interactions of Aβ (Aβ42GFP and GFPAβ42) with metals, 
particularly copper, and the effects of CQ on yeast cells. 
4.4.1 HSR assay of yeast producing Aβ and treated with copper (Cu) 
To evaluate the effect of Cu on Aβ toxicity, increasing amounts of Cu (up to 0.8mM) were 
added at mid-log phase to yeast (strain W303-1a) producing GFP, Aβ42GFP and GFPAβ42. Wild-
type yeast that normally produced β-galactosidase (K. lactis) was also included as a control to 
check if Cu2+ affected β-galactosidase activity. Following 2 hours incubation with Cu2+, β-
galactosidase activity and growth of all cell lines were analysed (Fig.4.27). A slight drop in yeast 
β-galactosidase activity was noted in K. lactis, but was considered insignificant in contrast to the 
rise in HSF directed β-galactosidase that was observed in yeast producing GFP, Aβ42GFP and 
GFPAβ42. No significant difference was detected in yeast cells producing Aβ fusions, compared 
to GFP producing yeast. Growth of all cell lines was affected by increasing levels of Cu2+ (see 
Fig.4.27 - inset). 
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Fig. 4.27 Effect of Cu2+ on β-galactosidase (and HSR) activity. Growth and β-galactosidase 
levels in yeast (W303-1A) transformed with pAS1N.GFP, pAS1N.Aβ42GFP and pAS1N.GFPAβ42 
(n=2) as well as the heat shock reporter plasmid and the yeast (K. lactis) that naturally produces 
β-galactosidase (n=1) were examined. Growth curves of all cultures are shown in inset. Cultures 
were grown overnight at 30°C in selective or minimal media, refreshed the following day and 
grown further to reach similar cell density (A600 nm). At mid-log phase, each culture was treated 
with increasing amounts of Cu2+ and grown for 2 hours at 30°C. Cell density and β-galactosidase 
activity was measured after 2 hours. Error bars in graph represent standard deviation from mean 
(SD). 
 
4.4.2 HSR assay of yeast producing Aβ and treated with CQ 
 Since no particular effect was detected with Cu2+ treatment with the metal chelator, CQ, 
was considered as an alternative to evaluate the interaction of Aβ with metals. Preliminary 
studies were conducted in yeast (W303-1A) producing GFP, Aβ42GFP and GFPAβ42 by treating 
with increasing amounts of CQ and incubating overnight. Interestingly, decreasing HSR levels 
were observed in both Aβ42GFP and GFPAβ42 compared to a generally stable HSR in GFP 
producing cells (Fig.4.28 A). Cell growth was stable at lower levels of CQ (up to 0.1µM) in all cell 
lines, but not surprisingly, there was total inhibition at higher levels i.e. 5µM and 40µM (Fig.4.28 
B). For statistical significance, CQ treatment was performed with triplicate samples. Yeast 
producing GFP, Aβ42GFP and GFPAβ42 were treated with 0.5µM CQ and grown for 2 hours 
post-treatment. Though 0.5µM CQ seemed to be slightly cytotoxic (Fig.4.28 D), there was a 
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highly significant drop (P<0.001) in the HSR levels of Aβ42GFP and GFPAβ42, with no effect on 
GFP producing cells. 
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Fig. 4.28 Growth and HSR in HSE reporter containing yeast (W303-1A) transformed with 
pAS1N.GFP, pAS1N.Aβ42GFP and pAS1N.GFPAβ42 as well as the heat shock reporter plasmid 
on treatment with CQ. [A] HSF directed β-galactosidase activity was measured in cultures grown 
with increasing amounts of CQ (n=1). Cells were grown overnight post-treatment. [B] Cell 
density (A600 nm) after overnight incubation with CQ was measured as an estimate of growth 
(n=1). [C] HSF directed β-galactosidase activity was measured in cultures grown with 0.5µM CQ 
(n=3). Cells were grown for only 2 hours post-treatment. Error bars in graph represent standard 
error of mean (SEM). [D] Cell density (A600 nm) after 2 hour incubation with CQ was measured 
as an estimate of growth (n=3). CQ treatments in all experiments were done at mid-log phase of 
the cultures and at similar cell densities. Error bars in graph represent standard error of mean 
(SEM). All cultures were grown in selective media. 
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4.4.3 Flow cytometry analysis of yeast producing Aβ and treated with clioquinol 
 As CQ could reduce the stress levels in yeast producing Aβ (Fig.4.28 A and C), the 
impact of CQ on the protein folding of Aβ would be important to know as it would help us 
understand its mechanism of action. For this, yeast (W303-1A) cells producing GFPAβ42 were 
subjected to flow cytometry after 2 hours of treatment with increasing amounts of CQ. This 
experiment was performed by Mehrnoush Lotfi-Miri (CSIRO-MHT). There was a steady and 
significant drop (P<0.001) in fluorescence with increasing CQ up to 0.5µM, after which a rise in 
fluorescence was observed (Fig.4.29). Cell death increased significantly above 1µM CQ. 
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Fig. 4.29 Green fluorescence produced in yeast (W303-1A) transformed with pAS1N.GFPAβ42 
on treatment with CQ (n=2). Cultures were initiated at the same cell density (A600 nm) and grown 
at 30°C. At mid-log phase, cultures were treated with increasing amounts of CQ for 2 hours, 
after which the percentage of live cells exhibiting fluorescence was determined by flow 
cytometry. Error bars in graph represent standard deviation from mean (SD). 
4.4.4 Assaying CQ cytotoxicity in wild-type yeast 
CQ was further studied in wild-type strains to find the cytotoxic levels. Wild-type yeast 
(BY4743) was cultured in rich media and treated with increasing amounts of CQ (0.5µM to 
20µM) at a very low cell density (A600~0.15). Growth was monitored following overnight 
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incubation (Fig.4.30). A steady decline in growth was seen until 2.5µM, after which the growth 
was generally stable. Unlike the yeast transformants of the earlier experiment (Fig.4.28 B), a 
total growth inhibition was not observed in wild-type yeast in liquid cultures (Fig.4.30). However, 
complete inhibition of wild-type yeast by CQ was observed when cultured on solid media 
(Fig.4.26). 
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Fig. 4.30 Growth curve of wild-type yeast (BY4743) treated with increasing amounts of CQ 
(n=3). Cultures were grown overnight at 30°C in rich media (YEPD), refreshed the following day 
and grown further to reach similar cell density (A600 nm). At A600~0.15, each culture was treated 
with increasing amounts of CQ and either sampled immediately (t=0) or grown further at 30°C 
for 20 hours (t=20 hours).  Cell density was then measured. Cultures with 0µM CQ were treated 
with the highest amount of 100% DMSO (CQ solvent) that was present in the CQ treated 
samples. Error bars in graph represent standard error of mean (SEM). 
 
4.4.5 Effect of metals on CQ cytotoxicity in wild-type yeast 
 To investigate if metals could rescue the cytotoxicity of CQ, wild-type yeast strains 
(BY4741 and BY4743) were grown overnight in the presence of 0.5µM CQ and different 
amounts of Cu2+, Fe3+ and Zn2+. Metal levels were added in multiples of the basal level of each 
metal present in the media. Remarkably, the cytotoxicity of CQ was abolished by Cu2+ (Fig.4.31). 
The toxic effect of CQ was, however, unaltered by Fe3+ and worsened by Zn2+. It is also notable 
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that growth of cells was unaffected by increasing amounts of Cu2+ and Fe3+ to the levels used, 
but was highly inhibited by increasing Zn2+ (Fig.4.31). The rescue of CQ cytotoxicity by Cu2+ was 
further demonstrated on solid media (Fig.4.32). 
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Fig. 4.31 Rescue of CQ cytotoxicity in wild-type yeast (BY4741 and BY4743) by metal ions – 
Cu2+, Fe3+ and Zn2+ (n=6). Cultures were grown overnight at 30°C in rich media (YEPD), 
refreshed the following day and grown further to reach similar cell densities (A600 nm). At 
A600~0.3, each culture was split into two batches. One batch was treated with appropriate 
amounts of CQ and metals, while the other batch was treated with equivalent amounts of CQ 
solvent (DMSO) and metal ions. After treatment, all cultures were grown overnight at 30°C and 
cell density was measured the next day. Final concentration of CQ and metals in the cultures 
were as follows: CQ – 0.5µM, 1xCu – 40µM, 5xCu – 200µM, 10xCu – 400µM, 1xFe – 200µM, 
5xFe – 1mM, 10xFe – 2mM, 1xZn – 400µM, 5xZn – 2mM and 10xZn – 4mM. Calculation of 
metal levels to be added was based on the basal levels of each metal in the rich media (YEPD). 
Error bars in graph represent standard error of mean (SEM). 
 113
0.3µM CQ
1µM CQ
3µM CQ
10µM CQ
0 µM CQ
40 µM Cu 80 µM Cu 400 µM Cu
Cu2+
C
Q
cells cells cells cells cells cells
C
Q
 
Fig. 4.32 Rescue of CQ cytotoxicity by Cu2+ in wild-type yeast (BY4741) on YEPD plates (n=4). 
Solid media containing increasing amounts of CQ and Cu2+ were stamped with different dilutions 
of cell culture and incubated at 30°C for three days. 
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4.4.6 Effect of metals on CQ-treated yeast producing Aβ  
 The effect of copper on CQ-treated yeast producing Aβ demands investigation in light of 
the rescue of CQ cytotoxicity by copper (Fig.4.31 and 4.32). For this, the influence of Cu2+ and 
CQ on Aβ folding was studied. Yeast (W303-1A) cells producing GFPAβ42 was subjected to flow 
cytometry after 2 hours of treatment with Cu2+ and CQ. This experiment was performed by 
Mehrnoush Lotfi-Miri (CSIRO-MHT). While Cu2+ alone did not affect fluorescence of GFPAβ42, 
CQ reduced its fluorescence significantly (Fig.4.33). This reduction in fluorescence of GFPAβ42 
was totally rescued when both Cu2+ and CQ were added simultaneously. It is also notable that 
the levels of Cu2+ and CQ used were non-toxic to the cells as the growth was not affected. 
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Fig. 4.33 Green fluorescence produced in yeast (W303-1A) transformed with pAS1N.GFPAβ42 
treated with CQ and/or Cu (n=2). Cultures were initiated at the same cell density (A600 nm) and 
grown at 30°C. At mid-log phase, cultures were treated with appropriate amounts of Cu2+ and 
CQ for 2 hours, after which the percentage of live cells exhibiting fluorescence was determined 
by flow cytometry. Error bars in graph represent standard deviation from mean (SD). 
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4.4.7 Intracellular metal levels in wild-type yeast treated with CQ 
  As copper could abolish or revert the effects of CQ in normal (Fig.4.31 and 4.32) and Aβ 
producing cells (Fig.4.33), there exists a possibility that CQ may chelate intracellular Cu to 
mediate its effect. To verify this, an estimation of intracellular metal levels was done on wild-type 
yeast cells (BY4741) treated with 1µM and 5µM CQ (Fig.4.34). Contrastingly, with increasing CQ 
treatment, a rise in Cu levels and a simultaneous drop in Zn levels were observed.  
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Fig. 4.34 Intracellular metal levels in wild-type yeast (BY4741) treated with CQ (n=3). Cultures 
were grown overnight at 30°C in minimal media (YNB+HULM), refreshed the following day and 
grown further to reach similar cell density (A600 nm). At A600~0.3, each culture was split into three 
batches. Two batches were treated with appropriate amounts of CQ, while the remaining batch 
was treated with equivalent amounts of CQ solvent (DMSO). Cultures were grown overnight at 
30°C post-treatment. After measuring cell density, cells were harvested, washed and processed 
for ICP-MS analysis (see methods section). Error bars in graph represent standard error of 
mean (SEM). 
4.4.8 Discussion 
 In vivo toxicity of Aβ involves metal binding and can be modulated by CQ: In vitro, Aβ is 
known to be a metalloprotein with affinities highest for Cu, moderate for Fe and lowest for Zn 
(Atwood et al., 1998; Atwood et al., 2000; Melov, 2002). It has also been shown that Aβ-metal 
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complexes in vitro, particularly those with Cu and Fe, are toxic (Huang et al., 1999a; Huang et 
al., 1999b). In this study, HSR levels were used as a measure for toxicity of GFP-Aβ fusions. 
Increasing levels of Cu2+ demonstrated that the fusion was not differentially affected by 
increasing levels of Cu2+ in comparison to GFP (Fig.4.27). This may be because all the Aβ 
produced in the cells may be bound to Cu2+ from the media or yeast cell prior to external Cu2+ 
addition. However, a reduction in HSR levels was observed in vivo when treated with CQ 
(Fig.4.28). It is postulated that CQ chelates metals from Aβ, with greater selectivity for Zn2+ and 
Cu2+ ions (Di Vaira et al., 2004) and has a higher affinity than Aβ for these metals (Ferrada et al., 
2007). Hence, CQ could possibly reduce the toxicity (or HSR) of Aβ via metal chelation and may 
subsequently reduce metal-associated protein aggregation or oxidative stress. Conversely, the 
cells displayed a decrease in GFPAβ42 fluorescence when treated with CQ (Fig.4.29), indicating 
an aberrant folding of Aβ that quenches GFP fluorescence. A possible explanation would be that 
CQ modulates the folding of Aβ into a non-toxic conformation, which may not essentially be a 
properly folded state. Other cell studies have shown that CQ degrades Aβ by metal-dependent 
activation of phosphoinositide-3-kinase (PI3K) and c-jun N-terminal kinase (JNK), resulting in 
JNK-mediated up-regulation of metalloprotease activity (White et al., 2006; Filiz et al., 2007; 
Caragounis et al., 2007).  New findings also illustrate that CQ can protect against oxidative 
stress by activation of a PI3K-dependent survival pathway and blocking p53-mediated cell death 
(Filiz et al., 2007). 
Cu reverts the effects of CQ: The toxic potential of CQ has been previously reported 
(Tsubaki et al., 1971; Meade, 1975; Arbiser et al., 1998). Consistent with those studies, 
cytotoxicity of CQ was observed in wild-type yeast cells (Fig.4.30) and cells producing 
recombinant proteins (Fig.4.28 B, 4.28 D and 4.29). The toxic levels were found to be 0.5µM and 
above (Fig.4.29 and 4.30). Upon addition of Cu2+ in molar excess, there was a clear rescue of 
CQ toxicity in wild-type yeast (Fig.4.31 and 4.32); however no variation was observed with the 
addition of Fe3+ or Zn2+ in molar excess (Fig.4.31). Though CQ has affinity for Fe3+ (Todorich 
and Connor, 2004), Cu2+ and Zn2+ (Regland et al., 2001), it has greater affinity for Cu2+ (Ferrada 
et al., 2007) such that it forms complexes with Cu2+ even in the presence of competing ions 
(Ferrada et al., 2007). This explains why Cu could significantly rescue the CQ toxicity. Similarly, 
within non-toxic concentrations, Cu2+ reversed the effect of CQ on cells producing GFPAβ42 
(Fig.4.33) clearly indicating that Cu2+ binds to CQ and prevents its activity. In fact, a transgenic 
AD mouse model that examined the intrinsic toxicity of CQ showed reduced lifespan with CQ 
administration but a normal lifespan with CQ plus Cu supplementation (Schafer et al., 2007).  
Copper levels in brains were lowered with CQ supplementation, but restored to normal with 
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CQ+Cu supplementation, suggesting the protective nature of Cu against CQ (Schafer et al., 
2007). 
Is CQ a metal chelator or metal transporter? Although earlier studies portray CQ as a 
metal chelator, recent studies point towards a metal transporting mechanism for CQ. A yeast 
(Pichia pastoris) model study indicated that CQ may act as an intracellular Cu transporter 
(Treiber et al., 2004). Biochemical studies on CQ and other metal ligands rules out the possibility 
of a receptor-mediated interaction and rather emphasizes metal transport (Caragounis et al., 
2007). A transgenic AD model indicated that CQ may act as a Cu transporter that crosses the 
blood brain barrier (BBB) resulting in a redistribution of Cu (Schafer et al., 2007). 
Complementing these observations, CQ-treated wild-type yeast cells show increasing 
intracellular Cu levels (Fig.4.34). Nevertheless, it is critical to question whether the metal 
estimation truly reflects intracellular Cu levels. The possibility that CQ-Cu complexes may stick 
to the outer cell membrane and cause false-positives cannot be ruled out.  Further studies to 
elucidate this may require analyses of metallo-enzymes, or transcriptional profiling studies. 
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CHAPTER 5 
SUMMARY 
Our current understanding of AD is incomplete due to uncertainties in experimental 
models and the multi-faceted nature of Aβ.  These difficulties have not prevented models being 
used to explore AD preventatives and therapeutics.  As a result, a plethora of hypotheses on the 
cause of AD and a range of assays to measure outcomes in different treatments have evolved. 
However, knowledge of the precise causes of AD is fundamental to develop rational preventative 
measures and treatment. My research has aimed at elucidating some of the biological effects 
and toxic mechanisms of intracellular Aβ, which is implicated in causing AD. Chapter 1 provides 
a comprehensive literature review on the research progress in AD and introduces the aims of 
this research. The various experimental methods and materials used in my research have been 
described in Chapter 2.  
5.1 SUMMARY OF RESULTS 
Chapter 3 describes my research to identify the molecular and biochemical pathways 
affected by intracellular Aβ in yeast using microarrays. The high-throughput nature of microarray 
analysis allowed comparison of the genome-wide transcription in yeast producing intracellular 
Aβ fused to GFP (i.e. likened to a disease state with Aβ) against yeast producing GFP (i.e. 
likened to a normal state without Aβ). Although Aβ is present normally in humans, it is at a much 
lower level than in the diseased state; hence the comparisons in yeast seem reasonable. The 
analysis implied that intracellular Aβ may affect cell cycle, intracellular Cu availability and MAPK 
signalling pathway. Stress responses like oxidative stress response, heat shock response and 
response to various stimuli (metals, protein, abiotic, etc.) were also suggested. Overall, there 
was a strong indication of heat shock response (HSR) inferred from the signs of protein 
misfolding, oxidative stress, proteasomal activity and ubiquitination, in the functional analysis of 
differentially expressed genes.  
In Chapter 4, the HSR is confirmed by constructing strains with Aβ and a heat shock 
reporter. In these strains, HSR was specifically induced by toxic species of intracellular Aβ, 
precisely, Aβ42GFP, GFPAβ42 and GFPAβ40. Due to the specificity of HSR induction by toxic 
intracellular Aβ, the HSR was further utilized as an assay for determining the biological effects 
and toxicity mechanisms of Aβ. Studies using the HSR reporter assay denoted that aberrant 
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protein folding and oxidative stress are, indeed, toxicity factors of the intracellular Aβ. Further 
analysis of known mutations in Aβ (section 4.2) revealed that mutations of Aβ residues 
responsible for protein aggregation reduced the stress on cells; while those mutations that 
amplify toxicity increased the stress on cells. Analysing the nature of these mutations, it was 
found that hydrophobicity was the underlying cause of Aβ toxicity in these mutants. This could 
be possible as accumulation of abnormally folded protein usually generates a highly unstable 
increase in the protein hydrophobicity, which may lead to non-specific protein interactions, and 
consequently compromise protein turn-over and cell viability (reviewed in Chen et al., 2005). 
In light of the rapid increase in the incidence of AD and lack of effective therapeutics, 
there is enormous significance for the development a robust assay that allows identification of 
compounds that target underlying causes. The yeast HSR assay was established to be a robust 
and reliable assay as it could accurately reproduce the increased and decreased toxicity of 
known mutants (section 4.2). Being a eukaryotic system, yeast assays are advantageous over 
bacterial assays in AD. Advantages and limitations for the HSR assay for screening chemo-
preventatives against AD are discussed below: 
 Advantages: As HSR is a critical cellular stress response that is highly conserved evolutionarily 
from yeast to humans (Sorger and Pelham, 1987), this reporter system can readily be adapted 
as an AD model to study Aβ biology as well as to screen for inhibitors of Aβ toxicity. Apart from 
detecting intracellular Aβ toxicity, the HSR reporter assay can be employed to evaluate the 
stress elicited by secretable and extracellular Aβ on cells. Moreover, it offers more potential in 
conjunction with an assay that sheds light on the folding status of Aβ, such as the Aβ-GFP assay 
used here. Conversion of HSR assay into a high-throughput format can be done with ease by 
replacing the β-galactosidase reporter in the HSR plasmid with a luminescent or another 
fluorescent reporter. The combined assay enables large libraries of compounds to be screened 
simultaneously for the effects on the toxicity, protein folding and localization of Aβ. That both of 
the assays are in vivo allows measurement of the direct effects of compounds in the screen on 
both Aβ and the cell, at the same time. Consequently, it facilitates better understanding of the 
compound’s mechanism of action, making it a versatile tool. The HSR assay, by itself and in 
combination with the GFP assay, is simple and cost-effective.  
 Limitations: Using the β-galactosidase reporter for assaying HSR poses two general limitations 
and a third limitation in the context of Aβ. Firstly, the cell permeabilisation step, involved in the 
protocol, is time-consuming and laborious when large libraries have to be screened. Secondly, 
the possibility of interference to the β-galactosidase activity, and not HSR, by compounds in the 
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library cannot be ruled out (e.g. Fig.4.8 and 4.9). Both these limitations can be overcome by 
replacing the lacZ reporter in the HSR plasmid with a more robust reporter like luminescent or 
fluorescent tags. Thirdly, though declining HSR indicates reduction in cellular stress and Aβ 
toxicity, an enhanced HSR is also beneficial. Hence, a supplementary assay, like the GFP 
assay, that reflects Aβ folding may need to be used in conjunction with HSR assay. 
HSR manifests as a dramatic increase in the production of chaperones that are known to 
facilitate proper folding or refolding of partially unfolded/misfolded proteins or to sequester 
damaged proteins for proteolytic digestion. Thus, HSR is a protective response that either 
prevents aggregation or facilitates proper folding of proteins. Consistent with this idea, it is 
observed that sustaining HSR can protect against Aβ toxicity (section 4.3). By increasing stress 
defence mechanisms, the protein renewal and turn-over may be increased, thereby reducing cell 
damage. In fact, enhanced HSR was observed to abolish the α-synuclein mediated apoptosis in 
a yeast model of Parkinson’s disease (Flower et al., 2005). Thus, the HSR pathway could be an 
important target for AD therapeutic development. Neuroprotection by molecular chaperones is 
an emerging therapeutic concept in neuroscience. Curcumin, derived from the curry spice 
turmeric, is a powerful antioxidant and strong inducer of HSR. Curcumin supplementation has 
been considered as a nutritional approach in the treatment of AD (Calabrese et al., 2003). 
These studies may affect our understanding of Aβ biology in the context of AD. It is 
notable that though HSR is elicited in cells expressing Aβ, it is not sufficient to eliminate or 
improve the toxicity; whereas an enhanced HSR enabled better folding of Aβ. This might, in fact, 
be the scenario in AD brains. In spite of evidence for HSR in AD brains, toxic aggregations of Aβ 
exist, probably due to the inadequate HSR that fail to prevent aggregation or facilitate proper 
folding. Hence, compounds that can boost HSR may be highly advantageous. The yeast HSR 
model presented in this study and data from the literature reinforces the development of HSR as 
an ideal AD therapeutic target as it confers protection against the multiple effects of the 
pleiotrophic AD proteins. 
The indication of reduced intracellular copper in cells producing Aβ (Chapter 3) led to a 
closer examination of the in vivo interactions of Aβ with metals and a metal-chelator that has 
been suggested to be an AD chemo-preventative, namely clioquinol, for the insights that it might 
provide (section 4.4). My analysis points towards the involvement of metals in the in vivo toxicity 
of Aβ as CQ reduced the stress induced by Aβ-GFP fusions in yeast cells. On the other hand, a 
reduction in the fluorescence of GFP-Aβ by CQ suggested aberrant folding of Aβ. Thus, it is 
inferred that CQ may modulate the folding of Aβ into a non-toxic conformation. A protective role 
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for Cu2+ and not Fe2+ or Zn2+ against CQ toxicity was also observed. Though preliminary data 
suggests a metal transport function for CQ, further studies are required to elucidate the exact 
role of CQ and its mechanism of action. 
5.2 MAJOR CONCLUSIONS 
This study has elucidated some of the mechanisms involved in Aβ toxicity and pathways that 
can be targeted for drug development. Taking together our existing knowledge and the data 
obtained from this study, the following conclusions are drawn: 
♦ Intracellular Aβ may affect cell cycle and intracellular Cu availability and can also elicit 
stress responses like oxidative stress response and heat shock response, probably via 
the MAPK signaling pathway.  
♦ The Aβ species, Aβ42 and Aβ40, are toxic enough to living cells to induce stress 
responses, particularly, a heat shock response in the cells.  
♦ Truncated Aβ species, Aβ28 and Aβ16 produce only basal stress levels similar to that seen 
in GFP producing cells. 
♦ Though it is not clear whether Aβ caused GFP to misfold or the fusion to oligomerize, 
aberrant protein folding, oxidative stress and hydrophobicity of the residues in Aβ are 
noted as factors that influence the toxicity of Aβ. These factors may have the potential to 
convert normal Aβ to pathological plaques. 
♦ Enhanced HSR can protect against Aβ toxicity and hence poses as an ideal AD 
therapeutic target to confer protection against the multiple effects of the pleiotrophic AD 
proteins. 
♦ In vivo toxicity of Aβ involves metals and can be modulated by clioquinol. 
♦ Cu2+, and not Fe2+ or Zn2+, reverts the effects of CQ when added in molar excess and 
hence protects against the cytotoxicity of CQ. 
♦ The interference of β-galactosidase activity by anti-oxidants questions the robustness 
and cautions against the common use of β-galactosidase assays as a standard reporter 
assay. 
♦ The HSR assay can be used reliably in conjunction with a supplementary assay, like the 
GFP assay, that reflects on the Aβ folding, to screen compounds simultaneously for its 
effect on the toxicity, protein folding and localization of Aβ. 
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5.3 FUTURE PROSPECTS 
My studies have relevance in understanding the role of Aβ in the death of neuronal cells, and 
indicate that yeast may be a new tractable model system for the screening for inhibitors of the 
stress caused by Aβ. Some of the future experiments proposed and its significance are: 
♦ Develop HSR into a high-throughput assay to look for inhibitors of Aβ toxicity. 
Development of this assay in yeast is of significance as the yeast HSR is highly 
coordinated involving a variety of transcription factors with each of them performing a 
specific function to maintain homeostasis.   
♦ Evaluate the stress (HSR) elicited by secretable and extracellular Aβ on yeast cells to 
elucidate the differential effects of these on cells. This is important because Aβ is 
primarily secreted in neuronal cells and is found to exist both intracellularly and 
extracellularly in AD. 
♦ Study the behaviour of Aβ in yeast deletion mutants of the HSR pathway. This study 
enables specific identification of the proteins in the HSR pathway that may be particularly 
involved in dealing with the damaging effects of Aβ. 
♦ Further analyse the microarray data via pathway analysis, followed by confirmation using 
Northern blots or real-time PCR to identify the specific genes that are affected by Aβ and 
the differential interaction of C and N terminals of Aβ. 
♦ Measure metal levels in yeast producing Aβ by ICP-MS and confirm the levels by 
analysis of the metalloproteins or transcription profiling studies. This would provide 
critical insights into the association of Aβ with metals and how this association may affect 
other cellular proteins. 
♦ Analyse the metalloproteins or transcription profile of yeast treated with CQ to confirm 
the mechanism of action of this prospective AD drug. 
New insights from the above studies provide critical information and impinge on our knowledge 
of Aβ biology in the context of AD. 
 
 
“This is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the 
beginning.” - Winston Churchill 
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Appendix 
I. Statistical design of microarray experiments (Speed and Yang, 2002) 
(http://polyploid.agronomy.wisc.edu/approaches/expression/microarrays/spotted_array.html) 
Two common statistical designs for microarray experiments are the direct and the 
indirect comparisons. Comparing the gene expression in two samples on the same 
microarray slide is referred to as a direct comparison. In an indirect comparison, the 
comparison of gene expression in two samples on different microarray slides is through a 
third reference sample. 
Dye-swap experiments can be considered as a direct comparison. A dye swap 
experiment involves two treatments and two arrays. The two treatments, T1 and T2 are 
labelled with dye 1, D1 (Cy3), and dye 2, D2 (Cy5), respectively, on the first array, A1. These 
labels are then reversed for the second array, A2 i.e. T1 receives D2 and T2 receives D1. 
The advantage of the dye-swap is that it permits estimation of all parameters in the ANOVA 
model, since the factors are balanced (i.e. every possible combination of factors is 
observed). In statistical terms, the dye-swap is equivalent to a Latin square experiment. 
Loop designs can be considered as an indirect comparison. A loop design involves 
constructing a cyclic sequence of a treatment on n arrays, with each treatment represented 
twice, each time labelled with a different dye. Although not all treatment pairs occur together 
on an array, comparisons between such pairs can be made by utilising the cyclic nature of 
the loop design. For example, if T1 and T2 are labelled with dye 1, D1 (Cy3), and dye 2, D2 
(Cy5), respectively, on the first array, A1 and T2 and T3 are labelled with dye 1, D1 (Cy3), 
and dye 2, D2 (Cy5), respectively, on the second array, A2, then T1 can be compared to T3 
by first comparing T1 to T2 and then comparing T2 and T3. The loop design, therefore, has 
the advantage of allowing inter-treatment comparisons to be made without requiring that the 
treatments appear together on an array. The price paid for this is increased comparison-wise 
variance, but for small loops, this effect is minimal. 
II. Quality measures and visual analysis of microarray data (Smyth et al., 2003) 
Quality assessment of arrays can be global (i.e. on the entire array) or on individual spots of 
the array. 
a) Global assessment Æ The quality of signals (data) from each array is denoted by its 
distribution of log intensity, range of M and A values, background levels, spatial variation and 
artefacts.  
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b) Spot quality assessment Æ The quality of a spot is denoted by its physical characteristics 
like size, shape, background intensity, signal to noise ratio, etc. and whether the observed 
spot intensity agrees with those from other spots. This can be estimated via spot weighting 
i.e. assigning weight according to the quality of the spot. For example, spot weight w can be 
calculated as a/ aF, where a is the spot pixel area and aF is the area of a full-sized spot. 
Exploratory graphical displays of the microarray data permit assessment of 
experimental success and data quality. The visual analysis also guides the choice of 
statistical analysis parameters to overcome the specific problems in the arrays. The various 
types of graphical representations are: 
1) Overlay of Cy3 and Cy5 channels Æ Co-registration and overlay of the two channels 
provide information on colour balance (eg. yellow indicates equal balance), uniformity of 
hybridisation, spot uniformity, background and artefacts. A rough impression of DE genes is 
also gained. 
2) Scatter plot Æ It is a scatter plot of the two channel intensities, log2 R versus log2 G. 
3) MA plot Æ MA plot is the scatter plot turned by 45° with a re-scaling of axes to provide 
more room. It has M values (M = log2 R/G) on the vertical axis and A values (A = (log R + log 
G) /2) on the horizontal axis, where R and G are background corrected intensities. Hence, M 
values represent units of fold change in expression and A values represent units of fold 
increase in brightness (intensity). The logarithmic transformation spreads the values evenly 
across the range and provides readier visualisation of data. It also makes variability more 
constant (as measured by standard deviation) and converts the ratios R/G into differences. 
An MA plot displays the relationship between differential expression (DE) and intensity and 
hence allows identification of any non-linearity that may be present in the array. 
4) M Box plot Æ M box plots compare M values between various groups and displays a 5-
part summary i.e. the three quartiles and the maximum and minimum. First quartile cuts off 
lowest 25% of data, second quartile (or median) cuts data in half and the third quartile cuts 
off highest 25% or lowest 75% of data. 
5) Spatial plot Æ Spatial plots of the background or M values reveal spatial trends, artefacts 
and trends that stand out eg. image array plots give an impression of variations in red-green 
bias across different parts of the array 
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III. Cellular functions of HSP chaperones [adapted from (Muchowski and Wacker, 2005) 
HSP chaperones are known to facilitate proper folding or refolding of partially 
unfolded/misfolded proteins or to sequester damaged proteins for proteolytic digestion. They 
are also involved in a wide range of cellular processes such as autophagy, vesicle fusion, 
ubiquitination and proteolysis, vesicular transport, cell wall organization, small molecule 
transport, carbohydrate metabolism, energy generation, apoptosis, signal transduction and 
oxidative stress mechanisms. 
 
AIF: apoptosis-inducing factor, ER: endoplasmic reticulum, ERAD: endoplasmic reticulum-
associated degradation, HSF1: heat shock transcription factor 1, HSP: heat shock protein, 
LAMP: lysosomal-associated membrane protein, ROS: reactive oxygen species. 
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IV. Localisation of HSPs in yeast cells and mammalian cells [adapted from (Seppa, 
2005)] 
Yeast Cell 
 
CP: cytoplasm, CW: cell wall, ER: endoplasmic reticulum, M: mitochondrion, N: nucleus, PM: 
plasma membrane, V: vacuole, VM: vacuolar membrane. 
 
Mammalian Cell 
 
CP: cytoplasm, ER: endoplasmic reticulum, M: mitochondrion, N: nucleus, PM: plasma 
membrane, P: peroxisome. 
 
Hsp25 
αβ-crystallin 
Heme oxygenase/Hsp32 
TCP-1 
Hsp90 
Apg-1 
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